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Abstract
Autoimmunity represents a misdirection of the adaptive immune response against the self. The pre-
valence of human autoimmunity is increasing, including an increasing prevalence of autoimmune
liver disease. Novel therapeutic options are required and failure of the regulation of CD4+T cells has
been implicated in pathogenesis. OX40, ligated by OX40L, is a secondary co-stimulatory molecule
which promotes activation and survival of CD4+ T cells and has been proposed as a therapeutic
target in autoimmunity and regulatory failure.
Complete deficiency in FOXP3-positive regulatory T cells results in a lymphocytic hepatitis associ-
ated with autoantibodies and loss of effector CD4+ T cell control. This thesis confirms this finding
and demonstrates similar pathology in mice deficient in the regulatory molecule CTLA4 and in
Roquin sanroque mutant mice. Each of these mouse models is shown to hyperexpress OX40 on
liver-infiltrating CD4+ T cells. In FOXP3 deficiency, blockade of OX40-OX40L interactions abrog-
ates hepatitis; whereas in CTLA4 deficiency and the Roquin sanroque mutant mouse, OX40-OX40L
blockade is ineffective.
Complementary to these findings, increased expression of OX40 is demonstrated in human autoim-
mune liver disease, and a negative regulatory mechanism on the expression of OX40L by T cells by
the action of gamma-chain cytokines including interleukin-2 is described.
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1 Introduction
1.1 Immunity and autoimmunity
The immune system represents an interplay of multiple cell types and organ structures that serves to
resist a variety of potential insults to the host organism. These insults are primarilymicrobial, and the
immune system serves to prevent its host from being over-run by such invaders.[81] In addition, the
immune system has functions in removing cancerous and pre-cancerous cells and in clearing dead
and senescent matter from the host. Broadly, the immune system’s response to a challenge may be
split in two: those components that are, and those that are-not, affected by prior contact with the
challenge concerned. These responses are termed innate and adaptive immunity respectively.
The innate component of the immune system represents a generic response to pathogens. The innate
system recognises its triggers through a number of receptors that are pre-encoded in the germline
and not subject to the random recombination of receptors and with positive- and negative-selection
that characterise the receptors of cells of the adaptive immune response.[274] The cells of the im-
mune system include phagocytes such as macrophages, dendritic cells and neutrophils, as well as
natural killer cells, eosinophils, basophils and mast cells. Each of these express a variety of pattern-
recognition receptors which respond to a specific component of a pathogen. The family of Toll-like
receptors (TLRs) recognise variousmolecules includingmicrobial glycoproteins, lipopolysaccharide
and free double-stranded nucleic acids, whilst other distinct ligand-recognition domains, including
leucine-rich repeats, C-type lectin domains and various nucleic acid binding domains triggering
other innate responses.[165]
Activation of the initiating receptors of the innate immune response promotes a variety of mech-
anisms of host defence including complement activation, which targets pathogens for phagocytosis
or lysis, release of directly anti-microbial cytokines, the extrusion of neutrophil extracellular traps,
release of oxidative respiratory burst, the release of vasoactive peptides like histamine, promotes ac-
cumulation of other immune cells via chemokines and through induction of cell adhesionmolecules;
a further key component of the innate system is the expression of interferons and down-regulation
2
of surface major histocompatibility complex (MHC) protein by cells infected by viruses.[274, 188]
Importantly, the activation of the innate immune system in turn influences the activation of the ad-
aptive response: innate cells present processed antigen to T cells on MHC molecules, cytokines
produced by the innate immune system focus the adaptive response by polarising and differen-
tially activating T- and B cells, and by promoting the production of different antibody classes by
B cells.[165]
Adaptive immunity
The adaptive immune response encompasses responses that vary depending on an organism’s pre-
vious exposure to the pathogen or other antigen concerned. The adaptive response primarily con-
cerns the functions of the two major groups of lymphocytes: T cells and B cells. There is induction
of quantities of specific antibody by B cells which agglutinate pathogens, promote killing of invad-
ing cells by fixing complement or promote antibody-dependent cell-mediated cytotoxicity, promote
phagocytosis, and neutralise some toxic chemicals. Equally, activation of T cells includes promotion
of CD8+ or cytotoxic T cell killing of other cells, whilst CD4+ T cells control ongoing activation of
CD8+ T cells, B cells, phagocytes including macrophages and the production of several systemically
active cytokines.[296]
This chapter considers autoimmunity and autoimmune disease in general. It then considers the role
of the liver as an important immune organ and then how the liver may be affected by autoimmunity.
In two major autoimmune liver diseases, a role for dysregulated CD4+ T lymphocytes appears im-
portant. Different mechanisms of regulation of CD4+ T cells are discussed, especially with rela-
tion to the effects of disruption of such regulatory mechanisms with a specific focus on regulatory
T cells. The manipulation of a tumour necrosis factor (TNF) receptor-ligand pair known as the
OX40-OX40L pathway is then considered in relation to the regulation of T cell function, including
as potential therapeutic target. Finally, consideration is given to mouse models with disturbances
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Figure 1.1: Autoimmunity and autoinflammation. A proposed classification of immune-mediated diseases
into classical autoimmune conditions and atypical autoinflammatory conditions. Classical autoimmune condi-
tions typically demonstrate autoantibodies, female preponderence, co-incidence with other autoimmune con-
ditions, MHC class II variant risk associations and evidence of an adaptive immune response to self-antigens.
Figure adapted from McGonagle & McDermott (2006).[272]
of immune control and that develop hepatitis. These serve as useful systems for exploration of the
effects of OX40-OX40L blockade.
Autoimmunity
Autoimmunity may be described as the combination of an adaptive response directed against self
tissue with tissue damage or disruption of other physiological processes.[272, 247]More specifically,
there is typically a clinical syndrome of single or multi-organ damage or dysfunction caused by the
activation of T or B lymphocytes, or both, in the absence of an ongoing infection or other ongoing
discernible cause.[79] Typically, this autoimmune adaptive response is defined by the development
of autoantibodies: where an antibody’s specificity is directed against a self-antigen. Although indi-
viduals may develop inflammation that is damaging to self tissues, it is the specificity of the response
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Figure 1.2: Increasing prevalence of autoimmunity worldwide. Figure redrawn from Bach (2002).[12]
that differentiates autoimmunity from simple autoinflammation. Whilst autoinflammation may in-
duce the presence of autoantibodies as a side effect of an uncontrolled innate-like response, in true
autoimmune disease there is typically autoantibody production prior to disease development, a fe-
male preponderance, genetic association with specific variants in MHCII molecules, and specific
increased occurences in the development of autoimmunity in other organ systems (Figure 1.1). The
spectrum of severity of autoimmunity ranges from the development of the harmless autoantibodies
that may occur in up to 25% of the healthy population to lethal multi-organ disease.[316]
Worldwide, the prevalence of autoimmune conditions is increasing with current estimates suggest-
ing that up to 10% of individuals are affected by an autoimmune disease.[65, 64] Where there are
longer-term data available, the prevalence of many autoimmune conditions has increased markedly
over the last half-century (Figure 1.2). In addition, a pre-disposition to autoimmunity appears to
represent a systemic, rather than organ-specific, deficit with the development of one autoimmune
disease predisposing to the development of a second ormore.[390, 391]The examination of autoim-
munity affecting the liver as part of more generalised autoimmunity is the focus of this thesis.
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The liver
The liver functions as both a metabolic and lymphoid organ and is the largest internal organ of the
human body. It typically accounts for around 2% of body weight, with this proportion being consist-
ent across mammalian species.[37] Derived from endoderm in early embryogenesis and occupying
the superior-right portion of the intra-peritoneal space, the liver receives three-quarters of its blood
supply as venous blood from the gastrointestinal tract and spleen via the portal vein. The remainder
of its blood supply is arterial from the abdominal aorta via the hepatic artery, and together these two
components account for 25% of cardiac output. The portal vein and hepatic artery enter the liver
together at the porta hepatis where they branch into smaller venules and arterioles before draining
into fenestrated and ultimately discontinuous sinusoidal capillaries. Here blood flow is slow and in
direct contact with the major functional cell type of the liver, the hepatocyte. Such slow-flowing
direct contact facilitates several of the myriad functions of the liver. The sinusoidal capillaries then
drain back into venules that coalesce to form the hepatic vein which in turn drains back into the
inferior vena cava (Figure 1.3).[230, 45, 259]
The liver has critical homeostatic functions in glucose metabolism, protein synthesis, maintenance
of coagulation function, lipid metabolism, the breakdown and excretion of both endogenous waste
and drugs, endocrine control of blood pressure, and, in early life, it is the major haematopoietic
organ.[458, 70, 45]. Most of these metabolic functions are performed by hepatocytes with bili-
ary epithelial cells (BECs) providing some excretory function. Liver failure represents the loss of
these and other functions and presents with jaundice through the disordered metabolism of biliru-
bin, coagulopathy through alterations in the production of clotting factors, hypoglycaemia through
impaired glucagon metabolism, and encephalopathy through impaired metabolism of nitrogenous
compounds originating in the gut. Uncorrected, liver failure is lethal and necessitates transplanta-
tion to avoid death.[501]
In addition to its major metabolic functions, the liver represents a key component of the immune
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Figure 1.3: Schematic diagram of the functional anatomy of the liver. The liver receives the majority
of its blood supply from the portal vein which is formed by the confluence of the superior mesenteric and
splenic veins. The superior mesenteric vein receives blood from much of the gastrointestinal tract and the
blood it contains is rich in antigen. The liver also receives arterial blood via the hepatic artery. Blood from both
sources feeds the liver through progressively smaller venules and arterioles. Together with bile ductuoles,
these vessels form the portal triad and area arranged in a roughly hexagonal pattern around central hepatic
venules. Blood travels from the portal triad vessels to the central vein by way of fenestrated capillaries. These
fenestrations permit exposure of liver resident immune cells and hepatocyte to bloodborne antigen and permits
interaction of circulating immune cells with other cells through fenestrations.
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Figure 1.4: Approximate immune cell composition of the human liver. Adapted from Racanelli and
Rehermann 2006.[347]
system. The liver’s unique vasculature interfaces slow-flowing blood with a large cell surface area.
Whilst this facilitates metabolic exchange, it also permits interaction with antigen by the large liver-
resident population of immune cells (Figure 1.4); blood in the portal vein, by nature of its contact
with the gastrointestinal tract, is particularly antigen-rich.[347] The liver contains large numbers
of intravascular macrophages – known as Kupffer cells – and these are seen lining the sinusoids.
Lymphocytes are also frequent in the sinusoidal lumen.[206]
Relative to other immune-cell rich structures, the function of the liver is tolerogenic.[173] A num-
ber of elegant experiments have highlighted this tolerogenic effect: in early transplant studies per-
formed in pigs, co-transplantation of livers reduce immune-mediated rejection of kidney grafts[48]
and such work correlates with the reduced immunosuppressive requirements of human combined
liver-kidney recipients as compared to those who receive livers alone, especially those who receive
both organs from the same donor.[382] In addition, the liver is unique among solid organs in that it
can be transplanted across major MHC mismatches[303] and in that a significant proportion of in-
dividuals immunosuppression may successfully be completely withdrawn.[84] Animal studies have
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demonstrated an ability to induce tolerance through oral or portal venous introduction of antigen,
but not through the liver-bypassing systemic venous route.[49] Some of this may be through the
induction of antigen specific regulatory T cells (Tregs).[51] In addition, hepatic Kupffer cells are
known to constitutively express molecules with immunoregulatory properties such as programmed
death protein ligand 1 (CD274) (PDL-1) at high levels and also to tend to release immunosuppressive
IL-10 in response to the usually pro-inflammatory TLR ligands such as lipopolysaccharide ligating
TLR4.[140]. A similar phenomenon is seen with hepatocytes and sinusoidal epithelial cells, which
also express multiple TLRs. The liver is also a location where chronic infections such as schistoso-
miasis, malaria, and viral hepatitis may persist [486, 56, 71].
Despite its tolerogenic potential, adaptive immune responses are well documented within the liver.
For example, specific antibodies are generated to viral antigens in hepatitis and to bile-salt exporter
pump proteins in patients transplanted because of insufficiency of the functional protein.[168, 220,
56] Elegant experiments exploitingT-cell receptor (TCR)-transgenicmice and liver transplants between
mice have shown that CD8+ T cells may be primed and activated entirely within the liver (i.e.
without the requirement for migration through secondary lymphoid tissue)[202, 83] and that the
same is true of CD4+ T cells for at least some antigens.[413]
Liver autoimmunity and its clinical features
In addition to the ability of the immune system to generate adaptive responses to exogenous anti-
gens within the liver, several autoimmune conditions may affect the liver. The three most frequent
autoimmune diseases affecting the liver comprise PBC, AIH and primary sclerosing cholangitis
(PSC). There is some overlap in clinical and pathological features between the three diseases (Fig-
ure 1.5).
Both PBC and AIH have been described as ‘archetypal’ autoimmune diseases.[143, 435, 319]. Both
demonstrate a female preponderance, frequent autoantibodies, and strong associations with a vari-
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Figure 1.5: Overlapping features in autoimmune liver diseases. Some features of autoimmune liver
disease are shared between subtypes. autoimmune hepatitis (AIH) and primary biliary cholangitis (previously
primary biliary cirrhosis) (PBC) share the production of anti-nuclear antibody (ANA), polyclonal elevations in
immunoglobulins, and the development of histological hepatitis. Figure adapted from Webb et al.[470]
ety of other autoimmune conditions. There is however less consensus that PSC is as typical – it
is male-predominant, its associations with autoantibodies are less strong, it is associated with a
markedly increased risk of malignancy, and no defined target antigen has been found. It is also
strongly associated with inflammatory bowel disease, the ongoing presence of which may affect its
development.[432] This last has led some to speculate that PSC represents a response to dysbiosis
or another autoinflammatory process rather than a true autoimmune phenomenon.[359] However,
a shared genetic architecture with other autoimmune conditions and increased risk of concurrent
autoimmunity in other organ systems have led others to support its classification as an autoimmune
condition.[176] The remainder of this work considers PBC and AIH, both of which have markedly
rising prevalences.
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Clinical features of primary biliary cholangitis
PBC represents a chronic immune-mediated destruction of biliary epithelial cells of the small intra-
hepatic bile ducts.[145]Over time, there is a variable inflammatory infiltrate, the loss of bile ductules,
and cholestasis leading to progressive fibrosis over years and ultimately cirrhosis with liver failure
and complications of portal hypertension.[53] During this process, cholestasis eventually causes
clinically-evident obstructive jaundice, with resultant malabsorption. PBC has a peak incidence at
the age of approximately 55 years, a 5:1 to 10:1 female preponderance and a current UK prevalence
of approximately 35 per 100,000 persons/year.[52, 466] The disease may present with pruritus, fa-
tigue, pain in the upper abdomen, symptoms and signs of liver failure, or, in a significant proportion
of cases, be asymptomatic. Patients may have xanthelasma and/or xanthomata from the hyperlip-
idaemia that is often present in PBC, there may be hepatomegaly resulting from cholestasis. The
cause of the condition is unknown although there are environmental associations with smoking,
nail varnish and hair dye exposure, and deprivation.[154, 110, 66, 342, 273] These is marked con-
cordance between monozygotic twins and a number of disease risk-modifying genetic variants have
been identified.[473]
PBC is strongly associated with the development of autoantibodies. In over 90% of cases, antibodies
directed against the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) are detectable
and are commonly referred to as anti-mitochondrial antibody (AMA). The majority of patients that
do not develop AMAs develop specific ANA.[144] In common with other autoimmune diseases,
autoantibodies develop before the onset of clinical disease and predict disease development in un-
affected patients.[255]
Other laboratory analyses in PBC typically record an elevation in serum alkaline phosphatase (ALP)
activity. In humans, this enzyme is particularly concentrated in the biliary system and is released into
the serum by biliary damage. Similarly, the transaminase enzyme alanine aminotransferase (ALT)
is concentrated in hepatocytes and its serum activity is typically elevated when there is damage to
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hepatocytes. In PBC, elevations in ALT activity are frequent. In addition, for unknown reasons,
serum total IgM levels are often increased in patients with PBC.
PBC is generally not responsive to immunosuppressants, but its course is slowed by the drug urs-
odeoxycholic acid. A proportion of patients require liver transplantation to avoid death from liver
failure or to treat intractable pruritus. Recurrence of PBC is well-recognised post-transplantation,
and may require repeat transplantation[306, 57]; high titre AMAs typically persist after transplant-
ation highlighting that they are more than an epiphenomenon.
Clinical features of autoimmune hepatitis
AIH represents an adaptive immune response directed against hepatocytes. If uncontrolled, it results
in an insufficient number of surviving hepatocytes to provide homeostatic functions and clinically
evident liver failure results. AIH may be rapid in onset or more indolent: acute cases may result in
liver failure in days, whilst chronic cases progress through increasing fibrosis before established cir-
rhosis and chronic liver failure. Althoughmost cases respond to treatment with immunosuppressive
medications – predominantly corticosteroids, thiopurine antimetabolites, calcineurin inhibitors and
mycophenolic acid – a minority of cases are progressive despite therapy and ultimately require liver
transplantation.[238, 67]
AIH has a female preponderance of some 3:1 to 9:1 women to men affected.[67] It has a bimodal age
of incidence with peaks in the second and sixth decades of life.[466] Autoantibodies are frequent in
AIH. A minority of patients have the same AMA as seen in PBC but most develop ANAs, antibodies
to components of smoothmuscle such as F-actin, elements of the cytochrome P450 system including
P450 2D6 , and the Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase that is known
as soluble antigen of liver and pancreas cytoplasm.[263, 480, 256, 434] AIH has associations with a
number of drug triggers including minocycline, nitrofurantoin, hydralazine and tienilic acid.[36,
231, 118, 7]
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Figure 1.6: Increasing prevalence of autoimmune hepatitis and primary biliary cholangitis. Data are
based on an interrogation of The Health Improvement Network of nationwide UK pseudonymised general
practice records.[467]
As with PBC, elevations in serum ALT activity are common in PBC and reflect ongoing damage to
hepatocytes. In addition, serum total immunoglobulin G (IgG) is often increased. Both of these
laboratory indices act as proxies of ongoing inflammation. Similarly to PBC, recurrent disease after
transplantation is recognised although difficult to distinguish clinically from rejection.[86]
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Overlapping disease
The prevalence of both AIH and PBC is rising in the UK population (Figure 1.6) and also more
generally.[31, 125, 430] As noted above, a number of features are shared between the diseases: their
frequent co-incidence with other autoimmune phenomena, the presence of autoantibodies, elev-
ations in immunoglobulins, female preponderances, peak ages of incidence, and the fact that a
proportion of cases do not respond to standard immunosuppression. A minority of cases of both
diseases with shared features are described as overlap syndromes. Typically, these cases are more
aggressive and less responsive to standard therapy.
In addition, both diseases clearly represent a problem that is primarily immune rather than a primary
hepatic problem as demonstrated by the fact that recurrence is well-reported in both.[306, 290]
CD4+ T cells are implicated in the pathogenesis of autoimmune liver disease
Anumber of findings have suggested a central role for a subtype of T lymphocyte: the CD4+T cell in
autoimmune liver disease. Most simply, there is a great increase in the number of CD4+ T cells seen
on both biopsy and explant studies of AIH and PBC livers (Figure 1.7).[248, 371, 133, 249] CD4+
T cells respond to antigen presented by antigen-presenting cells. Antigen is recognised by specific
T cell receptors on the surface but only when presented by the MHC class II molecule, which is
in turn encoded by the human leucocyte antigen (HLA)-D locus on the short arm of chromosome
six.[128] In many autoimmune conditions, associations with specific variants in HLA-D have been
associated with an altered risk of developingmultiple autoimmune conditions. In keeping with their
being typical autoimmune diseases, such associations have been described both for AIH and PBC
in candidate gene studies and also in all genome-wide association studies to date (Figure 1.8). [147,
146, 246, 300, 80, 345]
Supporting observations that antigen presentation to CD4+T cells is important in autoimmune liver
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Figure 1.7: CD4+ T cells are prominent in autoimmune liver disease. Representative sections of inflam-
matory infiltrate from explant livers affected by AIH and PBC. Stained with a rabbit anti-CD4 primary antibody
and visualised using an anti-rabbit ALP-conjugated secondary antibody with a red chromogen. Tissue ob-
tained via the University Hospitals Birmingham liver transplantation programme and stained by the author.
disease (AILD) is the fact that MHCII (HLA-DR) is strongly expressed on both hepatocytes in AIH
and on BEC in PBC.[429, 16] Such expression is not seen in health. This pattern of expression is
also seen on the target tissues of others autoimmune diseases: for example, HLA-DR is expressed
on joint synovium in rheumatoid arthritis but not in health.[284]
Both AIH and PBC have defined target antigens: for a proportion of AIH patients the target antigen
is LKM-2 and in PBC it is the PDC-E2 subunit that is the target of AMAs.[143, 435, 319] In both,
AIH and PBC an IL-2 ‘cytokine signature’ is present: there are increases in expression in the diseased
tissue.
T-cell receptor oligoclonality suggestive of an antigen-specific T cell response has been reported for
both CD4+ and CD8+ cells in both diseases.[8, 496, 286] Evidence of T cell activation is also sup-
ported by evidence of both antibody class switching and production of interferon-gamma (IFNγ) in
both diseases [470]. In PBC, where larger numbers of individuals have been studied with genome-
wide association techniques, risk conferring variants cluster around genes involved in the T helper
cell type 1 (Th1)-IL-12 pathway with its integral role for CD4+ T cells (Figure 1.9). Further evid-
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Figure 1.8: HLA-D variants are associated with autoimmune liver disease. Genome-wide association
studies of PBC and AIH have demonstrated significant associations with the carriage of multiple single nucle-
otide variants. In all fivemajor studies of patients with PBC and the single AIH study to date, the strongest asso-
ciation is with variants in HLA-D which encodes MHC class II. Top-left : PBC patients from North America[147];
top-right : PBC patients from Japan[300]; centre-left : British PBC patients[277]; centre-right : Chinese PBC
patients[345]; bottom-left : Italian PBC patients[246]; bottom-right : white European AIH patients[80]. Figures
adapted from publications referenced.
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ence for a central role for CD4+ T cells is the provocation of syndromes similar to AIH after the
administration checkpoint inhibitors for cancer immunotherapy, which primarily influence T cell
activity[441]. Similarly, a hepatitis indistinguishable from classical type-1 AIH has been reported in
immune reconstitution – the recovery of the CD4+ T cell count – during anti-retroviral treatment
of the acquired immunodeficiency syndrome.[315]
In aminority of cases, AIH is associatedwith genetic syndromes associatedwithmulti-systemautoim-
munity: in each of these cases, disorders of CD4+ T cell control are central to the condition. For ex-
ample, in the syndrome autoimmune polyendocrinopathy candidiasis ectodermal dystrophy there
is dysfunction in autoimmune regulator (AIRE) and resultant impaired presentation of otherwise
tissue-restricted antigen to developing T cells and so aberration of both positive and negative selec-
tion. Alongside autoimmunity affecting other organs, around20%of autoimmunepolyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) patients develop AIH.[437] In addition, AIH is also
reported in patients with heterozygous dysfunction of cytotoxic T-lymphocyte associated protein 4
(CTLA4)[222, 366] and in some cases of the autoimmune lymphoproliferative syndrome where
there are aberrations in the T cell apoptosis signalling molecule Fas and its ligand FasL.[331, 388,
484]
Th1 cells are particularly prominent in both PBC and AIH, and genetic variants in molecules im-
plicated in the IL-12-Th1 pathway are associated with PBC (Figure 1.10).[473] This and the other
observations above suggest a rationale for further considering CD4+ T cells in the pathogenesis of
AIH and PBC, and as a potential therapeutic target.
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Figure 1.9: Both primary biliary cholangitis and autoimmune hepatitis share risk-conferring single
nucleotide variants in loci shared with other autoimmune diseases. Numbers 1-22, X and Y denote the
human genome split by chromosomes in descending size. Lines represent the genomic position of loci in which
variants have been associated with altered risk of one or more major autoimmune diseases. Symbols on inner
circles denote an association between variants in the gene concerned and risk of autoimmune disease. Image
produced using Circos[218] and modified from Webb et al.[468] AA = autoimmune alopecia; AS = ankylosing
spondylitis; ATD = autoimmune thyroid disease; JIA = juvenile idiopathic arthritis; MG = myaesthenia gravis;
MS = multiple sclerosis; Narc = narcolepsy; Pso = psoriasis; RA = rheumatoid arthritis; Scl = scleroderma; Sjo
= Sjögren syndrome; SLE = systemic lupus erythematosus; T1DM = type 1 diabetes mellitus; UC = ulcerative
colitis; Vit = vitiligo.
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Figure 1.10: Multiple genetic variants associated with PBC are involved in the IL-12-Th1 pathway.
Diagram represents the interaction between antigen-presenting cell and CD4+ T cell shown with primary stim-
ulation through presentation of antigen on MHC II to the TCR with secondary stimulation via CD28 from CD80
and CD86. The antigen presenting cell is activated by recognition of danger-associated molecular patterns
exemplified by TLR ligation. Genetic association studies have identified a number of signalling molecules key
to the IL-12/Th1 pathway. Key elements of that pathway are illustrated with factors with significant genetic
associations with PBC highlighted in red and likely associations highlighed in blue. Figure adapted fromWebb
et al.[473]
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1.2 CD4+ T cells
The development of CD4+ T cells
CD4+ T cells represent a subset of lymphocytes. Lymphocytes derive their name from lymphatic
vessels and represent the most frequent cell types within lymphatic fluid. They include B cells,
T cells, natural killer cells, and natural killer T cells amongst other groups. Haematopoietic stem
cells produce committed lymphoid progenitors that migrate to the thymus.[395] Here the lymphoid
progenitor cells go through a series of maturation steps before entering a process of negative and
positive selection. Initially, there is development of a pre-TCR where there is rearrangement of the
beta chain. If the beta chain successfully pairs with an alpha chain, cells proliferate and express both
CD4 and CD8: so-called double-positive cells.[109] At this point recombination activating genes
(RAG) are suppressed preventing further TCR variation. Double positive cells then continue to ma-
ture in the outer and then inner cortex. However, if they receive insufficient signalling through TCRs
and co-stimulation, which is the case in around two thirds of cells, there is death by neglect.[364]
Depending on whether they receive stronger signalling through CD4 or CD8 associated TCRs, cells
become single positive (Figure 1.11).
After selection in the cortex, cells migrate to the thymic medulla. A further sequence of selection
ensues, with negative selection now prominent. Here, cells are exposed to self-antigens expressed on
medullary thymic epithelial cells. Those that react strongly are selected for deletion, those that react
more weakly take on effector phenotypes whilst those of intermediate reactivity – in the presence
of sufficient – take on a regulatory phenotype. Within the thymic medulla there is also expression
of antigens that are otherwise restricted to non-immune tissues. This allows deletion of potentially
autoreactive T cells and selection of self-antigen specific Tregs. Expression of tissue-restricted anti-
gens is mediated by two proteins specific to the thymic medulla: AIRE and Fezf2. Dysfunction of
these proteins results in specific and differing patterns of autoimmunity, including in humans with
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Figure 1.11: (Previous page.) Thymic T cell selection. Lymphoid progenitors migrate from the bone marrow
to the thymic cortex. Here they develop through a number of intermediate stages termed double-negative
(DN) 1 to 4 where the cells remain negative for both the CD4 and CD8 co-receptors. During this process,
the cells lose expression of CD44 and transiently express the IL2 receptor. There is rearrangement of the
T cell receptor beta chain, and then if the beta chain successfully pairs with the pre-alpha chain, the alpha
chain is rearranged, the cells proliferate and then enter a double-positive (DP) stage expressing the TCR, CD4
and CD8. Here, if the cells receive adequate signals through their TCR in response to antigenic sequences
expressed by cortical thymic epithelial cells, they survive and are polarised towards persistent expression
of either CD4 or CD8 depending on their specificity. If cells do not receive sufficient stimulation, they enter
apoptosis: so-called death by neglect. Next, single-positive (SP) cells enter the thymic medulla and interact
with self-antigens expressed onmedullary thymic epithelial cells. The expression of otherwise tissue-restricted
self antigens is mediated by AIRE and Fezf2. Cells that receive weaker signals adopt an effector phenotype,
cells that receive intermediate signals adopt a regulatory phenotype whilst cells that receive strong signals
from self antigen enter apoptosis. Figure adapted from Germain (2002), Nature Reviews in Immunology.[109]
some types of dysfunction, autoimmune hepatitis.[406, 200]
CD4+ T cell effector functions
The overall roles of activated effector CD4+ T cells include the production of effector cytokines,
promoting the recruitment of eosinophils, neutrophils, and basophils to sites of activation by sup-
porting the production of chemokines such as CCL5/RANTES, supporting B cell affinitymaturation
and activation, supporting persistence of memory in CD8+ lymphocytes, promoting increased pha-
gocytic activity inmacrophages and regulating the innate immune system bymodulating expression
of pattern recognition receptors. As such they have been described as “orchestrating the full panoply
of immune responses”.[510]
The functional role of CD4+ T cells overall can be demonstrated by their deficiency. In mice, this
is best achieved by knocking out MHC class II rather than CD4 – if CD4 is knocked out, CD4-
and CD8- double negative T cells fulfil some of the roles of CD4+ T cells.[27] Mice lacking MHC
class II have minimal CD4+ cells and do not develop germinal centres, show reduced production
of immunoglobulin alongside an absence of T cell specific antigen response.[69] Such mice also
demonstrate a lack of induction of a cytotoxic CD8+T cell response[23], marked susceptibility to the
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intracellular infectionmycobacterium tuberculosis[54], susceptibility to leishmaniasis andprotozoa,
and exhibit reduced allograft rejection.[127] In humans, the phenotype of patients with low CD4+
counts is visible in the context of human immunodeficiency virus infection. Such individuals show
susceptibility to infection with tuberculosis and encapsulated bacteria and fungi, failure to control
several viral infections, loss of some specific antibody responses and a tendency tomalignancy.[287]
A similar phenotype is seen in the rare disease idiopathic CD4+ lymphocytopaenia.[88]
CD4+ effector T cell subtypes
For some time, it has been recognised that CD4+ T cells do not represent a homogeneous group, but
that they have unique functions. Primarily, they are subdivided on the cytokines that they produce
on stimulation: initially Th1 and T helper cell type 2 (Th2) cells were identified based on their re-
spective polarisation towards either production of IFNγ or IL-4 upon stimulation.[510] Subsequent
to this, a number of differently differentiated T cell subsets have been described (Figure 1.12).[349]
The longest recognised effector T cell subset is the Th1 cell. These cells are characterised by their
expression of IFNγ on stimulation and their expression of the transcription factor Tbet. Polarisation
towards a Th1 phenotype primarily occurs through the action of IL-12. The function of Th1 cells
is primarily defined by the effects of their deficiency: susceptibility to intracellular infections such
as mycobacteria.[401] The functional importance of IFNγ in this regard is further demonstrated
by the susceptibility of humans with genetic aberrations in the IFNγ pathway.[180] Th1 cells have
been identified as the major component of target antigen specific T cells in autoimmune diseases
such as multiple sclerosis.[317] In several animal models of of autoimmune disease, blocking IFNγ
is protective whilst exogenous additional IFNγ worsens pathology.[122]
Th2 cells produce high levels of IL-4 and IL-10 after polarisation by the action of IL-4 and IL-35
and show significant interdependency with innate lymphoid cells such as ILC2.[240] They typically
23
MAF
FOXP3-FOXP3
TbetGATA3 ROR!t BCL6
FOXP3
IFN!
IL4
IL5
IL10
IL17
IL6
IL10TGF"
IL21
IL10TGF"
Naïve T!cell
T  1T  2 T  17 TFHHH H
Tr1pTregtTreg
THYMUS Transdifferentiation
IL4
IL12
IFN!
IL4
IL33
IL1" / TGF"
IL6
IL23
IL6
IL21
TGF"
Figure 1.12: CD4+ T cell subsets. T cells leave the thymus in a naïve, antigen non-experiened state. After
contact with antigen, T cells may take on one of numerous subsets. These subsets are defined by their
cytokine secretion profiles and the transcription factors necessary for their development. Dashed line shows
reported transdifferentiation between subsets. Effector subsets are shown at the top of the diagram whilst
regulatory subsets are shown at the bottom.
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express the transcription factor GATA3. Their role is characterised as being in promoting allergic
and anti-parasitic responses: although deficiency in GATA3 is embryonically lethal, their role can
be demonstrated by animals deficient in IL-4 which are resistant to allergic responses.[43] Deficien-
cies in their function predispose to various parasitic infections and cause reduced production of
immunoglobulin E (IgE).[301]
Th17 cells develop in response to signals from IL-6, IL-23, transforming growth factor-beta (TGFβ)
and tend to express the retinoic acid receptor-related orphan receptor gamma (RORγ). They are
characterised by their expression of IL-17 and, as below, they appear to be a particularly plastic
subtype of T cell. Their absence is characterised by susceptibility to bacterial and fungal pathogens,
and to tumourigenesis.[77, 44] Th17 cells become increasingly frequent in end-stage PBC.[490, 320]
T follicular helper cell (Tfh) cells are characterised by their expression of the transcription factor
Bcl6. They also tend to express CXCR5, which aids in their positioning in lymphoid tissue, and
variable levels of programmed death protein 1 (CD279) (PD-1) and inducible T-cell costimulator
(ICOS). They promote germinal centre formation, antibody affinity maturation and the formation
of memory B cells. In their absence, specific antibody responses are absent or severely blunted.[75]
Both Th9 and Th22 effector T cells, which produce IL-9 and IL-22 respectively have been identified
but are less well described. Th9 T cells are involved in the regulation of mast cell migration and
Treg survival and there are reports of their involvement in allergy, autoimmunity and anti-tumour
immunity.[184] Th22 cells have major roles in epidermal immunity but equally have been proposed
to influence the development of autoimmunity and anti-tumour immunity.[175]
Importantly, T cells are not permanently commited to a specific subset. This process of transdiffer-
entiation has been described using cells that display fate-mapping markers after expressing IL-17:
for example, Th17 type cells in inflammatory environments may take on a Th1, IFNγ secreting,
phenotype.[103] Th17 also appear to be able to take on a regulatory phenotype during resolution of
inflammation.[142]
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1.3 Regulatory T cells
Tregs are a subset of CD4+ T cells. The role of Tregs is primarily to control the activation of effector
T cells and their importance is keenly demonstrated by the drastic effect of their absence. Mice
lacking functional Tregs developmulti-organ infiltrates of activated T lymphocytes, withmarked in-
creases in effector cytokine production and a wasting disease that is typically lethal by four weeks of
life.[113] Transfer of Tregs prevents the development of disease.[100]The requirement for the action
of Tregs is ongoing through life: in mice in which a deficiency in Tregs is inducible by the adminis-
tration of diphtheria toxin, such depletion rapidly results in lethal multi-system autoimmunity.[194,
224] This same model is also sufficient to demonstrate that the autommunity is due to the excess ac-
tivation of non-regulatory CD4+ T cells – simultaneous depletion of CD4+ T cells prevents disease.
Tregs may be identified by their expression of the master transcription factor forkhead box P3
(FOXP3). Functional FOXP3 is required both for normal development and activity of Tregs and
its transfection alone into naïve T cells promotes the development of a regulatory pheonotype.[153]
In mice, the expression of FOXP3 is sufficient to identify Tregs, but in humans the situation is more
complicated and activated lymphocytes may also briefly express FOXP3. Tregs also demonstrate
constitutive high expression of the IL-2 receptor alpha subunit, relatively low expression of the
IL-7 receptor alpha subunit, and constitutive expression of CTLA4 and (the protein encoded by)
lymphocyte-activation gene 3 (LAG3). The adoption of a Treg phenotype is not a permanent status
and cells may transdifferentiate from other CD4 T cell subsets into FOXP3 expressing cells [103] and
that FOXP3 expression may be lost by a proportion of Tregs in inflammatory environments.[283]
Subtypes of regulatory T cell
A number of subtypes of Treg have been proposed and the nomenclature has varied over time.
Broadly, there are three types functional in vivo: the directly thymic-derived tTreg, the peripherally
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derived pTreg which differentiate from naïve T cells and from effector T cells, and Tr1 cells.[1, 379]
The former two require FOXP3 for their development, which Tr1 cells do not. The existence of peri-
pherally derived FOXP3-negative cells expressing TGFβ or IL-35 and termed as Th3 and TR35 has
also been proposed.
Regulatory T cell effector mechanisms
How the FOXP3-dependent pTregs and tTregs exert their suppressive effects on other T cells is in-
completely defined but several important mechanisms have been identified (Figure 1.13).[436, 178]
Their respective importance and their functional redundancy are not fully assessed.
First, Tregs produce several cytokines with inhibitory actions on effector T cells. These include
IL-10[6, 396], IL-35[63], and TGFβ.[350] A probable role for Treg membrane-bound TGFβ has
also been suggested by the demonstration that is it strongly expressed on Treg membranes and that
cell-impermeable membranes prevent the anti-TGFβ sensitive suppression of effector T cells in co-
culture experiments.[299]The role of IL-10 has also beenmade less clear by the suggestion that Tregs
in fact influence other cells to express immunosuppressive IL-10 via an unknown mechanism.[189,
4]
Second, Tregs have been demonstrated to produce some of their immunosuppressive effects via
granzyme B mediated cytolysis, with reduced suppressive capability with Tregs isolated from gran-
zyme B deficient animals.[116]
Third, Tregs constitutively express high levels of IL-2 receptors and upregulate these further when
activated. It has been proposed that uptake of IL-2 by Tregs prevents sufficient uptake by other
activated T cells to avoid apoptosis.[323]
Fourth, reverse signalling through an uncertain mechanism induces increased Treg expression of
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Figure 1.13: Mechanisms of immunosuppression by regulatory T cells. Several mechanisms of sup-
pression of the activity of other cells by Tregs have been proposed. These include the production of immun-
osuppressive cytokines including TGFβ (which can be membrane-bound), IL-10 and IL-35. In addition, it is
reported that Tregs are able to induce other T cells to express IL-10. Expression of cytotoxic granzyme B
may permit Tregs to cause the death of other cells. Various interactions with antigen-presenting dendritic
cells including induction of TGFβ and IL-10 via TIGIT and interactions between LAG and MHC encourages
productions of immunosuppresive TGFβ and IL-10. In addition, because Tregs express high levels of high
affinity IL-2 receptors, they appear to have some activity by depriving other T cells of sustaining IL-2.
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the immunoregulatory enzyme indoleamine 2,3-dioxygenase and that this in turn has immunsup-
pressive effects on effector T cells.[343]
Fifth, the two ectoenzymes CD39 and CD73 are highly expressed on Tregs. Recent work has sug-
gested that they convert extracellular 5’-adenosine mono- and triphosphate to adenosine, which in
turn has immunosuppressive functions.[208, 34]
Sixth, molecules expressed on the cell surface of Treg surface mediate immunosuppressive effects.
Two examples include LAG3, which binds avidly to MHCII and is reported to reduce dendritic cell
maturation and co-stimulatory capacity [155], and the immune receptor TIGIT, which decreases
production of the effector cytokine IL-12 by dendritic cells.[498]
Finally, and likely to account for a major proportion of the immunosuppressive efficacy of Tregs, the
moleculeCTLA4prevents signalling throughCD28on effector cells and so reduces co-stimulation.[449,
450]
Regulatory T cells in autoimmune liver disease
In addition to evidence for uncontrolled action of effector CD4 T cells, other factors support con-
sideration of failures of T cell regulation in the aetiology of AILD. Initial reports suggested that
numbers of Tregs were decreased in the inflammatory infiltrate of AIH as compared with other
liver diseases.[96] Others have described a decrease in peripheral Treg numbers in AIH.[251, 250,
239, 237] More recently however, reassessments of both peripheral numbers and liver-infiltrating
numbers of Tregs with improved molecular phenotyping with specific staining for the transcription
factor FOXP3 of both histological samples and cell suspensions prepared from explant livers have
demonstrated that both are similar or increased when compared to other liver diseases and, in the
case of the peripheral blood, to health.[321, 330, 412, 22]
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The function of peripheral Tregs isolated from autoimmune hepatitis patients has been sugges-
ted to be impaired in their regulation of activation and proliferation of conventional T cells[250].
Again however, more recent examinations have suggested that this is not the case for Tregs isolated
from inflamed liver tissue, highlighting that hepatic and peripheral leucocyte populations may dif-
fer in autoimmune hepatitis, and possibly suggesting that more activated Tregs migrate to inflamed
tissue.[330, 60, 170] In PBC there is a similar story with regards to Tregs: early reports were made
of reduced numbers of Tregs circulating peripherally and in liver tissue[227, 459], but this has been
challenged in more recent studies.[321]
In addition, evidence that those treated with drugs that interfere with or deplete Tregs may develop
AIH suggests a key role for T cell regulation. TheHirschfield grouphas also recently reported the first
direct association between a complete absence of Treg and AIH in a patient with germline mutation
of GATA2.[465]
Complete deficiency in regulatory T cells.
The key role of Tregs can be demonstrated by examining mice with loss of function mutations in the
master transcription factor controlling the development of regulatory T cells, FOXP3.[113] In mice
the gene for FOXP3 is carried on the X chromosome and a spontaneous mutation affecting FOXP3
in a colony of mice in the Oak Ridge National Laboratory in Tennessee lead to the development of
male mice that developed multi-system autoimmunity including lymphadenopathy, autoimmune
haemolytic anaemia and marked lymphocytic infiltrates of the liver, skin and bowel.[113] Numbers
of CD4+ and CD8+ T cells are greatly expanded, demonstrate increased proliferation, and are hy-
perresponsive to stimulation.[436] Mice generally die at 3-5 weeks of age. It has been noted that the
generalised loss of control of lymphocytes seen in FOXP3 dysfunction is analogous to loss of func-
tion of other key regulatory molecules like CTLA4 and to graft-versus-host-disease.[416, 462, 512]
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These observations weremade before the discovery of FOXP3, but it was later established that muta-
tions in the X-chromosome gene later named FOXP3 were the cause of the syndrome.[42] Formal
identification of and cloning of FOXP3 occurred soon after this identification with the demonstra-
tion that FOXP3 expression identified a subset of CD4+T cells with the ability to suppress the activity
of other effectors T cells.[100, 153, 191] It was clarified that allografting normal bone marrow was
curative[387] and that the disease was primarily driven by CD4+ T cells through the demonstration
of ameliorating effects of their depletion. This contrasted with the ineffectiveness of depletion of
CD8+ T cells.[28]
In humans, the rare condition immunodysregulation polyendocrinopathy enteropathy X-linked
syndrome (IPEX) bears many phenotypic similarities to mice with deficiencies in FOXP3: there
is lymphadenopathy, autoimmune haemolytic anaemia and marked lymphocytic infiltrates of the
liver, skin and bowel accompanied by multiple endocrinopathies including diabetes mellitus.[482]
The disease requires aggressive immunosuppression, with subsequent protection from infection,
and bone marrow allografting for long-term cure.[18] Notably, human IPEX typically represents a
spontaneous mutation and some mutations may result in the persistence of FOXP3-positive cells
but with a relative loss of function.[85]
Strong corollaries between human and mouse conditions are further highlighted by the fact that
transfer of total peripheral T cells from IPEX patients into humanised mice recapitulates the phen-
otype of mouse FOXP3 dysfunction[115] and that IPEX patients’ T cells can be induced to display
a regulatory phenotype by FOXP3 gene transfer.[82]
As a result of their combination of peribiliary hepatitis and the development of AMAs in the con-
text of multi-system autoimmunity, mice lacking FOXP3+ Tregs have been described as a potential
model of inflammatory PBC.[504] By analogy, AMAs are also reported in a proportion of human
cases of IPEX.[422]
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Attenuating autoimmune disease in regulatory T cell deficiency
As a condition representative of loss of regulatory control, numerous interventions have been tried
to ameliorate the autoimmunity of FOXP3 dysfunction. A number of key manipulations of the
FOXP3KO mouse have highlighted several key aspects of the autoimmunity that occurs when there
is a loss of regulatory control (Table 1.1). Firstly, signalling through the TCR is required: when mice
transgenic for a TCR on a RAG deficient background so that all T cells are specific for a non-self an-
tigen are crossed with mice with FOXP3 dysfunction, no disease is apparent. Secondly, CD4s drive
pathology: although both CD4+ and CD8+ cells are greatly increased in number and activation
state in FOXP3 dysfunction, co-deficiency in CD8+ T cells does not protect against disease whilst
disease is slowed by co-deficiency in CD4+ T cells. Thirdly, Th1 type disease is the mechanism that
drives lethality: co-deficiency in the transcription factor Tbet or in IFNγ increase lifespan whereas
deficiency in signal transducer and activator of transcription 6 (STAT6) or IL-4 do not.[377, 402]
Fourth, co-stimulation is important to the generation of pathology: mice co-deficient in CD28 have
a greatly ameliorated phenotype, as do those co-deficient in OX40.[105] Fifth, non αβT cells have a
regulatory role: both B cells and γδT cells are reported to ameliorate disease to some extent.[9, 426]
Interestingly, some interventions have divergent effects on different organ systems. For example,
with co-deficiency in IL-2, skin inflammation is reduced but colitis and hepatitis persist; CD8 de-
pletion is relatively protective for hepatitis but fails to extend lifespan.[507, 377]
1.4 CD28 co-stimulation and CTLA4 control
Co-stimulation of T cells through CD28
Recognition of antigen by a TCR alone is insufficient for full activation of the T cell: cells stimulated
in culture without non-T-cells may become anergic or poorly responsive with reduced proliferation
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Table 1.1: Preventing autoimmunity in FOXP3 deficiency
Co-deficiency Change in phenotype Lifespan Reference(s)
None N/A 4-5 weeks [113]
CD28-/- Reduction in expression of activation markerson lymphocytes; reduced circulating cytokines
25-30
weeks [385]
IL-2-/- Skin inflammation reduced 9-10 weeks [507, 377]
Faslpr/lpr Delay in onset but unchanged phenotype 16-18weeks [507]
AIRE-/- Endocrine organs protected 4 weeks [61]
NOD More severe 3-4 weeks [61]
CD4-/-
No CD4+ T cells; minimal change to eventual
phenotype. Note that CD4-negative T cells are
proposed to fill some of the role of the missing
CD4+ cells.
>12 weeks [28, 271]
β2M-/- No CD8+ T cells; some reduction in hepatitisbut otherwise no change 4-5 weeks [28]
IFNγ-/- Lymphocyte expansion delayed 7-8 weeks [377, 402]
Tbx-/- Lymphocyte expansion delayed 7-8 weeks [402]
IL-4-/- IgE and IL-4, 5 & 13 production decreased 4-5 weeks [377]
STAT6-/- IgE and IL-4, 5 & 13 production decreased 4-5 weeks [402]
IL-10-/- No change 4-5 weeks [377]
Tg.TCR×RAG All T cells express a T cell receptor specific to anon-self antigen; disease is abolished Normalised [499]
µMT-/- No B cells. Reduced autoantibody titres;reduced T cell activation
10-12
weeks [9]
OX40-/- Long delay in onset of otherwise similarphenotype 30 weeks [105]
CD30 -/- Short delay in otherwise similar phenotype 6-7 weeks [105]
γδ T cells Reduced organ inflammation includingreduced hepatitis; reduced T cell expansion
Not
reported [426]
Table adapted and expanded from Ju et al.[182]
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and reduced cytokine production.[171]This observation has been demonstrated to relate to a lack of
co-stimulation through the CD28 molecule, with ligating antibodies to the CD28 molecule able to
restore responsiveness to pure T cell cultures.[265] The reverse – administration of an antibody that
prevented signalling throughCD28 –was able to prevent a specific immune response to transplanted
pancreatic islet cells.[234]
CD28 is the initial member of a subfamily of co-stimulatory molecules characterised by a variable
extracellular immunoglobulin-like domain. Other related molecules in the family include ICOS,
CTLA4 andPD-1.[94]CD28 is constitutively expressed onmouse T cells and expressed by amajority
of human T cells.[126, 94]
The ligands for CD28 are CD80 and CD86, together known as B7. The expression of both CD80
and CD86 are variable and is upregulated by the activation of antigen-presenting cells. Primarily
this occurs through the ligation of pattern recognition receptors (PRRs) such as TLRs and repres-
ents a link between the adaptive and innate immune systems where greater antigen-presenting cell
(APC) activation will in turn provide stronger co-stimulatory signals to the T cell recognising the
antigen.[165] Activation of APCs also increases antigen presentation.
Cellular effects of CD28 ligation
The cytoplasmic domain of CD28 has no intrinsic enzymatic activity but contains highly conserved
tyrosine motifs that become phosphorylated after both CD28 ligation and TCR engagement.[94]
Once phosphorylated, these motifs complex with a number of kinases and adaptor proteins which
initiate signalling cascades that end in altered transcription, primarily through the NFκB, NFAT and
AP1 pathways.
Ligation of CD28 has numerous cellular effects on T cells. These include augmentation of TCR
signalling[30], promotion of formation of the immunological synapse (or supramolecular activa-
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tion cluster) of signalling molecules that forms around ligated TCRs[493], promotion of cellular
actin remodelling[493], upregulation of anti-apoptotic proteins such as BCLXL[192, 464], increased
IL-2 transcription through NFAT, AP-1 and NFκB[101, 464], mRNA stabilisation resulting in in-
creased production of cytokines including IL-2 and other effector cytokines too[242, 340], increased
vesicular transport, enhanced DNA replication and repair[94], and upregulation of secondary co-
stimulatory molecules such as CD40L[201] and OX40[448]. Additional effects on Tregs include
promoting the thymic development of thymic-derived cells[405] and peripheral differentiation into
pTreg development of iTreg[130], maintenance of Treg survival separate from IL-2[503] and pro-
motion of Treg CTLA4 and PD1 expression[503].
T cells stimulated in the absence of CD28 co-stimulation lacking the above effects are typically de-
scribed as anergic, where there is a general reduction in proliferation and effector function that is
partially reversible by exposure to IL-2 or OX40.[367]
CTLA4
The molecule CTLA4 has close homology to CD28 and binds CD80 and CD86. In both mice and
humans, the gene for CTLA4 is located near to that for CD28 – on chromosome 1 in mice and on
chromosome 2 in humans. CTLA4 is constitutively expressed by FOXP3+ Tregs and is expressed on
conventional T cells after activation through the TCR and especially after co-stimulation through
CD28.[357]
Mice deficient in CTLA4 demonstrate multi-organ lymphocytic inflammation with activated T cells
and succumb to their generalised autoimmune disease at around five weeks of age.[416, 462] The
phenotype of these mice is similar to that seen in FOXP3 dysfunction, but differs in that there is
typically myocarditis and pancreatitis, but less overt skin involvement.
As exemplified by the effects of its deficiency, CTLA4 has an immunosuppressive role. A num-
35
ber of mechanisms for this have been proposed and include outcompeting CD28 for its ligands
CD80 and CD86, to which CTLA4 binds with higher affinity.[451] It has also been suggested that
CTLA4 may have phosphatase activity and so negatively regulate the phosphorylation that is in-
duced by CD28 signalling.[232] Additionally, the ripping, or transendocytosis, of CD80 and CD86
from antigen-presenting cells, so preventing their further co-stimulatory action.[346] Controver-
sially, reverse signalling through CTLA4’s ligands CD80 and CD86 and induction of immunosup-
pressive indoleamine 2,3-dioxygenase (IDO) by dendritic cells has been proposed as one mechan-
ismof immunsuppression.[276]However, CTLA4 blockade remains immunogenic in IDO-deficient
mice.[151] Finally, direct signalling through CTLA4 has also been proposed to regulate cell func-
tion, but this is not consistent and is disputed by some authors.[207, 450]
Recently two cohorts of humans heterozygous for loss of function mutations in CTLA4 have been
described.[222, 366]These have varying patterns of autoimmunity with lymphocytic infiltration of a
variety of organs alongside autoantibodies. The pattern of autoimmunity is similar to that seen with
administration of the blocking anti-CTLA4 antibody ipilimumab[475] and is alleviated by treatment
with CTLA4 immunoglobulin (CTLA4Ig).[233]
Manipulations of CTLA4-deficient mice
Similar to the situation in FOXP3 dysfunction, there is an ongoing requirement for CTLA4 through
life. One model demonstrating this is a transgenic mouse in which a LoxP flanked CTLA4 gene
may be selectively deleted in adulthood by inducing transcription of a Cre recombinase using a
tamoxifen-sensitive promoter.[205] These mice develop multi-system lymphocytic inflammation
in a similar pattern to constitutively deficient animals. It has been demonstrated that the lethal
autoimmunity of CTLA4 deficiency is dependent on interactions between the co-stimulatory re-
ceptor CD28 and its major ligands CD80 and CD86: deficiency in either prevents disease.[261, 262]
A number of key experiments have clarified the in vivo role of CTLA4 (Table 1.2): First, given
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that it has been proposed that both CD28 and CTLA4 interact with ligands other than CD80 and
CD86[58], two experiments have clarified that it is in fact the interactionwithCD80 andCD86 that is
dominant. Firstly,mice deficient inCD28 andCTLA4donot develop significant autoimmunity[262]
and in a complementary experiment,mice deficient inCTLA4, CD80, andCD86 are also protected.[261]
Secondly, the creation of a mouse chimeric for wildtype and CTLA4-deficient bone marrow resul-
ted in complete protection from CTLA4-deficiency disease. This included the demonstration that
neither subset of cells developed the upregulation of activation markers typically associated with
CTLA4 deficiency disease.[13] Thirdly, experiments employing CTLA4-deficient regulatory T cells
have demonstrated that deficiency on this subset is sufficient to allowunchecked autoimmunity.[483]
Fourthly, similarly to the requirement for FOXP3, there is a peristent requirement for CTLA4 ex-
pression through life and inducible deletion precipitates lethal autoimmunity.[205] Fifthly, interac-
tions with self-antigens are key: T cell transfer from CTLA4 deficient mouse peripheral organs are
specifically reactive with the same organs in other mice.[162] Manipulations of mice deficient in
CTLA4 are discussed in (Table 1.2).
1.5 Immune checkpoints as therapeutic targets
Recent years have seen a large increase in the use of immune checkpoint inhibitors for the therapy of
human diseases, primarily in use in the treatment of cancers (Figure 1.14). These drugs inhibit the
action of immunoregulatory molecules to provoke an increased immune response to cancers. Their
marked efficacy first became apparent in the treatment of metastatic melanoma, an immunogenic
cancer with poor survival[149], but their use is broadening to multiple different cancer types[325],
with new applications reported frequently.[376, 281, 104]
At present two major classes of immune checkpoint inhibitors are in clinical use: those directed
against CTLA4 and those directed against either PD-1 or its ligand PDL-1.
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Table 1.2: Preventing autoimmunity in CTLA4 deficiency
Intervention Change in phenotype Reference(s)
CTLA4 deficiency
alone
Massive lymphocyte activation and
expansion, multi-organ infiltration
and early death
[462, 416]
CTLA4Ig Reversal of disease [190]
Deplete CD4+ T cells Disease prevented [55]
Deplete CD8+ T cells Little change to organ infiltration [55]
CD80-/-CD86-/- Disease prevented [262]
CD28-/- Disease prevented [261]
CTLA4-/- and WT bone
marrow chimera Disease prevented [13]
Depletion of CTLA4 in
adulthood
Multi-organ infiltration, lymphoid
organ enlargement and early death [205]
Depletion of CTLA4 on
Tregs only†
T cell activation and expansion,
slowed multi-organ infiltrate and
much delayed death
[166]
Depletion of CTLA4 on
Tregs only†
Rapid autoimmunity, T cell
activation, organ infiltration and
death
[483]
Depletion of Treg
CTLA4 in adulthood
Some cell activation, no
multisystem autoimmunity, relative
resistance to induction of
experimental allergic
encephalomyelitis (EAE)
[327]
†Note: different mouse backgrounds used
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Figure 1.14: Use of immune checkpoint inhibitors is increasing. Graph shows sales to date and estimated
future sales of major immune checkpoint inhibitors in the United States, France, Germany, Italy, Spain, United
Kingdom and Japan. Sales shown in US$ million. Figure redrawn from Webster, 2014.[476]
CTLA4 blockade as immunotherapy
As discussed above, the major function of CTLA4 is to negatively regulate effector T cell activation
largely throughmodulation of signalling throughCD28. Preventing the action of CTLA4with drugs
such as ipilimumab (IgG1) and tremelimumab (IgG2) may therefore increase signalling through
CD28 and promote an adaptive immune response. The primary mechanism of anti-CTLA4 med-
ications has been however been the source of some debate. Suspicions as to whether anti-CTLA4
antibodies could penetrate the immune synapse lead to a search for othermechanisms: an alternative
major mechanism is the suggestion that the primary clinical activity is through depletion of Tregs,
and it has been suggested that reductions in Treg numbers correlate with clinical response.[384, 354]
Conversely however, mice made to express human CTLA4 on effector T cells and murine CTLA4
on Tregs through combinatorial adoptive transfer from transgenic hosts develop more significant
immune activation with selective blockade of the CTLA4 on effector cells but not with blockade of
CTLA4 on Tregs.[329]
Consistent with their role as inhibitors of immunomodulatory function, inhibitors of CTLA4 are
associated with the induction of autoimmunity. Most commonly this includes colitis[475, 21], but
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may also include hepatitis[195, 119, 177] and a variety of other organs.[441] Such immune-related
adverse events are frequent and affect up to 68% of those treated with ipilimumab, the most widely
used anti-CTLA4 agent.[474]
PD1/PDL1 blockade as immunotherapy
The second major class of immune checkpoint inhibitors in current use is those that inhibit inter-
actions between the receptor PD-1 and its ligands, which include PDL-1.[325] Ligation of PD-1 de-
creases cytokine production by T cells and promotes apoptosis and it has been proposed that the sys-
tem therefore represents a negative feedback mechanism to prevent damage to self tissues during an
immune response. Whilst the human anti-PD-1 agents nivolumab and pembrolizumab and the anti-
PDL-1 agent atezolizumab are effective as cancer immunotherapies, similar to anti-CTLA4, they too
have a high rate of immune-related adverse events, which include hepatitis.[266, 108, 513] Similarly
to anti-CTLA4 therapy there has also been speculation that nivolumab also depletes Tregs.[409]
As the use of immune checkpoint inhibitors continues to grow for the therapy of cancer, the incid-
ence of immune-related adverse events is also likely to grow and this new frontier of autoimmunity
represents a key area for future control. The frequent hepatitic reactions in response to these drugs
may be considered a subtype of autoimmunity.
1.6 OX40, OX40L and the TNF-receptor ligand family
The tumour necrosis factor receptor superfamily represents a related group of at least 17 transmem-
brane cytokine receptors primarily expressed on leucocytes.[257]The family receives its name froma
shared ability to bind tumour necrosis factors through cysteine-rich extracellular domains.[135]The
receptors may respond to both soluble and membrane bound ligands and the receptors are chiefly
expressed on immune cells.[463] Ligation of TNF-receptors tends to have stimulatory effects on
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T cells, but may also be inhibitory. Because the expression of many of the TNFR receptors and their
ligands is altered, and typically increased, after leucocyte activation, the TNFRs have been referred
to as secondary co-stimulatory molecules.[72]
There is marked heterogeneity in sequence between the receptors of the superfamily with little ho-
mology in either extra- or intracellular domains consistent with ligand specificity amongst family
members and a number of diverse signalling effects.[158] The tumour necrosis factor receptor su-
perfamily has numerous functional roles.[460] These include altering the functional adjuvant qual-
ities of antigen-presenting cells including dendritic cells[179, 294], in the development of lymph-
oid structures[199], in mediated cell death, in modulating the innate immune response[11], and
in mediating apoptotic stimuli.[444] In T cells, TNF receptor signalling modulates survival, pro-
liferation, cytokine production, and cytokine polarisation.[72, 73] As such, compounds altering
receptor-ligand interactions have been proposed as potential therapeutic targets for the manage-
ment of autoimmunity.[99]
OX40 and OX40L
OX40 (TNFSFR4) and its ligand OX40L (TNFSF4) represent a cognate tumour necrosis factor re-
ceptor and ligand pair. OX40 has also been referred to as CD134 and OX40L has also been referred
to as CD134L, CD252 and gp34: the names OX40 and OX40L will be used hereafter.
OX40 and OX40L are relatively typical of the TNFR and TNF superfamilies: OX40 has a cysteine-
rich extracellular domain, a single transmembrane domain and trimerises when acting to form a re-
ceptor. OX40L is a type II transmembrane protein expressed in trimeric form. One trimeric OX40L
molecule binds to three OX40 molecules with high affinity and slow dissociation.[471]
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Expression of OX40 in health
Since its identification, the expression profile of OX40 has been confirmed as being predominantly
expressed on activated lymphocytes, and, amongst these, predominantlyCD4+T cells; recently how-
ever there have been reports of expression on intrahepatic iNKT cells.[226]On humanCD4+T cells,
there is no expression of OX40 at rest, although in Tregs constitutive expression is reported.[408]
Expression is seen on activated, memory and regulatory CD4+ T cells[47, 389, 74], at lower levels
on activated CD8+ cells[293] but not on naïve cells. OX40 expression is also a marker of thymic T
cells receiving positive selection signals[204]. Further, lower-level OX40 expression is reported on
NKT cells[500, 226], NK cells [275] and neutrophils[20].
TCR ligation alone is sufficient to drive OX40 expression on CD4+ T cells, but co-stimulatory liga-
tion of CD28 augments expression, as does CD40-CD40L ligation.[448, 355] IL-2may induce OX40
on T cells and IL-1 and TNF also contribute.[353, 72] Further, the proteins Roquin 1 and 2 act as
posttranscriptional regulators of protein expression and appears to act to degrade OX40 mRNAs:
deficiency in functional Roquin results in increased expression.[439]
Reports on the time-course of OX40 expression vary, but typically expression on previously un-
stimulated CD4+ T cells reaches maximal 48 hours after TCR stimulation in both mouse [121] and
human.[360] Murine memory T cells will re-express OX40 within 4 hours of restimulation.[121]
Such rapid re-expression of OX40 also appears to be partly regulated by Sp1/Sp3, YY1 and NFκB.
NFκB histone acetylation has been demonstrated in memory T cells, which express OX40 in a few
hours on stimulation.[418]
Consistent with observations that it is restricted to activated T cells, OX40 expression is often con-
fined to sites of inflammation and immune activation in human disease.[398] In myelin-immunised
rats, which go on to develop EAE, OX40 denoted those T cells that were specific for myelin[478] and
that OX40 demarcates antigen specificity is also true after Th1-type response promoting Listeria
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infection.[264] In humans, OX40 expression on T cells has been reported to identify autoreactive
cells in various autoimmune conditions including type 1 diabetes mellitus.[92]
Expression of OX40 ligand
OX40L expression is upregulated after antigen-presentation on multiple antigen-presenting cells:
these include B cells [245], macrophages[185] and dendritic cells,[172] The repertoire of cells that
can be induced to express OX40L is wider than for OX40 and reports exist of expression on mast
cells[186, 298], bronchial smooth muscle[216], malignancies [46], vascular endothelial cells [159],
and Langerhans cells[363]. There is constitutive expression on lymphoid tissue inducer cells.[198]
Factors promotingOX40L expression other than antigen presentation and accompanying co-stimulation
include IFNγ, in an IFNγ-receptor dependentmechanism[456, 223], prostaglandin E2 [215], thymic
stromal lymphopoietin (TSLP)[164] and IL-18[270]. Finally, human serum solubleOX40L increases
with age.[453]
Expression of OX40L on T cells
The original description of OX40L was as an unidentified glycoprotein on human CD4+ T cells fol-
lowing human T-lymphotropic virus (HTLV) infection of human CD4+ T cells.[420, 282] This was
later identified as OX40L.[19, 407] Subsequently, there have been reports of OX40L expression on
both human[211, 210] andmurine T cells[197] without viral infection, includingmarked expression
on gut-derived CD8+ intraepithelial lymphocytes.[452]
On antigen-presenting cells, OX40L is minimally expressed on quiescent cells, however expression
is upregulated by activation.[352] In addition the cytokines IL-18, tumour necrosis factor-alpha
(TNFα), and TSLP are all reported to upregulateOX40L, as is signalling throughCD40.[313, 97, 148,
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164, 270] Expression is also reported to be increased by may be enhanced by IL-12 exposure, with
CD4+ cells showing greater expression than CD8+.[278, 393]. On neonatal CD4+ CD3- lymphoid
tissue inducer cells, TNF-like protein 1A (TL1a) induces expression of OX40L.[198]
In contrast to the situation for OX40, factors controlling expression of OX40L on T cells are poorly
described. However, similar to OX40, T-cell receptor ligation is required for expression.[452]. These
andother factors that appear to influence expression ofOX40LonT cells are summarised asTable 1.3.
Similarly, the function of OX40L expression on T cells is uncertain, although one analysis suggested
that a reduction in T cell:T cell interaction reduced proliferation and reduced survival both in vitro
and in vivo.[393] Much other work in this area has involved animals with a generalised deficiency
or over-expression of OX40L. Effects cannot therefore be attributed to changes in T cell OX40L
expression alone.[294, 295]
Functions of OX40-OX40 ligand interactions
Ligation of OX40 produces a range of effects (Figure 1.15). Experiments with a soluble form of
OX40Lhave shown that its engagement amplifiesT cell proliferative responses to a range of stimuli.[114]
Activation does not affect early proliferation and activation, but controls late proliferation and ac-
tivation states (Figure 1.15).[355, 393]
In vivoworkhas shown thatOX40 ligationpreferentially expands the antigen-specificT cell pool.[120,
269] Correspondingly, there is reduced CD4+ expansion in OX40 or OX40L deficient mice and con-
stitutiveOX40L expression by eitherDCs[40] or T cells[295] results in a greater numbers of activated
CD4+ T cells, and transfecting dendritic cell (DC)s with OX40L messenger RNA (mRNA) increases
their CD4+ T cell stimulatory potency and increases T cell polarisation.[78]
OX40 ligation results in augmentation of effector cytokine production[121] and prolongation of ac-
tivation, and this is partially mediated through stabilisation of mRNA.[280]. An important mech-
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Table 1.3: Factors reported to influence the expression of OX40L on T cells
Reported to increase OX40L
expression on T cells
Reported to decrease OX40L
expression on T cells
Mouse
Signalling through
TCR.[452] IL-4.[196]
Th0 conditions i.e. anti-IL-4
and anti-IL-12.[196] IFNγ.[278]
IL-12.[278]
STAT4 activation.[278]
Lower concentrations of
antigen or stimulatory
antibody.[278]
Human
Signalling through the T cell
receptor.[211] IL-12.[211]
DNA damage.[210] TGFβ.[211]
Co-culture with OX40L
expressing Chinese Hamster
Ovary (CHO) cell line.[39]
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OX40
OX40L
Cytokines
Cytokines
Cytokine production
Increased effector phenotype
Increased survival Increased mobility
Reduced regulatory phenotype Perpetuation of activation
IL-2, IL-4, IL-5, IL-17, IFN-γ (T)
IL-1, IL-6, IL-12 (APC)
Chemokine 
receptors
Chemokine receptor expression
(Including CXCR5)
Reduced L-selectin expression
↑ Bcl-2
↑ Bcl-xL
↑ BCL2A1
↓ FAS
↓ FoxP3
CD4⁺ T-cell
APC
IL-2Rα expression, IL-2 production
T-cell OX40L expression
Reduced CTLA-4 expression
Reduced TGFβ1 expression
Reduced FoxP3 expression
Increased Bcl-2, Bcl-xL, 
BCL2A1 expression
Reduced FAS expression
Increased IL-12Rβ2 expression
Increased Th1, Th2, Th17 polarisation
IL-2R
IL-2CTLA-4
TGF-β1
TRAFs
IL-12R
IFN-γ
Signaling 
molecules
NFκB
PI3KERK
AKT
Figure 1.15: Effects of OX40-OX40L interaction. Summary diagram of the effects of OX40-OX40L inter-
action. Major effects of OX40 ligation are highlighted in bold with effector mechanisms below. Arrows denote
positive effects; barred lines denote negative effects; dashed lines show relations. Adapted from Webb et
al.[471]
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anism by which T cells may prolong activation is through T cell:T cell interactions. By expres-
sion of both OX40L and OX40 on activation, T cells may stimulate other T cells, so sustaining
activation.[393]Thus, proliferation is reduced in stimulated pure T cell cultures byOX40L blockade.
An intriguing observation with relevance to autoimmunity is that T cells activated through OX40
become resistant to subsequent regulation by Treg.[408]
The direction of T cell polarisation is dependent on the cytokine milieu and may favour Th1, Th2
[164, 172], Th9 [487] or Th17 [506] type cytokine profiles depending on circumstances; naïve T cells
predominantly produce IL-4.[314] OX40 ligation’s general net effect of promoting immune activa-
tion was demonstrated in a landmark experiment where a single dose of agonistic OX40 antibody
was demonstrated to break tolerance that had been induced to an exogenous peptide.[15]
OX40 and T cell regulation
Both mice and humans lacking OX40 have reduced numbers of natural Tregs alongside a reduc-
tion in other non-naïve T cell subtypes.[408, 46] Correspondingly, mice that constitutively express
OX40L on T cells have increased numbers of Tregs in their spleens alongside autoimmunity.[295]
OX40, together with the other TNFR superfamily members, appears to couple the signal strength
of TCR signals and modulate sensitivity to IL-2.[258] Given that both TCR signal strength and IL-2
receptor signalling contribute to thymic Treg selection, this is consistent with the observation that
OX40 marks thymic T cells receiving signals of positive selection.[204]
OX40 agonists can drive Treg expansion in TGFβ-treated cultures, although again the cytokine mi-
lieu is key. If IFNγ and IL-4 are present, there is preferential expansion of effector CD4+; with
blockade of IFNγ and IL-4, there is Treg expansion.[356]. However, OX40 stimulation without IL-2
produces weakly proliferating, poorly suppressive Treg whilst exogenous IL-2 is sufficient to correct
this.[487]. Further experiments in lymphocyte cultures treated with the combination of anti-CD3
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and anti-CD28 antibodies with exogenous IL-2 have suggested a Treg inhibiting role of OX40: in
vitro TGFβ-driven conversion to Treg is reduced by OX40 ligation in both mouse and human.[389,
440] In a variety of carcinoma models, agonistic anti-OX40 injected into tumours causes Treg de-
activation and depletion, and also mediated tumour regression.[335] Similarly, the expansion and
regulatory capability of established ‘ICOS+IL-10+’ or Tr1 Tregs is inhibited by OX40.[163, 440]
OX40-deficient Treg appear to have reduced suppressive function.
In a study of transfer colitis, Tregs lacking OX40 were ineffective at correcting disease whereas their
replete counterparts were effective [124], and in a skin allograft model, OX40 treated Tregs were less
able to suppress rejection, effector T cell proliferation or IFNγ production.[442]
OX40 interactions facilitate adhesion and migration
OX40-OX40L interactions facilitate the adhesion of activated T cells to endothelia and their sub-
sequent transmigration. Blockade ofOX40L has been demonstrated to reduce T cell adhesion to cul-
tured vascular endothelial cells.[159] In mice with constitutive OX40L expression on dendritic cells,
there is greater accumulation of CD4+ T cells in stimulated lymphoid tissue and this has been inter-
preted as evidence of increased migration, although increased proliferation cannot be excluded.[40]
OX40 deficient T cells proliferate faster in vitro than OX40-sufficient T cells but survive less well.
OX40-OX40L interactions upregulate a number of molecules implicated in migration: CXCR5,
which is associated with trafficking to germinal follicles [448] but also sites on inflammation[310];
CXCR4[181]; and RANTES/CCL5[214]. In animals, there is evidence that OX40 deficient T cells
may be impaired fromreaching sites of inflammation in addition to their reduced effector function.[141,
310, 124]
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OX40 and OX40 ligand aberrations in transgenic mice
A key study highlighting OX40-OX40L interactions’ role in autoimmunity was performed in 2002
when Murata and co-workers generated mice transgenic for TNFSF4 with the transgene under the
control of the lck promoter.[295] This resulted in the constitutive expression of OX40L on all T cells.
Phenotypically, these mice had greatly elevated numbers of CD4+ T cells of which an increased
proportion were of a memory phenotype, greatly enlarged lymphoid organs, enhanced antigen-
specific T cell responses as measured by proliferation and cytokine production, increased serum
antibody concentrations and Th2-type cytokines prior to stimulation and – perhaps most interest-
ingly – multi-lineage infiltrates of both lung and colon; these changes were prevented by the admin-
istration of a blocking OX40L antibody. A further interesting observation from the study was that
autoimmunity was only induced in C57BL/6 mice and not BALB/c, perhaps relating to the former’s
greater tendency to produce Th1-type immune responses. Of note, autoimmunity may be similarly
induced with constitutive expression of other TNFR ligands such as LIGHT.[374]
If OX40L is constitutively expressed on dendritic cells, increased numbers of CD4+ T cells are seen
in B-follicles and these cells are of a more activated phenotype after immunisation with an antigenic
nitrophenol conjugate but not at rest or after lipopolysaccharide alone. In contrast to mice with
over-expression of OX40L on T cells, there is not overt autoimmunity.[40]
Mice deficient in OX40 were generated in the late 1990s. Such mice breed normally and appear able
to generate both immunoglobulin M (IgM) and IgG subclass responses to pathogens such as vesicu-
lar stomatitis virus and also to haptenised proteins withmaintained germinal centre formation.[213,
336] CD8+ cytotoxic lymphocyte responses are maintained, but stimulated CD4+ T cells show re-
duced proliferation and IFNγ responses to viruses. However, viral response in OX40 deficiency
appears variable and numbers of infiltrating cells on bronchoalveolar lavage in response to influ-
enza virus were reduced in OX40 deficient animals.[213] Similarly, the generation of CD4 memory
is greatly impaired in total OX40 deficiency, although haplosufficiency of OX40 appears sufficient
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for a phenotypically normal CD4+ response.[120]
Rationale for targeting OX40-OX40L interactions in autoimmunity
OX40-OX40 ligand interactions form part of pathogenic pathway in a number of human diseases
and animal models. Thus, whether aberrations in such interactions form part of aetiopathogenesis
and initiation of autoimmunity themselves as in constitutively OX40L expressing mice or whether
they are resultant on other pathways, preventing their activation may ameliorate disease.[295]
Firstly, blockade of OX40-OX40L interactions ameliorates autoimmunity in a number of models
of human autoimmunity (Table 1.4). As identified above, in certain models the effect of OX40-
OX40L blockade is superior to T cell depleting therapies alone.[105, 131] This supports exploration
of interruption of OX40-OX40L signals in human diseases characterised by loss of T cell regulation.
Secondly, OX40-L should provide inherent targeting to areas of immune activity: expression is
largely confined to activated cells and especially autoantigen-specific cells.[478, 264] Certainly in-
creased expression of both OX40 and OX40L is reported in a number of human autoimmune con-
ditions (Table 1.5). Such site-specificity has been demonstrated clinically by OX40 upregulation on
the T cells of inflamed tissue but not in peripheral blood in both human colitis and rheumatoid
arthritis.[111, 454].
Thirdly, the ideal therapy in autoimmunity would provoke the re-establishment of immune toler-
ance. The observation that activation through OX40L may render T cells resistant to regulatory
signals makes this a logical target.[408, 454] Further, in systems such as CD40L-deficient islet cell
allograft recipients, OX40 agonism or blockade alone is enough to determine graft tolerance.[59]
Fourthly, migration of activated T cells across endothelia appears to be at least partly dependent
on OX40-OX40L.[159, 160] This observation, coupled with apparent selective tissue expression in
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certain autoimmune disease states suggests that inhibition of the interactionmight reducemigration
into inflamed areas.[10] Work in EAE mice suggests that pathogenic T cells may persist after OX40
blockade, but that they are no longer able to migrate to target sites.[307]
Fifthly, OX40-L blockade appears to be effective after disease onset – e.g. in a diabetes model.[322]
Although several animal studies have demonstrated that OX40-L inhibitionmay ameliorate autoim-
munity, many have used OX40/L blockade at, or before, disease onset: something that differs from
the clinical situation in which a patient will present for treatment after symptom onset making the
observation in diabetic mice particular important.
Sixthly, topical therapy is feasible and effective inmousemodels e.g. OX40-agonists intra-tumour[335]
or intravitreal OX40L blockade in a uveitismodel have powerful disease-modifying effects from top-
ical application alone.[502]
Seventhly, and of particular importance, is the fact that OX40 and OX40L have been recorded as
being upregulated in a variety of human autoimmune disease (Table 1.5). To date, no assessment
of expression in human liver tissue affected by autoimmune disease or other pathologies has been
reported.
A final and particularly promising aspect of targetingOX40-OX40L for the therapy of autoimmunity
is the lack of severe side effects in the animal studies reported above and the long-term relative health
of OX40 deficient mice and the single OX40 deficient human reported to date (with the caveat of the
development of treatment-resistant Kaposi’s sarcoma) suggests a low side-effect burden.[213, 46]
The one trial of humanised anti-OX40L did not cause significant adverse effects.[107]
1.7 Animal models of autoimmune liver disease
In order to make preliminary assessments of the efficacy of therapeutics and their immunological
effects taking into account the multiple immunological interactions within an organism, in vivo
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experiments are necessary. This thesis aims to address whether liver autoimmunity may be reduced
by interruption of OX40-OX40L interactions and therefore animal models that recapitulate features
of human AILD are required.
Numerous investigators have sought to develop models of autoimmune liver disease. For PBC the
major requirements of an animal model have been interpreted as peri-biliary inflammation in the
context of the development of AMAs. In AIH, T lymphocyte-mediated liver damage – as demon-
strated by elevations in serum transaminase activities – has been interpreted as sufficient to describe
a model as reminiscent of human autoimmune hepatitis[139], but in other models the presence of a
lymphocytic infiltrate, hypergammaglobulinaemia and the development of fibrosis have improved
representativeness.[470]
There is a convergence between described mouse models of PBC and of AIH towards models in
which T cell regulation is derranged.[470, 235, 338] A multitude of different interventions in this
pathway produce lymphocytic peri-biliary hepatitis alongside autoimmunity in other organs, with
the expression of AMAs alongside other autoantibodies in many models (where they are reported).
Thus parallels may be drawn between mice lacking functional FOXP3[504], IL-2, the IL-2 receptor
alpha subunit[446], those expressing a dominant negative TGFβRII subunit on T cells (which im-
pairs the generation of regulatory T cells), AE (which is key for Treg survival) [361], thymectomised
mice lacking PD-1, AIRE-deficient mice, mice with medullary thymic epithelial TRAF6 dysfunc-
tion, and mice with global TGFβ dysfunction (Tables 1.6 & 1.7).
Notably, similar to observations in human diseases, the various mouse models of PBC and AIH
demonstrate upregulation of cytokines associated with all T cell subtypes[504] and in numbers of
T cells with these phenotypes[491], but with the predominant subtype being Th1. In addition, many
of these mouse strains have documented evidence of extra-hepatic autoimmunity consistent with
their reported hepatic inflammation being a product of a systemic tendency to autoimmunity.
Of relevance to considering the role ofOX40 in autoimmunity involves considering its hyper-expression.
52
Roquin 1
Roquin 2
sanroque
RckEdc4
Rck Edc4
Roquin 2
Nucleus
ICOS & 
OX40 
mRNAs
Controlled levels  
of mRNA Excess mRNA
degradation no degradation
Regulated ICOS & 
OX40 translation
Excess ICOS & 
OX40 translation
Figure 1.16: Schematic depiction of post-transcriptional regulation of ICOS and OX40 mRNA by
Roquin. mRNA encoding both ICOS and OX40 is transcribed in the nucleus. Usually, a proportion of this
is degraded before translation into functional protein in a process of post-transcriptional regulation. Either
Roquin 1 or Roquin 2 binds the 3-prime untranslated regions of ICOS or OX40 mRNA where they stabilise
the binding of two RNA decay proteins known as Edc4 and Rck and collectively facilitate degradation. Re-
ducing the amount of mRNA to be translated into protein regulates the amount of ICOS and OX40 ultimately
produced. Because the actions of Roquin 1 and 2 in this regard are redundant (although Roquin 1 binding is
preferential), if one or the other is dysfunctional, the other may take its place. In the sanroque mutation, there
is a mutation in Roquin 1. The mutant Roquin 1 protein retains the ability to bind mRNA but does not stabilise
binding of Edc4 and Rck and so does not degrade mRNA. As such, more mRNA is available for translation
into functional protein and hyper-expression with resultant autoimmunity follows.[24, 439, 341, 167] (Image
adapted from [24])
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An additional model of loss of immune control is the Roquin sanroque mutant mouse. The RNA-
binding proteins Roquin 1 and Roquin 2 usually function to stabilise proteins that act to degrade
messenger RNA for the co-stimulatory molecules OX40 and ICOS acting as a limiting factor on
their expression (Figure 1.16).[497, 439] However, in mice with a single amino acid substitution
from methionine to arginine (M199R) in the ROQ domain of the regulatory protein Roquin 1 –
so-called Roquin mutant or sanroque mice – there is reduced degradation of both OX40 and ICOS
with resultant autoimmunity. These mice homozygous for the sanroque mutation (RoquinM/M) de-
velop splenomegaly, lymphadenopathy, autoantibodies to nuclear proteins, glomerulonephritis and
lymphocytic hepatitis.[438, 497] In addition, the wide expression of ICOS ligand means that signals
through ICOS arewidely available and are able to replace some of the requirement for co-stimulation
through CD28.[244] Notably, the function of mutant Roquin is to actively stabilise mRNA and is
more than just a loss of pro-degradation function of the intact wildtype protein: total deficiency in
Roquin does not result in similar autoimmunity.[25]
Of additional interest when considering the RoquinM/M mice as potential models of liver autoim-
munity is that as well as hyper-expression of OX40 and ICOS, these mice over-express IFNγ. As
mentioned above, it has recently been shown that hyperexpression of IFNγ alone is sufficient to
cause lymphocytic hepatitis and the development of AMAs.[14]
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1.8 Summary
The adaptive immune response may be misdirected against self-antigens. The result is autoim-
munity. Autoimmunity may cause organ damage and major clinical disease and its prevalence is
increasing. Autoimmune liver disease is also becoming more prevalent, with a proportion of pa-
tients resistant to standard therapies and going on to require transplantation to avoid death.
Of the autoimmune liver diseases, the two most frequent – AIH and PBC – display multiple char-
acteristics that suggest a key role for CD4+ T cells in their pathogenesis. The activation of CD4+
T cells may be controlled by the actions of regulatory T cells and by modulating signals through
co-stimulatory molecules expressed on CD4+ T cells such as CD28 and the tumour necrosis factor
receptorOX40. Many existingmousemodels of human autoimmune liver disease usemanipulations
of CD4+ T cell regulation to produce their phenotype.
OX40-OX40L interactions have important pro-effector activity for T cells and modulation of signals
through the receptor-ligand pair has been shown to ameliorate autoimmunity in a number of mouse
models of human autoimmune diseases. In addition, their expression is abnormally upregulated in
a variety of human non-liver autoimmune diseases. A potential role for OX40 in autoimmune liver
disease in either mouse models of autoimmune liver disease or human patients has not been invest-
igated to date. Using mouse models of defective T cell regulation provides an experimental platform
in which a potential role for blocking OX40-OX40L for therapeutic effect may be investigated.
1.9 Aims
The aims of this thesis relate to the control of CD4+ T cells by Tregs and by the interactions of OX40
and OX40L.
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1. To establish a Treg deficient model of liver injury that re-capitulates findings reported else-
where, to demonstrate that the disease of Treg deficiency could be transferred between anim-
als, and to explore requirements for its generation.
2. To assess whether prevention of OX40-OX40L signals could control autoimmune liver disease
in the context of Treg deficiency.
3. To assess whether prevention ofOX40-OX40L signals could control disease in a secondmouse
model of regulatory failure resulting in generalised and hepatic autoimmunity: the CTLA4-
deficient mouse.
4. To assess whether prevention of OX40-OX40L signals could control disease in amousemodel
of regulatory failure resulting fromexcessive co-stimulation and IFNγproduction: theRoquinM/M
mouse.
5. To assess factors controlling OX40L expression on CD4+ T cells.
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Table 1.4: Effects of blocking OX40-OX40L on models of autoimmune disease
Disease and model Intervention Effect
Systemic lupus
erythematosus
BXSB mouse
Combined OX40 and
CTLA-4 blockade of
splenocytes in vitro
Reduced proliferation with
combined blockade but not
either agent alone.[509]
NZB×NZW F1 mouse
Agonist OX40 exacerbated
renal disease and
increased inflammatory
cytokines; inhibitory
anti-OX40 fusion protein
ameliorated disease.[386]
Colitis
Dextran sulfate
sodium-induced colitis in
mice
Blocking OX40-IgG fusion
protein
Reduced clinical score, T cell
migration to lamina propria
and T-bet mRNA
transcription[310]
Transfer colitis in mice Neutralising OX40L Ab
Reduced histological score, T
cell infiltrates and weight
loss[260, 419]
Transfer of
OX40-deficient Tregs
Unable to control colitis in
contrast to intact Tregs[124]
IL-2-/- mice Antagonistic OX40-IgGfusion protein
Amelioration of histology,
reduced T cell infiltrate and
reduced pathogenic
cytokines including IL-12,
IFNγ and TNFα[141]
Hapten-induced
(intrarectal
trinitrobenzene sulfonic
acid)
Antagonistic OX40-IgG
fusion protein
Amelioration of histology,
reduced T cell infiltrate and
reduced pathogenic
cytokines including IL-12,
IFNγ and TNFα[141]
Rheumatoid arthritis
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Disease and model Intervention Effect
Collagen-induced arthritis
OX40L blocking mAb
Amelioration of clinical
score, less production and
collagen-specific IgG2a when
Ab administered at day
-1[495]
OX40L:Ig fusion protein Abolished evidence ofdisease[131]
Pegylated OX40 blocking
Fab fragment
Reduction in joint
inflammation and
degradation of bone and
cartilage[131]
Uveitis
EAU in rats OX40 agonistic antibody
Prolonged inflammation,
increased Th1 and Th17
cells; increased IFNγ in cell
cultures exposed to
antigen[485]
EAU in mice OX40L blocking antibody
Worsening of clinical score
and IFNγ production with
early administration; when
given late had no effect[428]
OX40L deficiency
Worsening of clinical score
and IFNγ production with
early administration; when
given late had no effect[428]
Intravitreal ovalbumin in
OTI mice
OX40L blocking antibody Amelioration of clinicalscore[502, 506]
OX40 agonistic antibody
Worsened clinical score,
extent of lymphocytic
infiltrate and of Th17
cytokines[502, 506]
Type 1 Diabetes Mellitus
NOD mouse
Genetic co-deficiency for
TNFSF4
Prevention of the
development of diabetes[267]
OX40L blocking antibody
at 12 weeks of age
Reduction in incidence of
diabetes[322]
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Disease and model Intervention Effect
Multiple sclerosis
EAE in rats Soluble OX40 receptor
Increased survival and
ameliorated clinical
score[479]
EAE in mice OX40L deficiency
Reduced clinical score,
reduced IL-2 and IL-6[305]
OX40L Ab blockade
Reduced clinical score,
reduced spinal cord T cell
infiltration[307, 91]
Anti-GBM disease
(Goodpasture syndrome)
Mice given ovine
anti-GBM antibody. OX40L antibody blockade.
Exacerbation in intact mice
and CD86-/- mice;
amelioration in those also
co-deficient in CD80 and
CD86.[311]
IPEX
FOXP3 deficient mouse OX40 co-deficiency
Prolonged survival, reduced
organ T cell infiltration,
reduced T cell activation,
reduced autoantibody titres,
reduced clinical
manifestations.[105]
OX40L Ab blockade Similar to effects of OX40co-deficiency.[105]
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Table 1.5: OX40 and OX40L disturbances in human autoimmunity
OX40 OX40L
Systemic lupus erythematosus
Increased OX40 positivity on peripheral
T cells with correlation to clinical severity
markers[10, 328, 2, 508, 95, 219, 279]
Increased endothelial expression in
kidney biopsies from lupus nephritis
patients with the appearance of
glomerular positivity[10]
OX40 on infiltrating perivascular
leucocytes in lupus nephritis[10]
Increased peripheral sOX40L, with
further elevations in those with
nephritis[95]
More activated phenotype with increased
PI3/Akt activation[219]
Colitis
Expression increased on lamina propria
lymphocytes in inflamed colon
Increased expression on vascular
endothelium from inflamed –but not
uninflamed – colon[394]
Increased proportion of colonic T cells
OX40 positive in UC; peripheral counts
unchanged[455]
Increased biopsy staining of active colitis
and unchanged by corticosteroid
therapy.[398]
Coeliac disease
OX40-positive lymphocytes present in
disease but not control duodenal
biopsies[398]; peripheral OX40
expression not affected[332]
Rheumatoid arthritis
Increased OX40-positivity on
lymphocytes in synovial fluid from
inflamed joints[41, 495, 111, 326, 229]
OX40L expression on sublining layer of
sinovium from inflamed joints[495, 212]
Reduced sOX40[229] Increased sOX40L with correlation withautoantibody status[229]
Inflammatory myositis
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OX40 OX40L
OX40 expression present in
inflammatory myopathies but not
controls [411, 324]
OX40L seen on T cells, B-cells,
macrophages and myeloid dendritic cells
in inflammatory myopathies but not
controls[324]
Uveitis
Multiple OX40-positive infiltrating
lymphocytes from ciliary bodies of eyes
enucleated for uveitis[485]
Type 1 Diabetes Mellitus
Increased proportion of CD4+ cells
positive in peripheral blood of newly
diagnosed paediatric cases[403]
Systemic sclerosis
Elevated serum sOX40 concentrations in
comparison with SLE and healthy
controls[209]
Graves’ Thyroiditis
Increased OX40-positivity of circulating
CD4+ T cells in patients with anti-TSHR
antibodies[35, 454]
Increased OX40L-positivity of circulating
CD4+ T cells in patients with anti-TSHR
antibodies[454]
Elevations of sOX40L[453]
Multiple sclerosis
Reduction in OX40+CD26+ peripheral
CD4+ T cells correlating with clinical
response after treatment with
natalizumab[32]
OX40 expressed in MS brain and cord
sections[337]
Neuromyelitis optica
Increased OX40 positivity of pathological
brain specimens[337]
Sjögren syndrome
Increased OX40 expression on peripheral
T cells[511]
Increased OX40L expression on
peripheral B-cells and monocytes[511]
Myaesthenia gravis
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OX40 OX40L
Increased thymic OX40 staining[318] OX40L present in myasthenia gravisthymus but not control[318]
Increased OX40-staining on peripheral
CD4+ T cells[488]
Granulomatosis with polyangiitis
Increased OX40 expression on CD8+
peripheral T cells[112] and on CD4+ T
cells[481]
Henoch-Schönlein purpura
Increased OX40 positivity on circulating
CD4+ T cells[344] Increased sOX40L[344]
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Table 1.6: Mouse models of primary biliary cholangitis
Model Phenotype Ref(s)
T cell regulation
mediated
FOXP3 dysfunction
Affected male mice develop multi-system
autoimmunity with CD8+ T cell rich
peri-biliary lymphocytic infiltrates, serum
AMAs, elevations in IFNγ, IL-12, and TNFα
with death aged 3-4 weeks
[504]
Dominant negative
TGFβ receptor II under
CD4 promotor
At 24 weeks, mice had developed T cell
dependent peri-biliary lymphocytic infiltrates
with a CD8 T cell bias; AMAs, sp100 and gp210
ANA autoantibodies present; increases in
serum IFNg, TNFα, and IL-6
[312,
156]
Non-obese diabetic
crossed with c3c4 mice
Intra- and extrahepatic bile duct injury
associated with dense CD8+ T cell rich
infiltrates and the development of AMAs
[161]
AE2 exchanger
dysfunction
CD8+ T cell rich but Treg poor peri-biliary
lymphocytic infiltrate with BEC damage,
AMAs, elevations in serum IgG and death aged
3-4 weeks; notably the AE2 exchanger is
important to regulatory lymphocyte survival
[361]
IL-2Rα deficiency
Variable age of onset multi-system
autoimmunity with peri-biliary CD8+ T cell
rich lymphocytic infiltrate, AMAs, increased
serum IFNγ, TNFα, IL-2 and IL-12; 25%
mortality at 20 weeks
[446]
IFNγ over-expression
through deletion of 3’
regulatory region
Female-predominant periportal lymphocytic
(subtypes not reported) inflammation at 20
weeks with AMAs; extra-hepatic autoimmunity
not detailed; transferable by adoptive transfer
of CD4 T cells
[14].
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Model Phenotype Ref(s)
MRL/lpr mice
homozygous for
dysfunctional
Fas/CD95
Defective T cell apoptosis. At 24 weeks, CD8+
and CD4+ T cell rich peri-portal lymphocytic
infiltrates, AMAs alongside ultimately lethal
multi-system autoimmunity including
vasculitis, glomerulonephritis, arthritis and
sialadenitis
[423]
MHC mismatch
adoptive transfer into
sublethally irradiated
hosts
Although described as model of PSC, mice
develop dense periportal lymphocytic
infiltrates 12 weeks following cell transfer
[308]
Xenobiotic and
adjuvant mediated
Immunisation with
2-octynoic acid and
Complete Freud’s
adjuvant (CFA)
12 weeks post immunisation, peri-biliary
CD8+, and activated CD44+ lymphocyte
dominant infiltrates with Th1 cytokine
elevations in serum, AMA production; no
extra-hepatic autoimmunity
[447,
445]
Novosphingobium
aromaticivorans
injection of NOD 1101
mice
NKT cell dependent hepatic peri-portal
lymphocytic infiltrates and bile duct damage
with serum AMA development;
hepatosplenomegaly
[268]
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Table 1.7: Mouse models of autoimmune hepatitis
Model Phenotype Ref(s)
Cytokine release
Concanavalin A
injection
Rapid (hours), dose-dependent T cell and NKT
cell depenedent necrotic injury of periportal
hepatocytes not associated with autoantibodies;
blockade of IFNγ and TNFα reduces phenotype
[415,
285]
Lipopolysaccharide
injection
Rapid (hours), dose-dependent macrophage
derived TNFa-driven hepatocyte toxicity
without autoantibodies
[297]
Hepatic antigen
manipulation
Neoantigen expression
with specific T cell
transfer
T cell dependent injury with fulminant
hepatocyte necrosis, lymphocytic infiltrate,
elevations in serum IFNγ, TNFα; autoantibody
profile not reported; reported with hepatitis B
virus surface antigen and ovalbumin and
subsequent adoptive transfer of appropriately
specific T cells
[5, 83]
Disruption of T cell
regulation
Constitutive
over-expression of
CD28 ligands
CD4+ and CD8+ T cell dense lymphocytic
hepatic infiltrate with necrosis and fibrosis,
elevated IFNγ production, elevations in serum
transaminase activities
[68]
Neonatal thymectomy
with or without PD-1
deficiency
Autoantibodies to liver-specific membrane
lipoprotein and mild lymphocytic infiltrate;
with concurrent PD-1 dysfunction, fatal
necrotic hepatitis with dense CD4+ and CD8+
hepatic infiltrate that could be transferred by
transfer of total lymphocytes and controlled by
co-transfer of Tregs
[461,
193]
AIRE dysfunction
CD8+ T cell predominant lymphoplasmacytic
hepatic infiltrates, increased Tregs, elevated
serum TNFα and IL-2, autoantibodies to
multiple intrahepatic antigens; reversible by
transfer of intact Tregs.
[348,
132]
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Model Phenotype Ref(s)
TGFβ deficiency
CD4+ T cell and IFNγ dependent hepatitis
with CD4+ predominant lymphocytic infiltrate,
serum transaminase activity elevations;
autoantibodies not reported
[117,
358]
Targetted TRAF6
disruption on
medullary thymic
epithelium
CD4+-predominant hepatic lymphocytic
infiltrate, elevated serum IgG, ANA, fibrosis.
Preserved liver Treg numbers. Corticosteroid
responsive.
[29]
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2 Materials and Methods
2.1 Animals
Animal care
All animals were housed and maintained at the Biomedical Services Unit (BMSU), University of
Birmingham. Animals were kept and bred in accordance with UK Home Office Guidelines. Ex-
perimental procedures were performed in accordance with pre-specified UK Home Office project
licences.
Adult mice were used aged 6-12 weeks. For Roquin mutant mice, mice were aged to 16-20 weeks
to permit development of the Roquin mutant phenotype. For CTLA4-/- and FOXP3KO phenotypes,
mice were used at 3-4 weeks of age to prevent full development of their otherwise deleterious phen-
otypes.
Preparation
Where blood or serum was not required for analysis, mice were killed by cervical dislocation; where
blood or serum was required for analysis, mice were killed by cardiac puncture under terminal iso-
flurane anaesthesia. In some instances, blood was collected from the saphenous vein from live mice
into heparinised containers to permit flow cytometry.
Serum was prepared by allowing blood to clot on ice. Samples were then centrifuged at 8000 × g for
5minutes, and the supernatant then centrifuged for a further 5minutes at 8000 × g. The supernatant
sera were then frozen on dry ice before being kept at −20 ◦C until further analysis.
Survival analysis
Where survival was used as an outcome measure, the condition of mice was assessed by the staff of
the University of Birmingham Biomedical Services Unit who were unaware of the treatment groups
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to which individual animals belonged. Mice were observed for weight loss of 20% initial weight
or greater, continued piloerection, intermittent hunched posture, subdued behaviour for up to 48
hours, intermittent changes to respiration, or deterioration in the condition of fur or eyes. If any of
these signs of deteriorating condition were present, the mice were culled and analysed.
Tissues
Mice were dissected to obtain liver, spleen, thymus and lymph node tissues. Mice were sprayed with
70% v/v ethanol/distilled water (dH2O) solution to prevent fur contaminating the abdomen, laid on
their back and a midline laparotomy incision made.
The spleen was isolated by blunt dissection and removed in toto. The intestine was then unpacked
and the mesenteric lymph node chain removed in toto. The liver was then retroflected, the gallblad-
der ligament cut, the stomach dissected free and the liver removed in toto.
The liver was washed extensively in Roswell Park Memorial Institute medium (RPMI) before being
divided into lobes (Figure 2.1). The left lobe was fixed in formaldehyde solution for use in immun-
ohistochemical analysis, the median lobe frozen, and the caudate lobe used for preparations of cell
suspensions.
The incision was then continued to a midline thoracotomy and the two lobes of the thymus exposed
by blunt dissection and removed individually.
Induction of chemical hepatitis
For the induction of concanavalinAhepatitis, concanavalinA (Sigma)was dissolved in sterile phosphate-
buffered saline (PBS) and administered intravenously at a dose of 10mg kg−1. Mice were observed
for 24 hours and then sacrificed by cardiac puncture under teminal anaesthesia.[285]
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Diaphragm
Gall bladder
Median lobe
Right kidney
Spleen
Left kidney
Left lobe
Caudate lobe
Right lobe
Inferior vena cava
Xiphisternum
Figure 2.1: Basic mouse liver anatomy after laparotomy, removal of the gastrointestinal tract, and
retroflexion of the liver.
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For the induction of carbon tetrachloride hepatitis, a solution of 1:3 mineral oil:carbon tetrachlor-
ide (CCl4) (both Sigma-Aldrich) was prepared. Mice were administered the resulting solution at
1mg kg−1 by intraperitoneal injection. Mice were observed for 48 hours and then sacrificed by car-
diac puncture under isoflurane terminal anaesthesia.[365]
Genotyping
Genotyping was performed on ear punch specimens by Dr F McConnell using the commercial
Transnetyx® platform.
Mouse strains used
All mice were used on an inbred C57BL/6 genetic background. Details are recorded in Table 2.1.
2.2 Human samples
Liver
Samples of explant livers removed at the time of transplantation for various indications were ob-
tained from the tissue bank of the Centre for Liver Research, University of Birmingham. Control
samples of normal liver were obtained from either disease-free tissue removed during cancer resec-
tion surgeries or from potential graft organs that were not ultimately used for transplantation.
Liver biopsy samples were obtained as part of the Comprehensive Assessment of the Liver withMag-
netic Resonance Imaging (CALM) study run by the University of Birmingham. Those taking part
gave written informed consent prior to particpation.
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Table 2.1: Mouse strains used
Strain Gross phenotype Reference(s)
RAG1-/- (RAGKO) Complete deficiency in T cells and Bcells; appear well [289]
ZAP70-/- (ZAP70KO) Lack CD4+ and CD8+ T cells; appearwell [183]
OX40-/- (OX40KO) Mice appear well [213]
CTLA4-/- (CTLA4KO)
Lethal multi-organ autoimmunity as-
sociated with hepatitis and T cell activ-
ation at a few weeks of age.
[416]
FOXP3y/- (FOXP3KO)
Lethal multi-organ autoimmunity as-
sociated with hepatitis and T cell activ-
ation at a few weeks of age.
[62]
AIRE-/- (AIREKO)
Mice appear well; eventual develop-
ment of autoimmunity including hep-
atitis in some
[348]
CD80-/-CD86-/- Mice appear well [33]
CTLA4-/-CD80-/-CD86-/-
Mice appear well; they were crossed in-
house but phenotypically reflect those
reported elsewhere.
[261]
FOXP3-/-OX40-/-CD30-/- Mice appear well [105]
FOXP3-GFP All Tregs labelled with green fluores-cent protein [26]
BoyJ
Mice appear well; all leucocytes allo-
type marked as CD45.1; used as wild-
type controls
[378]
C57BL/6 Mice appear well; CD45.2 allotype;used as wildtype controls
Charles River or
in-house
CTLA4-/-OX40-/-CD30-/- not reported In-house
OTII.RAG-/- Mice appear well [288, 17]
Roquin sanroque mutant Splenomegaly, lymphadenopathy,multi-system autoimmunity [438]
RoquinM/MOX40-/-CD30-/- not reported In-house
VAV1-Cre OX40L(fl) Mice appear well In-house viaDr D Withers
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Blood and serum
Blood was obtained from patients as part of the Cellular Trafficking and Immune Responses in the
Human Liver project hosted at the University of Birmingham (approval: 06/q2708/11). Healthy
volunteers were used for control samples and gave informed consent.
Serumwas obtained by taking blood into a serum-separator tube and allowing it to clot at room tem-
perature. The tube was subsequently centrifuged at 400 × g for 5 minutes, the supernatant pipetted
off, re-centrifuged and stored at −80 ◦C until required.
Clinical characterisation
Blood results and results of other clinical investigations were obtained including values for upper
limit of normal (ULN) and lower limit of normal (LLN) as appropriate either directly from clinical
records (with written consent) or from a pseudonymised clinical database for biopsy specimens.
2.3 Enzyme-linked immuno-absorbance assays
For analysis of murine serum TNFα concentrations, IgG concentrations and IgE concentrations,
eBioscience ready-set-go enzyme-linked immunosorbent assay (ELISA) kits were used. ELISA for
IgE was performed by the laboratory of Dr Jessica Strid at Imperial College London.
Briefly, 96-well flat-bottomed plates were coated overnight with capture antibody in PBS. Plates were
washed thoroughly with PBS 0.5% Tween 20. Plates were then blocked with a protein-containing
solution from the kits. Serum samples were then incubated for ≥60minutes and washed thoroughly.
A standard curve was constructed by creating serial two-fold dilutions. A secondary detection an-
tibody was then added for a further 1 hour and plate again washed thoroughly. Wells were then
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filled with the provided 3,3’,5,5’-tetramethylbenzidine (TMB) containing solution and the reaction
observed. At either 15 minutes or the onset of strong colour change in a large number of wells, sul-
phuric acid was added to the well to prevent further reaction. Plates were then read on a plate-reader
at 450 nm.
For analysis of murine AMAs, a modification of a clinical anti-M2-3E ELISA kit (EurImmun) was
used. The secondary antibody was replaced with anti-IgG, anti-IgM and anti-immunoglobulin A
(IgA) horse-radish peroxidase conjugated antibodies (all Abcam) to permit measurement of the
three respective isotypes. The kit contains a 96-well plate pre-coated with recombinant PDC-E2.
Sera were diluted in phosphate-buffered saline and the plate incubated for 1 hour.
For analysis of human soluble OX40L an ELISA kit from Cusabio was used according to the manu-
facturer’s instructions – a similar protocol as that described above.
Where quantification was performed, the values of two-fold dilutions of solutions of known initial
concentration were plotted and a standard curve fitted using Prism (GraphPad). Values for other
wells were then interpolated against this curve.
2.4 Histology
Frozen tissue sections
Tissues were frozen after dissection by freezing on metal foil placed over dry ice before subsequent
storage at −80 ◦C. Tissues for staining were sectioned by cryostat to 5 µm, mounted on glass slides,
fixed in acetone and air-dried overnight. Sections were then stored at −20 ◦C until required. For
staining, sections were rehydrated with phosphate-buffered saline. For some tissues, non-specific
streptavidin-biotin binding was blocked with a Streptavidin/Biotin Blocking kit (Vector Labs). Tis-
sueswere then blockedwith 10%horse serum for 10minutes before sequential 30-60minute staining
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with primary and subsequent antibodies in 1% bovine serum albumin PBS solution. Secondary and
subsequent antibodies were pre-absorbed in 10% v/vmouse serum/PBS on ice. Nuclear staining vis-
ible after ultraviolet excitation was performed using 4’,6-diamidino-2-phenylindole (DAPI). Images
were taken using a Zeiss 780 confocal microscope (Carl Zeiss).
Formaldehyde-fixed paraffin-embedded tissue sections
Samples for examination were dissected and placed in 10% formalin-saline solution (4% formalde-
hyde; Ferndale) for at least five days. Sections were then paraffin embedded either by the staff of the
Department of Histology, Royal Orthopædic Hospital National Health Service (NHS) Foundation
Trust or the staff of the Centre for Liver Research, University of Birmingham. Samples were then
sectioned to 4 µm with a PFM Rotary 3003 microtome onto charged slides before oven-drying for
24 hours at 60 ◦C.
Samples were sequentially de-waxed by bathing in Clearene® (Leica), then the Clearene® displaced
with absolute ethanol, and then rehydrated in tapwater. Endogenous peroxidase activitywas blocked
by bathing for 10 minutes in 0.3% v/v hydrogen peroxide / methanol solution (Sigma). Antigen
retrieval was performed either in a high-pH ethylenediaminetetraacetic acid (EDTA)-based buf-
fer or a low-pH citrate-based buffer (both Vector Labs). Antigen retrieval buffers were pre-heated
for 5 minutes in an 800W microwave, slides added, and the solution then heated for a further 20
minutes. Non-specific staining was performed with a 2.5% goat serum / casein solution (Vector
Labs). Primary antibodies were applied in PBS for 30-60 minutes. Slides were then washed thor-
oughly in phosphate-buffered saline. Secondary antibodies conjugated to either horseradish perox-
idase (HRP) or ALP were then applied in phosphate-buffered saline for 30-60 minutes. Either 3,3’-
diaminobenzidine (DAB) orVector RedALP substrate (bothVector Labs) were used as chromogens;
DAB substrate was applied for 5 minutes and Vector Red for 15 minutes. In some circumstances,
both chromogens were used sequentially. For human liver biopsy sections, an automated staining
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system using the same parameters was used (Dako Autostainer Link, Dako; operated by Dr Gary
Reynolds). Slides were counter-stained with Mayer’s haemotylin solution and developed in a bath
of tap water at 37 ◦C. Where haematoxylin and eosin staining was employed, slides were prepared
similarly and Harris haematoxylin was used prior to staining with eosin solution.
Where histology was graded according to extent of OX40 expression, this was performed according
the greatest number of OX40 positive cells in any one inflammatory aggregate. For explant samples
these were categorised as a score of 0 for no positive cells, 1 for 1-5 as a single focus, 2 for 5-10 and
3 for >10 by a single pathologist who was unaware of the diagnosis. For liver biopsy specimens,
the total number of cells present was counted by an independent pathologist unaware of other case
characteristics. Samples were also graded subjectively as minimal, mild or moderate inflammation.
For presentation purposes these counts were logarithmically transformed.
Imaging and quantification
Images for representative purposeswere acquiredwith a LeicaDM6000microscope using aDFC310FX
digital camera. Images were individually white-balanced.
For quantification of sections stained with chromogens to demonstrate the presence of markers of
interest, five randomly positioned white-balanced images were taken from each tissue section at 10×
magnification. Images were then batched through FIJI according to the following workflow:
run("Subtract Background...", "rolling=50 light");
run("16-bit");
setAutoThreshold("Huang");
setThreshold(42, 172); // These values were set individually per batch
setOption("BlackBackground", false);
run("Convert to Mask");
run("Analyze Particles...", "size=0-Infinity circularity=0.00-1.00 show=Nothing
display clear summarize");
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Theworkflow removes variations in illumination from themicroscope using the ‘rolling ballmethod’,
converts the image into a 16-bit greyscale, thresholds a level of darkness that represents positive
staining (adjusted manually on a per batch basis), converts the image into a 1-bit black and white
bitmap, and then calculates the proportion of the image that is black (Figure 2.2). This value was
calculated for each image taken of each tissue section and used for statistical comparisons.
(a) Original image (b) 16-bit greyscale
(c) Thresholded image (d) 2-bit image
Figure 2.2: Digital processing of histological images. An example of image processing to permit quanti-
fication of positive staining. Here a section of FOXP3 deficient mouse liver tissue has been stained with an
anti-CD45 antibody and brown chromogen.
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2.5 Biochemical analysis of serum
Liver biochemical values
For the analysis of liver biochemical values, automated Beckman Coulter AU400 analysers were
used. Samples were processed with the assistance of the Department of Biochemistry, Birmingham
Women’s Hospital. Samples were assessed for ALT and ALP activity using clinical analysers. In
some cases, samples were pre-diluted with sterile PBS prior to processing and subsequent readings
corrected by the appropriate dilution factor.
Capillary blood glucose
Capillary glucose wasmeasured using an Accu-Chek Nano blood glucosemeter and single use gluc-
ose check sticks (both Roche) using blood obtained at cardiac puncture.
2.6 Cell suspension preparation and transfer
For the preparation of cell solutions for the analysis or further use of tissue leucocytes, tissues were
dissected as above, washed thoroughly with RPMI and then weighed. Tissues were then placed in
3ml RPMI and mechanically dissociated by repeated pressure with the reverse of a syringe plunger.
The resulting cell suspension was then passed through 70 µm pore NYTAL® mesh. The filtered cell
suspension was placed into BD Falcon 5ml round-bottomed polypropylene tubes and centrifuged
at 20 × g for 5 minutes. The pelleted débris was discarded and the supernatant was then transferred
to a clean tube, which was centrifuged at 400 × g for 5 minutes and the pelleted cells retained. These
cells were suspended in Gey’s Balanced Salt Solution to cause lysis of red cells. After 5 minutes, an
excess of RPMI was added to prevent further haemolysis and the cells washed before further use as
described below.
78
Adoptive cell transfer
For the preparation of cell solutions for cell transfer, the steps above were performed in sterile con-
ditions using sterile solutions. Suspensions were passed through 70 µm sterile filters (Falcon, BD
Biosciences) before resuspension at a concentration appropriate for injection in sterile PBS. Cell
counting was performed using a haemocytometer. Cell transfers were performed in volumes of
100 µl by either intravenous (IV) injection into one of the tail veins or intraperitoneal (IP) injection
to the iliac fossa. For the production of bone marrow chimeras, adult recipient mice were irradiated
with two exposures of 4.5Gy immediately prior to intravenous cell transfer.
For transfer of FOXP3 deficiency disease, 5 × 106 total thymocytes were transferred IP; for all other
transfers, preparations of 5 × 106 cells were transferred IV. For adoptive transfer of sorted Tregs,
1 × 105-2 × 105 cells were transferred IV
In some experiments, survival curves were generated. To do this, animals were monitored until
they developed signs of autoimmune disease. At this point, they were analysed individually. Those
mice that did not develop overt autoimmunity were analysed at the end of the planned experiment;
in general this was at 6 weeks. In other experiments, mice were analysed simultaneously at a pre-
determined time point.
Cell culture suspensions
For the preparation of lymphocyte suspensions for cell culture, spleens were cut into approxim-
ately 2mm pieces and placed into 3ml RPMI supplemented with 75 µg DNAse and 750 µg colla-
genase/dispase (Roche diagnostics) for 20 minutes. After 20 minutes, 120 µl of 0.5 m concentration
EDTA (Sigma-Aldrich) was added to prevent further enzymatic digestion. Cells were then washed
in RPMI and further used as described below.
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Purified mouse CD4+ T cells
For the generation of purified cultures of CD4+ T cells, a CD4+ EasySep® negative selection kit
(Stemcell Technologies) was used. First a cell suspension of total splenocytes was prepared as above.
Cells were resuspended in 500 µl of staining buffer. 25 µl rat serum was added and the sample left to
incubate for 10minutes at room temperature. 25 µl of negative selection cocktail was then added and
the sample incubated for a further 10 minutes. Then 37.5 µl of RapidSpheres magnetic beads were
added and the suspension resuspended with a pipette. The sample was incubated for 5 minutes and
then placed in an EasySep® magnet for a further 5 minutes before a suspension of of CD4+ T cells
>90% purity was poured off the magnet.
Human peripheral blood mononuclear cells
For the preparation of suspensions of human peripheral blood mononuclear cells, whole blood was
obtained and anticoagulated with EDTA. Whole blood was layered over Lympholyte® solution (Ce-
darlane Labs) and then centrifuged at 800 × g for 20 minutes. The peripheral blood mononuclear
cells containing interface between plasma and Lympholyte® was then aspirated and washed in PBS.
Haemolysis was performed with Gey’s Buffered Salt Solution. Cell suspensions were then depleted
of platelets by centrifugation at 200 × g and discarding the supernatant.
2.7 Flow cytometric analysis
Surface staining
Cell suspensions were prepared as described elsewhere. Cells were washed by centrifugation at
400 × g for 2 minutes before resuspension. Staining was performed in a 96-well U-bottomed plate.
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To permit exclusion of dead cells, cells were washed twice in phosphate-buffered saline before resus-
pension in 50 µl PBS containing a 1:2000 dilution of Zombie NIRTM Live-Dead exclusion dye (Bio-
legend), where they were left for 10 minutes at room temperature before being washed with PBS.
For primary antibody staining, cells were resuspended in 50 µl staining buffer containing primary
antibodies at pre-titrated concentrations. Cells were left to stain for 30 minutes at 4 ◦C. Cells were
then washed in staining buffer. In some instances secondary antibodies were then applied and left
for a further 30 minutes at 4 ◦C. After staining, cells were fixed in 4% formaldehyde solution for
30 minutes before resuspension in staining buffer.
Intracellular staining
For intracellular staining, primary antibodieswere applied as above. Cellswere thenfixed for 30minutes
in the fixatives supplied in either the BDBiosciences cytokine kit or eBiosciences transcription factor
staining kit (Thermo Fisher Scientific). Cells were then washed twice in 100 µl reconstituted per-
meabilisation buffer from the kit used before being resuspended in 50 µl permeabilisation buffer
with added intracellular antibodies. Cells were then stained for 30 minutes at room temperature
before a final 100 µl wash in permeabilisation buffer and then resuspension in staining buffer.
For intracellular staining of cytokines, cells were resuspended in a flat-bottomed 24-well plate in
1ml culture media supplemented with either 1 µg agonistic anti-CD3 antibody (clone 145-2C11)
and 1 µg agonistic anti-CD28 antibody (clone 37.51) orwith phorbol 12-myristate-13-acetate (PMA)
and ionomycin. Cells were then incubated for 1 hour at 37 ◦C and 5% CO2. After 1 hour, cultures
were supplemented with either monoensin (BD Biosciences) or brefeldin A (Sigma) before being
returned to the incubator for 3 hours. Cells were then fixed, permiabilised and stained for cytokines
of interest with appropriate antibodies as described above.
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Cell number quantification
Where cell numberswere quantified, AccuCount® counting beads (Spherotech)were added to samples.
The number of cells per gram of tissue was then calculated according to the following formula:
Ctotal = Ccounted.Fdilution.Badded/Bcounted.Wtissue
Where Ctotal is the total cells per gram; Ccounted is the number of cells of interest counted by flow
cytometry; Fdilution is the dilution factor used in preparing samples; Badded is the number of counting
beads added; Bcounted is the number of beads counted during flow cytometry; Wtissue is the weight of
tissue used in preparation
Acquisition
Acquisitionwas performed on an LSRFortessa X-20 flow cytometer using FACSDiva software v8.0.1
(both BD Biosciences). Cell suspensions with cells prepared so as to have populations positive and
negative for the fluorochrome of interest were prepared to allow compensation for spectral overlap.
Where necessary, control samples stained with a non-specific antibody of the same isotype but with
all other antibodies as normal (i.e. fluoresence minus one controls) were used to allow accurate
gating. Representative gating strategies are shown below (Figure 2.3 & 2.4).
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Figure 2.3: (Caption next page.)
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Figure 2.3: (Previous page.) General flow cytometry gating strategy. Representative plots from cells
isolated from liver samples with various staining protocols are shown. First, likely lymphocytes were gated
based on their forward scatter (FSC) and side scatter (SSC). To permit counting of cells, counting beads were
also selected based on their high SSC values (blue gate). Next, aggregations of two or more cells were
excluded by plotting SSC-width against SSC-area. Next, cells negative for a fixation-permanent live-dead
dye but positive for the pan-leucocyte marker CD45 were then selected. Next, plots of B220 against CD3
were created: B220+CD3- cells were defined as B cells (dark green gate), CD3+B220- cells were further
examined. CD3+B220- cells were sub-divided by plotting CD4 against CD8. CD8+CD4- negative cells were
defined as CD8+ T cells (orange gate), whilst CD4+CD8- cells were defined as CD4+ T cells and further
examined. Simple surface staining was used to examine T cell markers such as ICOS (purple gate). A BD
cytokine permiabilisation kit was used to permit staining for some intracellular proteins including CTLA4 and
Ki67 (grey gate). For transcription factor staining, an eBioscience transcription factor permiabilisation kit was
used (pale green gate). To reveal cytokine secretion profiles, cells were stimulated with PMA and ionomycin
prior to staining with the BD cytokine kit for IFNγ, IL-4 and IL-17 (ochre).
2.8 Cell sorting and cell purification
Cell sorting was performed by with the assistance of Drs Matthew Mackenzie and Andrew Owen,
University of Birmingham. For cell sorting, cell suspensions were prepared as for cell transfer. Cells
were then stained with antibodies as for flow cytometry. Cells were then sorted on an MoFlo XDP
Cell Sorter (Beckman Coulter). Purity checks were performed by passing a proportion of the sorted
cells back through the cell sorter to confirm that the purity of the desired population was >95%.
2.9 Cell culture
Cells were prepared as described above. For the assessment of cell proliferation or to label cells to
allow later discrimination, some cells were loaded with 5‐carboxyfluorescein diacetate succinimidyl
ester (CFSE): Cells were washed free of extracellular protein in RPMI and resuspended at between
1 × 106-5 × 106 cells/ml. CFSE in dimethyl sulfoxide (DMSO) was then added to a final CFSE con-
centration of 1 µmol L−1 and the cells allowed to stain for 10 minutes in a 37 ◦C water bath with
intermittent agitation. After 10 minutes, an excess of 4 ◦C culture media was added to absorb un-
bound CFSE and the cells washed. CFSE dilution through cell proliferation was assessed via flow
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Figure 2.4: Example gating strategy for cell culture experiments. Forward and side scatter were first
used to identify counting beads and likely cell populations; doublets were then excluded on side scatter-width;
cells positive for live-dead stain were excluded; CD11b and B220-negative, TCRβ or CD3-positive cells were
then selected. CD4+ T cells were identified as CD4+ CD8- cells from this population, and were then amenable
to further analysis, in this example by comparing OX40 to OX40L expression.
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Figure 2.5: Proliferating murine splenocytes. Murine total splenocytes proliferating after being cultured for
72 hours in the presence of agonistic anti-CD3 and anti-CD28 antibodies.
cytometry using the fluorescein isothiocyanate (FitC)/Alexa fluor 488 channel.
For culture, cells were plated in 24-well flat-bottomed plates at 1 × 106 cells in 1ml of culture me-
dium. In general, cultures were continued for 72 hours at 5% CO2 and proliferation was confirmed
by visual inspection (Figure 2.5). For murine cells, wells were generally supplemented with combin-
ations of agonistic anti-CD3 antibody with or without agonistic anti-CD28; for human peripheral
blood mononuclear cells cultures, the same procedure was followed but with antibodies of appro-
priate specificities substituted.
In some experiments, ovalbumin (323-339; isqavhaahaeineagr) peptide or concanavalinA (ConA)
(both Sigma-Aldrich) was used to stimulate T cells in place of agonistic anti-CD3 antibody.
In some experiments, blocking antibodies or immunomodulatory drugs were added to culture me-
dia. These were added at the beginning of culture in all cases. These are detailed in Table 2.7.
In some experiments, cell cultures were separated by a 0.4 µm Transwell® membrane (BD Bios-
ciences) to permit circulation of soluble molecules across the membrane but exclude movement
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of cells or direct contact between cells.
2.10 Statistics
For the comparison of two unpaired groups, the Mann-Whitney U test was used; for comparison
of distributed paired samples, the Kolmogorov-Smirnov test was used; for comparison of three or
more groups of non-normally distributed data, the Kruskal-Wallis test with Dunn’s post-hoc test for
multiple comparisons was used; for assessment of trend, the nptrend function in Stata (Statacorp)
was used; for comparison of two survival curves, log-rank analysis was used; for linear regression, a
least squares method was used. Values of p<0.05 were taken as representing statistical significance;
where p values for statistical tests were significant, they are depicted on graphs as horizontal lines
between the two groups being compared or across all groups being compared. Graphs showmedians
unless otherwise stated.
2.11 Software, reagents and suppliers
Software
Text was set in Minion Pro, Helvetica and Arial with LATEX and X ETEX using LYX v2.2.3. Figures were
constructed with TouchDraw v1.11.9 (Elevenworks software, Kansas City, MO, USA) and Acorn
v5.65 (Flying Meat Inc., Seattle, WA, USA). References were prepared with BibDesk v1.6.11. Image
analysis of photographs of immunohistochemical sections was performed with FIJI/ImageJ v2.0.0.
Calculations of statistical tests and the generation of graphs was performed with Prism v6.0 (Graph-
pad, La Jolla, CA, USA) and StataMP v13.0 (StataCorp, College Station, TX, USA). Flow cytometry
analysis was performed using FlowJo v10.0.7r2 (Tree Star software, Ashland, OR, USA).
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Reagents and suppliers
Solutions (Table 2.2), immunohistochemistry primary antibodies (Table 2.3), immunohistochem-
istry secondary antibodies (Table 2.4), flow cytometry antibodies (Table 2.5), in vivo antibodies
(Table 2.6), and cell culture additives (Table 2.7) used, together with a table of suppliers (Table 2.8)
are presented in table format below.
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Table 2.2: Solutions used
Solution Composition Supplier
RPMI
Complete Roswell Park Memorial
Institute 1640 Medium with
l-glutamine and phenol red
Gibco
Gey’s solution Used for osmotic haemolysis of redblood cells
In house, per
[292]
PBS Dulbecco’s PBS with MgCl2andCaCl2.
Gibco
Culture medium
RPMI + 10% fœtal bovine serum
(Invitrogen), 2mm l-glutamine
(Sigma) and 1% w/v penicillin &
streptomycin (Gibco)
Prepared in
house
Staining buffer PBS + 2% foetal bovine serum with2.5mm EDTA (Sigma)
Prepared in
house
Staining solution PBS + 1% w/v bovine serumalbumin (Sigma)
Prepared in
house
Table 2.3: Immunohistochemical primary antibodies
Target Clone Reference Manufacturer
Mouse OX40 OX86 14-1341-82 eBioscience
IgG1 control Polyclonal 13-4301-81 eBioscience
Mouse CD4 4SM95 14-9766-82 eBioscience
Mouse CD45 30-F11 14-0451-85 eBioscience
Mouse OX40 OX86 in house
Dr Margaret
Goodall, University
of Birmingham, UK
Mouse Ki67 Rabbit polyclonal none Dr Johannes Gerdes,Borstel, Germany
Mouse OX40 Rabbit polyclonal ab203220 Abcam
Human CD4 Rabbit polyclonal ab133616 Abcam
Human OX40 Ber-ACT35 350002 BioLegend
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Table 2.4: Immunohistochemical secondary antibodies
Target Clone Conjugate Reference Manufacturer
Rat Polyclonal HRP MP-7404 Vector
Mouse Polyclonal HRP MP-7452 Vector
Rabbit Polyclonal HRP MP-7401 Vector
Rabbit Polyclonal ALP MP-5401 Vector
ALP = alkaline phosphatase; HRP = horseradish peroxidase
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Table 2.5: Mouse flow cytometry antibodies
Manufacturer Code Description
Intracellular
eBioscience 53-7021-82 IL-2 Antibody, Alexa Fluor® 488 (Monoclonal,JES6-5H4)
eBioscience 16-0281-85 CD28 Antibody, Functional grade(Monoclonal, 37.51)
eBioscience 13-5773-82 FOXP3 Antibody, Biotin (Monoclonal,FJK-16s)
eBioscience 12-7321-82 TNF alpha Antibody, PE (Monoclonal,MP6-XT22)
eBioscience 16-0031-85 CD3e Antibody, Functional grade(Monoclonal, 145-2C11)
eBioscience 25-5698-82 Ki-67 Antibody, PE-Cyanine7 (Monoclonal,SolA15)
eBioscience 25-7311-82 IFN gamma Antibody, PE-Cyanine7(Monoclonal, XMG1.2)
eBioscience 48-5773-82 FOXP3 Antibody, eFluor® 450 (Monoclonal,FJK-16s)
eBioscience 11-5773-82 FOXP3 Antibody, FITC (Monoclonal, FJK-16s)
Biolegend 106314 PE/Cy7 anti-mouse CD152 Antibodyanti-CD152 - UC10-4B9
BD 554436 APC, Rat Anti-Mouse anti IL-4 11B11
BV421 / AF450
eBioscience 48-0452-82 CD45R (B220) Antibody, eFluor® 450(Monoclonal, RA3-6B2)
eBioscience 48-0081-82 CD8a Antibody, eFluor® 450 (Monoclonal,53-6.7)
eBioscience 48-5931-82 Ly-6G (Gr-1) Antibody, eFluor® 450(Monoclonal, RB6-8C5)
Biolegend 100336 Brilliant Violet 421 anti-mouse CD3epsilonAntibody anti-CD3e - 145-2C11
Biolegend 127628 Brilliant Violet 421 anti-mouse Ly-6GAntibody anti-Ly-6G - 1A8
Biolegend 400429 Brilliant Violet 421 Rat IgG1, kappa IsotypeCtrl
Biolegend 110732 Brilliant Violet 421 anti-mouse CD45.1Antibody anti-CD45.1 - A20
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Manufacturer Code Description
Biolegend 109831 Brilliant Violet 421 anti-mouse CD45.2Antibody anti-CD45.2 - 104
Biolegend 119411 Brilliant Violet 421 anti-mouse CD134 OX-40Antibody anti-CD134 - OX-86
AF700
Biolegend 100216 Alexa Fluor 700 anti-mouse CD3 Antibodyanti-CD3 - 17A2
Biolegend 109224 Alexa Fluor 700 anti-mouse TCR beta chainAntibody anti-TCR beta chain - H57-597
Biolegend 103232 Alexa Fluor 700 anti-mouse/humanCD45R/B220 Antibody anti-CD45R - RA3-6B2
eBioscience 56-5321-82 MHC Class II (I-A/I-E) Antibody, Alexa Fluor®700 (Monoclonal, M5/114.15.2)
eBioscience 56-0042-82 CD4 Antibody, Alexa Fluor® 700 (Monoclonal,RM4-5)
eBioscience 56-0251-82 CD25 Antibody, Alexa Fluor® 700(Monoclonal, PC61.5)
Phycoerythrin (PE)
eBioscience 12-0452-83 CD45R (B220) Antibody, PE (Monoclonal,RA3-6B2)
eBioscience 12-0031-83 CD3e Antibody, PE (Monoclonal, 145-2C11)
eBioscience 12-0081-82 CD8a Antibody, PE (Monoclonal, 53-6.7)
eBioscience 12-0251-83 CD25 Antibody, PE (Monoclonal, PC61.5)
eBioscience 12-5905-83 CD252 (OX40 Ligand) Antibody, PE(Monoclonal, RM134L)
eBioscience 12-0621-83 CD62L (L-Selectin) Antibody, PE(Monoclonal, MEL-14)
eBioscience 12-4031-82 Rat IgG2b kappa, PE Isotype Control
PE-Cy7
eBioscience 25-0452-82 CD45R (B220) Antibody, PE-Cyanine7(Monoclonal, RA3-6B2)
eBioscience 25-0441-81 CD44 Antibody, PE-Cyanine7 (Monoclonal,IM7)
eBioscience 25-3351-82 CD335 (NKp46) Antibody, PE-Cyanine7(Monoclonal, 29A1.4)
eBioscience 25-0041-82 CD4 Antibody, PE-Cyanine7 (Monoclonal,GK1.5)
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Manufacturer Code Description
eBioscience 25-0112-81 CD11b Antibody, PE-Cyanine7 (Monoclonal,M1/70)
Biolegend 100722 PE/Cy7 anti-mouse CD8a Antibody anti-CD8a- 53-6.7
Allophycocyanin (APC)
eBioscience 17-0081-83 CD8a Antibody, APC (Monoclonal, 53-6.7)
eBioscience 17-1341-82 CD134 (OX40) Antibody, APC (Monoclonal,OX-86)
eBioscience 50-4801-82 F4/80 Antibody, eFluor® 660 (Monoclonal,BM8)
eBioscience 17-0042-82 CD4 Antibody, APC (Monoclonal, RM4-5)
eBioscience 17-4321-81 Rat IgG2a kappa, APC Isotype Control
eBioscience 17-4301-81 Rat IgG1 kappa, APC Isotype Control
PerCP5.5
eBioscience 45-0453-82 CD45.1 Antibody, PerCP-Cyanine5.5(Monoclonal, A20)
eBioscience 45-0454-82 CD45.2 Antibody, PerCP-Cyanine5.5(Monoclonal, 104)
eBioscience 45-0042-82 CD4 Antibody, PerCP-Cyanine5.5(Monoclonal, RM4-5)
Alexa Fluor 647
Biolegend 313516 Alexa Fluor 647 anti-human/mouse/rat CD278ICOS Antibody anti-CD278 - C398.4A
Brilliant Violet 510
Biolegend 100559 Brilliant Violet 510 anti-mouse CD4 Antibodyanti-CD4 - RM4-5
Biolegend 107635 Brilliant Violet 510 anti-mouse I-A/I-EAntibody anti-I-A/I-E - M5/114.15.2
Biolegend 117337 Brilliant Violet 510 anti-mouse CD11cAntibody anti-CD11c - N418
Biolegend 313525 Brilliant Violet 510 anti-human/mouse/ratCD278 ICOS Antibody anti-CD278 - C398.4A
Brilliant Violet 711
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Manufacturer Code Description
Biolegend 100747 Brilliant Violet 711 anti-mouse CD8a Antibodyanti-CD8a - 53-6.7
Biolegend 100447 Brilliant Violet 711 anti-mouse CD4 Antibodyanti-CD4 - GK1.5
Biolegend 128037 Brilliant Violet 711 anti-mouse Ly-6CAntibody anti-Ly-6C - HK1.4
Brilliant Violet 785
Biolegend 109839 Brilliant Violet 785 anti-mouse CD45.2Antibody anti-CD45.2 - 104
Biolegend 100552 Brilliant Violet 785 anti-mouse CD4 Antibodyanti-CD4 - RM4-5
Biolegend 103059 Brilliant Violet 785 anti-mouse/human CD44Antibody anti-CD44 - IM7
BD 563329 BV786, Mouse, Anti-Human, CD335 (NKp46),9E2/NKp46
Brilliant Violet 650
Biolegend 100229 Brilliant Violet 650 anti-mouse CD3 Antibodyanti-CD3 - 17A2
Biolegend 102038 Brilliant Violet 650 anti-mouse CD25 Antibodyanti-CD25 - PC61
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Table 2.6: In vivo antibodies
Clone Target Dose Source
RM134L Murine OX40L 250 µg twice weekly
Dr Hideo Yagita,
Juntendo University,
Japan
OX40 FAb Murine OX40 250 µg twice weekly UCB pharma
XMG1.2 Murine IFNγ 500 µg twice weekly BioXCell
Table 2.7: Cell culture additives
Agent Source Concentration(s)used
CTLA4Ig (Abatacept®) Bristol-Myers-Squibb 100 µgml
−1
Mycophenolate mofetil Roche 0.2-20 µgml−1
Interleukin-2 PeproTech 10-40 ngml−1
Interleukin-4 PeproTech 10-40 ngml−1
Interleukin-7 PeproTech 10-40 ngml−1
Interleukin-12 PeproTech 10 ngml−1
Interferon-γ PeproTech 10 ngml−1
Pimozide Sigma-Aldrich 1 µm
Rapamycin Sigma-Aldrich 1 µm
Cyclosporin A Sigma-Aldrich 0.25 µgml−1
Dexamethasone Sigma-Aldrich 1 µm
Anti-CD40L (Clone:MR1) BioLegend 5 µgml−1
Anti-CD40 (Clone: 1C10) BioLegend 5 µgml−1
Anti-CTLA4
(Clone: UC10-4B9) BioLegend 5 µgml
−1
Anti-IL2 (Clone: JES6-
1A12) BioLegend 5 µgml
−1
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Table 2.8: Suppliers
Supplier Location
Abcam Cambridge, UK
Beckman Coulter High Wycombe, UK
BD Biosciences Oxford, UK
BioLegend London, UK
BioXCell West Lebanon, NH, USA
Cedarlane Labs Burlington, NC, USA
Cusabio Ltd. College Park, MD, USA
Dako UK Ltd. Cambridge, UK
EurImmun Lübeck, Germany
Ferndale Leeds, UK
Gibco via Thermo Fisher
Invitrogen via Thermo Fisher
Leica Microsystems Milton Keynes, UK
PeproTech London, UK
Roche Burgess Hill, Sussex, UK
Sigma-Aldrich Gillingham, Dorset, UK
Stemcell Technologies Cambridge, UK
Spherotech Inc. Lake Forest, IL, USA
Thermo Fisher Scientific Paisley, UK
UCB Pharma Slough, UK
Vector Labs Peterborough, UK
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3 Autoimmunity and hepatitis in regulatory T cell deficiency
3.1 Introduction
Acomplete loss of Tregs causes widespread activation of effector T cells with resultant autoimmunity
in multiple organs including the liver.[113] Because of the presence of AMAs, a T cell dominant
peri-biliary infiltrate and up-regulation of mRNAs suggestive of Th1 type response, mice deficient
in Tregs have been suggested to develop a phenotype partly reminiscent of PBC. This description
of FOXP3-deficient mice has however only taken place in a single laboratory.[504] Similar findings
have also been described in other models of disturbed Treg function and these have variously been
described as models of PBC[312, 446] and AIH.[348, 193, 117, 358, 29]
The protein AIRE is involved in the presentation of otherwise tissue-restricted antigens to develop-
ingT cells. Its absence causes deficits inAIRE-/- micewhichdevelop a hepatitiswith autoantibodies.[348]
A small proportion of human autoimmune hepatitis is related to an analogous mutation in the hu-
man AIRE gene. In a mouse model of hepatitis in AIRE dysfunction, the observation has been
made that transfer of wildtype, and therefore polyspecific, regulatory T cells corrects the deficit
and presents hepatitis.[132]The complimentary experiment of investigatingwhetherAIRE-deficient
Tregs are sufficient to prevent multi-system autoimmunity has not been reported. Notably the com-
bination ofAIREdeficiencywith FOXP3makes little difference to the phenotype of FOXP3-deficient
mice.[61]
This series of experiments aimed to recapitulate findings described elsewhere with respect to the
hepatic autoimmunity present in the FOXP3KO mouse and to confirm that FOXP3KO disease could
be transferred to other mice as a basis for later experiments. In addition, to confirm that the disease
was entirely due to a lack of FOXP3-positive Tregs by replacing them, I assessedwhether replacement
of polyspecificTregswould abolish liver autoimmunity, whether transfer of Tregs alonewas sufficient
to prevent disease and whether Treg self-antigen specificity was necessary to control disease.
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3.2 Results
3.2.1 Characteristics of FOXP3KO mice
Male mice deficient in FOXP3 (FOXP3KO) were bred and compared to their FOXP3 heterozygous
female littermates. After analysis at 3-4 weeks of age, FOXP3-deficient mice were phenotypically
smaller, demonstrated dermatitis affecting the tail and ears and developedmarked splenomegaly and
generalised lymphadenopathy (Figure 3.1A). To quantify splenomegaly, whole spleens were dissec-
ted and weighed. Those from FOXP3KO mice weighed significantly more (Figure 3.1B) whilst total
mouse weight was reduced (Figure 3.1C).
FOXP3KO mice develop lymphocytic hepatitis
To evaluate whether FOXP3KO mice developed lymphocytic hepatitis as reported elsewhere, liv-
ers were dissected and examined after haematoxylin and eosin (H&E) staining. This demonstrated
no significant infiltrate in FOXP3-sufficient mice but marked lymphocytic infiltration surrounding
portal triads in FOXP3-deficient mice (Figure 3.2A and B). To better demonstrate leucocytes within
liver tissue, sections were stained for the pan-leucocyte marker CD45 and this demonstrated dense
aggregates of CD45-positive cells surrounding the bile ducts of FOXP3KO mice with only scattered
positive cells in sections from FOXP3-sufficient littermates (Figure 3.2C and D). Subsequent com-
puter quantification demonstrated that there was a significant increase in the proportion of the liver
that was CD45-positive in FOXP3KO mice (Figure 3.2E).
To further characterise the hepatitis seen in FOXP3KO animals, frozen sections were stained with
markers for three different cell types: anti-CD4 to identify likely CD4+ T cells, anti-CD8 to identify
CD8+ T cells and anti-CD11b to demonstrate macrophages and other myeloid cells. Such stain-
ing confirmed the presence of multiple CD4-positive and CD8-positive cells with fewer CD11b-
positive cells centered around portal triads (Figure 3.3). To further characterise the hepatic infiltrate
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Figure 3.1: The FOXP3KO phenotype. (A) FOXP3KO mice (to the right of each panel) are smaller than
FOXP3het littermates at 3-4 weeks of age and develop dermatitis affecting the ears and tail with splenomegaly
and lymphadenopathy (right inguinal lymph node pictured). (B) Splenomegaly and (C) reduced growth were
consistent findings. Comparisons with Mann-Whitney U test.
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associated with FOXP3 deficiency, samples of freshly dissected liver were mechanically digested,
cell suspensions prepared, and fluorochrome-conjugated antibodies used to permit flow cytomet-
ric analysis. Flow cytometry demonstrated modest increases in intrahepatic B cells numbers and
major increases in numbers of CD4+ T cells and CD8+ T cells (Figure 3.4A). Further analysis of
CD3+CD4+ T cells demonstrated a small population that were OX40-positive in FOXP3-sufficient
mouse liver. The majority of these cells were FOXP3-positive indicating that they were Treg. In con-
trast, a significantly greater number of cells were positive for OX40 in FOXP3-deficient animals with
an expected absence of FOXP3-positive cells. Cells from an OX40KO animals was used to confirm
staining specificity.(Figure 3.4B). Further assessment of liver infiltrating cells demonstrated that a
higher ratio of CD8+:CD4+ T cells in FOXP3-deficiency (Figure 3.5A), that a higher proportion of
CD4+ T cells expressed the activation markers ICOS and CD44 (Figure 3.5B), and that a greater
proportion of CD4+ T cells expressed the proliferation marker Ki67 (Figure 3.5C).
FOXP3KO mice express OX40 on infiltrating cells
Having demonstrated flow cytometric evidence of CD4+ rich peri-biliary infiltrates with upregula-
tion of CD4+ T cell expression of OX40 and Ki67 in the livers of FOXP3-deficient mice, immun-
ohistochemistry was used to asssess for supportive evidence and to localise where these cells were
located within tissue. Staining demonstrated that CD4+ cells, OX40+ cells and Ki67+ cells were all
localised around portal triads and in peri-venular areas (Figure 3.6).
FOXP3KO mice display elevated ALT activity but reduced ALP activity
Serum obtained from FOXP3-deficient mice at cardiac puncture was analysed for serum ALT and
ALP activities. Mice deficient in FOXP3 demonstrated significantly increased serum ALT activity
when compared to controls, but demonstrated significant reductions in serum ALP activity (Fig-
ure 3.7A and B). Some samples were frozen and thawed prior to analysis. To ensure that this was
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Figure 3.2: FOXP3KO liver histology. FOXP3 sufficient mice (A) do not demonstrate hepatitis, whereas
FOXP3 deficient mice (B) demonstrate dense peri-biliary / peri-venular lymphocytic infiltrates on examination
of liver histology. Arrowheads denote bile ducts; star denotes extramedullary haematopoiesis. Images taken
at ×20 magnification, H&E. CD45 staining confirmed marked differences in the number of hepatic leucocytes
(C andD). When quantified, a significantly greater proportion of liver sections from FOXP3KOmice was CD45-
positive (E). Comparisons with Mann-Whitney U test through across median values; n=20.
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Figure 3.3: Confocal micrograph of inflammatory infiltrate in the liver of a FOXP3KO mouse. Red =
CD11b, Green = CD8, Cyan = CD4; Grey = DAPI nuclear stain; arrowhead denotes bile duct; ×50 magnific-
ation.
not affecting results, a selection of samples were split and analysed either without freezing or after
being frozen and thawed. No evidence of alteration in enzymatic acitivity was seen after freeze-thaw
for either ALT or ALP (Figure 3.7C and D). In an attempt to determine which of the two major iso-
forms of ALP was responsible for the readings, a technique used in clinical practice was employed.
The bone isoform of ALP is heat labile while the visceral isoform is heat stable. Samples were there-
fore measured before and after heating at 56 ◦C for 15 minutes to denature bone-derived ALP.[292]
Using this method, nearly all enzyme activity disappeared from samples (Figure 3.7E).
FOXP3KO mice demonstrate elevations in serum immunoglobulins
In humanAILD elevations in serum immunoglobulins are present. In order to assess whether serum
immunoglobulins were elevated in FOXP3-deficiency, ELISAs for total serum IgG and IgE were
performed. In both instances, FOXP3-deficient mice had significantly concentrations of serum im-
munoglobulin (Figure 3.8A and B).
103
Co
ntr
ol
FO
XP
3K
O
0
1!106
2!106
3!106
C
el
ls
 p
er
 g
ra
m
 o
f l
iv
er
 ti
ss
ue
p<0.001
Co
ntr
ol
FO
XP
3K
O
0
1!106
2!106
3!106
4!106
5!106
C
el
ls
 p
er
 g
ra
m
 o
f l
iv
er
 ti
ss
ue
p<0.001
Co
ntr
ol
FO
XP
3K
O
0
1!106
2!106
3!106
4!106
C
el
ls
 p
er
 g
ra
m
 o
f l
iv
er
 ti
ss
ue
p=0.022
!""#$%!%&'(() *+,$%-%&'(() *+.$%-%&'(()
/0123
0
1,
#
Co
ntr
ol
FO
XP
3K
O
0
5
10
15
%
 C
D
4 
T 
ce
lls
 F
O
XP
3 
po
si
tiv
e
p<0.001
Co
ntr
ol
FO
XP
3K
O
0
20
40
60
80
100
%
 C
D
4 
T 
ce
lls
 O
X4
0 
po
si
tiv
e
p<0.001
*45674( 01,#80/012380
9
!
Figure 3.4: Lymphocyte contents of FOXP3KO mouse liver. FOXP3KO and control FOXP3 sufficient mouse
livers were assessed at 3-4 weeks of age. (A) Numbers of B, CD4+ T cells and CD8+ T cells were increased
in FOXP3KO livers. (B) OX40 was expressed on a greater proportion of CD4+ T cells in FOXP3KO liver and
FOXP3-positive Treg were absent. Representative plots gated on CD4+ T cells. Comparisons with Mann-
Whitney U test. n=30
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Figure 3.5: Lymphocyte characteristics of FOXP3KO and FOXP3-sufficient mouse livers. FOXP3KO and
FOXP3-sufficient control mouse liver was assessed at 3-4 weeks of age. In FOXP3KO mice, the CD4:CD8
ratio was reduced (A), the proportion of CD4+ T cells that were ICOS positive was increased (B), and the
proportion of of CD4+ T cells that were Ki67 positive was increased. Comparisons using Mann-Whitney U
test. n=30
105
(a) anti-CD45 (b) anti-CD4
(c) anti-OX40 (d) anti-Ki67
Figure 3.6: Histology of the FOXP3KO mouse liver. Numerous (A) CD45-positive, (B) CD4-positive, (C)
OX40-positive, and (D) Ki67 positive cells were apparently within periportal, perivenular inflammatory infilt-
rates.
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Figure 3.7: FOXP3 ALT and ALP activities. When assessed on clinical analysers, FOXP3KO mice demon-
strated elevations in serum ALT activity (A) but unexpectedly reductions in serum ALP (B); n=30. Because
some samples were frozen prior to analysis, some (n=8) samples were split, frozen and then thawed before
being compared against the other half of the sample. This procedure made no difference to readings for either
ALT (C) or for ALP (D). Finally, to investigate whether mouse ALP was heat-labile liver derived or heat-stable
bone-derived, samples were heated at 56 °C for 15 minutes (E). This significantly reduced ALP activity in all in-
stances. Note: all values corrected for any prior dilution, typically 1:3. Comparisons with either Mann-Whitney
U test (A-D) or Kolmogorov-Smirnov test (E)
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Figure 3.8: FOXP3 deficient mice have elevated serum IgG and IgE. Serum was taken from 3-4 week old
FOXP3 sufficient and FOXP3KO mice and assessed for (A) IgG and (B) IgE by ELISA. The concentrations of
both antibodies were significantly increased in FOXP3KO mice. Comparisons by Mann-Whitney U test; n=30.
FOXP3KO mice demonstrate anti-mitochondrial antibodies
It has been reported elsewhere that mice deficient in FOXP3 develop AMA.[504] To confirm this,
either control FOXP3-sufficient or FOXP3 deficient serum was applied to composite sections of
rat liver, kidney and stomach followed by an anti-IgG FitC-conjugated secondary antibody. This
demonstrated diffuse cytoplasmic staining in proximal renal tubule, hepatocyte and gastric parietal
cell cytoplasm consistent with the presence of AMA (Figure 3.9A). Similarly, imaging of the sim-
ilar composite slides stained with serum and then stained with an anti-IgG or anti-IgM antibody
demonstrated positive staining in FOXP3-deficient but not FOXP3-sufficient animals (Figure 3.9B).
Having demonstrated evidence of AMA in the sera of FOXP3-deficient animals by microscopy, sera
were further assessed by ELISA (Figure 3.10). ELISA demonstrated signal for IgG AMA at up to 1
in 640 titre in pooled sera from FOXP3-deficient animals but not in sera from control animals (A).
When ELISAs were repeated across multiple animals, there were significant elevations in IgG, IgM,
and IgA (B).
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Figure 3.9: Indirect immunofluoresence demonstrates AMAs in FOXP3KO serum. (A) Serum applied
to composite section of rat liver, kidney and stomach demonstrated diffuse positive staining of cytoplasm in
FOXP3-deficiency but not in FOXP3 sufficient animals when assessed using an anti-IgG FitC-conjugated
secondary antibody (green). (B) Similarly, confocal imaging of composite liver, kidney and stomach sections
demonstrated positive staining for IgG (green; FitC) and IgM (red; 555 phalloidin) when analysed by confocal
microscopy.
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Figure 3.10: AMAs are present in FOXP3KO mouse serum. (A) Serial dilutions of FOXP3KO mouse serum
revealed high titre reactivity with recombinbant PDC-E2 demonstrating the presence of AMA. (B) In contrast
to FOXP3 sufficient littermates, FOXP3KO mouse serum contained significantly more IgG, IgM and IgA AMA.
Comparisons made with Mann-Whitney U test; n=30.
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3.2.2 Comparison of FOXP3KO and FOXP3KOOX40hetCD30het mice
Because of breeding limitations, the generation of mice deficient in FOXP3 in the experiments
described above was performed by crossing wildtype male mice homozygous for the CD45.1 al-
lele with females from an inbred colony of FOXP3-/-OX40-/-CD30-/- mice homozygous for CD45.2.
This had the result that female offspring had the genotype FOXP3+/-OX40+/-CD30+/- whilst male
offspring had the genotype FOXP3y/-OX40+/-CD30+/-. Phenotypically, the female pups appeared
normal as previously reported whilst the male pups developed features consistent with FOXP3-
deficiency.[105] Although this breeding wasmore predictable and sustainable in terms of producing
FOXP3-deficient animals for experimentation, it raised the question as towhether these animals het-
erozygous for functional OX40 and CD30 behaved similarly to animals purely deficient in FOXP3.
To assess this, a breeding programme beginning with females from the above cross was initiated
to re-derive pups purely deficient in FOXP3. Once female mice that were genotypically identical
to standard C57Bl/6 except for being FOXP3+/- were derived these were bred with normal males
so that half of male offspring were FOXP3-deficient. These FOXP3y/- pups were then compared
to FOXP3y/-OX40+/-CD30+/- from the original programme. There were no significant differences
between pups heterozygous and sufficient for functional OX40 and CD30 (Figure 3.11).
3.2.3 FOXP3KO disease transfers to ZAP70KO mice but is worse in RAGKO mice
In preparation for cohort experiments comparing groups of animals deficient in Treg, adoptive
transfer experiments were established. When consideringwhich transfer recipient hostmouse strain
to use, head-to-head assessment of RAG-/- and ZAP70-/- was performed (Figure 3.12). Animals
were simultaneously repleted with 5 × 106 total thymocytes from FOXP3-deficient donors. Mice
were monitored for three weeks before sacrifice and analysis. Results demonstrated no difference
in spleen weight but significant reductions in serum ALT activity, serum IgG, AMA concentration
as assessed by ELISA, and numbers of liver-infiltrating CD8+ T cells in ZAP70-/- as compared to
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Figure 3.11: FOXP3KOOX40hetCD30het mice are similar to pure FOXP3KO mice. Comparisons were made
between mice wildtype for FOXP3 (control), OX40 and CD30, mice deficient in FOXP3, and mice deficient in
FOXP3 and also heterozygous for OX40 and CD30 (FOXP3KO.het; n=8v5v5). Mice were analaysed at 3-4
weeks of age. (A) There was no significant difference in spleen size but FOXP3-deficient mice demonstrated
increased spleen weight (B), increased serum ALT acitivity (C) and increased titres of serum AMA (D) as
compared with control animals; there was no difference between FOXP3-deficient animals replete or hetero-
zygous for OX40 and CD30. FOXP3-deficient animals did not show any increase in hepatic B cells (E) but
demonstrated increases in CD4+ T cells (F) and CD8+ T cells (G). (H) Histological assessment after staining
with H&E is shown demonstrating the presence of similar peri-biliary lymphocytic infiltrates in both genotypes
of FOXP3 deficient mice. Comparisons made with Kruskal-Wallis test with Dunn’s post-hoc test; n=7v5v5.
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RAG-/- recipients. Representative sections of liver after H&E staining showed reduced extent of
hepatic lymphocytic infiltrate in ZAP70-/- recipients as compared to RAG-/- recipients.
3.2.4 FOXP3KO disease can be prevented by co-transfer of wildtype cells
To investigate whether transfer of intact Tregs could protect mice deficient in FOXP3 frommultisys-
tem and hepatic autoimmunity, a co-transfer experiment was performed: zeta-chain-associated pro-
tein kinase 70 (ZAP70)-deficient mice were repleted with 5 × 106 total thymocytes from FOXP3-
deficient mice. 5 days after initial transfer, hosts received a second transfer of total wildtype lymph-
ocytes sufficient to provide 100 000 Tregs. Mice were then observed for evidence of deterioration
by animal house staff unaware of their treatment group, or until 9 weeks. Mice that received wild-
type Tregs survived significantly longer than control animals, showed less splenomegaly and reduced
hepatic accumulation of CD4+ T cells and CD8+ T cells (Figure 3.13).
Similarly, flow cytometric assessment revealed that whilst co-transfer of intact Tregs did not alter
intrahepatic B cell numbers, it prevented intrahepatic accumulation of CD4+ and CD8+ T cells, and
reduced numbers of CD44+ CD4+ T cells, IFNγ-secreting CD4+ T cells, and ICOS-positive T cells
(Figure 3.15).
3.2.5 FOXP3KO disease can be prevented by co-transfer of regulatory T cells
To confirm that the liver inflammation of FOXP3 deficiency disease could be controlled by trans-
fer of Tregs alone, adoptive transfer of FOXP3KO thymocytes into ZAP70-/- hosts was performed.
Then, to test the potential for purified regulatory T cells alone to correct disease, some mice then
received a further transfer of 100 000-200 000 purified FOXP3-positive cells. Cells were purified to
over 95% purity by sorting on GFP-positive cells from cell suspensions prepared from FOXP3-GFP
mice (Figure 3.16). Co-transfer of Tregs abrogated FOXP3KO disease (Figure 3.17 & 3.18)
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Figure 3.12: FOXP3KO transfer hepatitis is more marked in RAG-/- than ZAP70-/- recipients. Total thymo-
cytes (5× 106) were transferred into either RAG-/- (n=6) or ZAP70-/- (n=7) recipients. These mice were mon-
itored for three weeks before analysis. There was no difference in spleen weight (A), but serum ALT was higher
in RAG-/- recipients. AMA were present in ZAP70-/- recipients but not RAG-/- recipients (C). D. Numbers of B
cells were greater in the livers of ZAP70-/- recipients, there was no difference in numbers of CD4+ T cells, but
numbers of CD8+ T cells were greater in RAG-/- recipients. H&E staining demonstrated more marked lympho-
cytic infiltration in RAG-/- than ZAP70-/- recipients (representative histology; 10×magnification). Comparisons
with Mann-Whitney U test; n=6v7
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Figure 3.13: Co-transfer of total wildtype cells rescues FOXP3KO transfer disease. ZAP70-/- mice re-
ceived adoptive transfer of total thymocytes from FOXP3-deficient animals. 5 days later mice received a
second transfer of either total wildtype lymphocytes or vehicle alone. Mice that received wildtype lymphocytes
showed increased survival (A), reduced splenomegaly (B), no change in AMA titre (C), a reduction in serum
ALT activity (D), and a reduction in serum TNFα (E). Comparisons with Log-Rank or Mann-Whitney U test;
n=13v13.
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100µm100µm
FOXP3KO transfer only FOXP3KO and WT transfer
Figure 3.14: Co-transfer of total wildtype cells rescues FOXP3KO transfer disease. ZAP70-/- mice re-
ceived adoptive transfer of total thymocytes from FOXP3-deficient animals. 5 days later mice received a
second transfer of either total wildtype lymphocytes or vehicle alone. Mice that received wildtype lymphocytes
showed did not manifest lymphocytic peri-venular infiltrates. Representative H&E images.
3.2.6 FOXP3KO disease can be prevented by transfer of AIREKO regulatory T cells
Having demonstrated that repletion with exogenous Tregs was sufficient to prevent the development
of multi-system autoimmunity and lymphocyte hepatitis in Treg deficiency, the issue of antigen-
specificity was considered. Mice bred with loss of function mutations in the AIRE gene were used
to prepare suspensions of total lymphocytes. These were assessed by flow cytometry with staining
for CD3, CD4 and CD25. CD3+CD4+CD25high cells were assumed to represent Tregs.
ZAP70-/- mice were repleted with 5 × 106 FOXP3-deficient total thymocytes. 5 days later somemice
received sufficient total peripheral AIRE-deficient or wildtype lymphocytes to provide 200 000 Tregs
or vehicle alone. Mice were then observed for up to 6 weeks or the point at which they were ad-
judged to be unwell by animal technicians unaware of the treatment arm. At the point of analysis,
those mice that had not received an additional cell transfer demonstrated significantly reduced sur-
vival (Figure 3.19A), increased serumTNFα (Figure 3.19B), increased splenomegaly (Figure 3.19C),
increased ALT activity (Figure 3.19D), but no significant difference in serum IgG AMA concentra-
tion as assessed by ELISA (Figure 3.19E).There were no significant differences between animals that
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Figure 3.15: Co-transfer of total wildtype cells rescues FOXP3 transfer disease. ZAP70-/- mice received
adoptive transfer of total thymocytes from FOXP3-deficient animals. 5 days later mice received a second trans-
fer of either total wildtype lymphocytes or vehicle alone. Mice that received wildtype lymphocytes showed no
difference in numbers of intrahepatic B cells (A), a reduction in intrahepatic CD4+ T cells, CD8+ T cells, CD44+,
IFNγ-producing and ICOS-positive CD4+ T cells (B-F). Comparisons with Mann-Whitney U test; n=13v13.
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Figure 3.16: Sorting of green fluorescent protein (GFP)-positive regulatory T cells. Prior to transfer
experiments, purified suspensions of regulatory T cells were prepared from FOXP3-GFPmice. Representative
plots gated on CD3-positive cells derived from the spleens of FOXP3-GFP mice. Approximately 95% purity
was obtained after sorting as demonstrated by flow cytometry examining GFP in cells without intracellular
staining (A) and by using an anti-FOXP3 antibody (B).
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Figure 3.17: Transfer of purified regulatory T cells prevents FOXP3 transfer disease. ZAP70-/- T cell
deficient mice received adoptive transfer of FOXP3KO cells. Some mice also received 200 000 purified Tregs
generated from FOXP3-GFPmouse spleen. Transfer of purified Tregs prevented overt development of autoim-
mune disease and increases survival (A), reduced the onset of splenomegaly (B), non-significantly reduced
serum ALT activity (C), non-significantly reduced serum AMA titre (D), did not significantly affect numbers of
hepatic B cells (E), reduced intrahepatic CD4+ T cell accumulation (F), and reduced CD8+ T cell accumulation
(G). Comparisons by Mann-Whitney U test; n=8.
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Figure 3.18: Transfer of purified Tregs prevents FOXP3KO transfer disease: histology. ZAP70-/- T cell
deficient mice received adoptive transfer of FOXP3KO cells. Some mice also received 200 000 purified Tregs
generated from FOXP3-GFP mouse spleen. Transfer of purified Tregs prevented the development of peri-
venular lymphocytic infiltrates (A), reduced numbers of intrahepatic cells staining positive for both CD45 (B),
and Ki67 (C). Representative images shown.
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received cells from wildtype and AIRE-deficient animals.
Similarly, flow cytometric analysis of liver-infiltrating cells demonstrated that, similar to mice that
received wildtype Tregs, mice that received AIRE-deficient Tregs showed a significant reduction in
the numbers of infiltrating T cells but with no differences between mice receiving the two different
types of Tregs (Figure 3.20). Consistent with flow cytometric findings, mice that received either
wildtype or AIRE-deficient Tregs did not develop the highly Ki67-positive CD4-rich lymphocytic
infiltrate seen in those mice that received only FOXP3KO cells (Figure 3.21).
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Figure 3.19: AIRE-/- cells protect against FOXP3KO disease: phenotype. ZAP70 T cell deficient mice
received adoptive transfer of FOXP3KO cells. Some mice also received either total wildtype splenocytes or
total AIRE-/- splenocytes. Receipt of either FOXP3KO or AIRE-/- cells increased survival (A), reduced serum
TNFα (B), reduced splenomegaly (C), reduced serum ALT (D), and showed a trend towards a reduction in
AMA titre; n=7v8v7.
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Figure 3.20: AIRE-/- cells protect against FOXP3KO disease: flow cytometry. Plots demonstrating that
although co-transfer of either wildtype or AIRE-/- cells into FOXP3KO recipients (A) makes no significant differ-
ence in numbers of B220+ B cells, (B andC) it reduces the extent of both CD8+ and CD4+ infiltrate, (D) reduces
numbers of CD44+ and (E) IFNγ-secreting CD4+ T cells. Comparisons via Kruskal-Wallis test; n=7v8v7.
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Figure 3.21: AIRE-/- cells protect against FOXP3KO disease: histology. Images show representative
liver histology from ZAP70-/- mice that received FOXP3KO cells. Some mice also received total wildtype (WT)
splenocytes or total AIRE-/- splenocytes. In mice that received only FOXP3KO cells, a dense lymphocyte
hepatitis with numerous CD45-, CD4-, and Ki67-positive peri-venular / peri-biliary cells developed. In mice
that also received either WT or AIRE-/- cells, this infiltrate was abolished.
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3.3 Discussion
The primary aim of this chapter was to recapitulate the striking findings of hepatic pathology repor-
ted by the Gershwin group: dense, T cell rich peri-biliary lymphocytic infiltrates with an increased
CD8+:CD4+ ratio, elevations in serum effector cytokines including TNFα, and the development of
AMA.[504] The results presented here indeed recapitulate those reported by the Gershwin group,
but also add some further findings that represent useful measures to be used in subsequent experi-
ments.
First, I record that both serum total IgG and total IgE concentrations are increased in mice with
FOXP3 deficiency: the former a typical finding in human AIH and common in PBC.[203] Second,
I demonstrate elevation in serum ALT activity: again a common finding in human AILD; notably
however, elevations in ALT activity were not as marked as in some other models of AIH.
A third outcome measured here was serum ALP activity. Unexpectedly, in comparison with others’
work suggesting a correlation between biliary injury and ALP in C57Bl/6 mouse models e.g. [373],
I record a consistent inverse correlation and subsequently via differential heat stability demonstrate
that the enzyme activity that was recorded was likely to be of extra-hepatic origin. This is consistent
with a recent analysis of the tissue origins of murine ALP.[241] This finding led to the discontinu-
ation of ALP measurements for the remainder of this project, and questions its suitability as an
outcome measure when considering liver disease, at least in the C57Bl/6 strain.
The work presented in this chapter was designed to assist in the design of future experiments. Spe-
cifically, because of the unpredictability of breeding, the short natural lifespan, and small size of
FOXP3 deficient mice, a transfer system into larger host animals that would permit multiple simul-
taneous experimental animals to be generated at once was desirable. Thus, the establishment of an
adoptive transfer model described represents a useful basis for future experiments.
In choosing potential hosts for these experiments, both RAG deficient and ZAP70 deficient hosts
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were used. Interestingly, in head-to-head comparison, the liver injury seen was worsened in RAG-
deficient animals. This observation corresponds to a contemporaneous report that γδ T cells have
some protective role in the autoimmunity resultant in T cell deficientmice repletedwith FOXP3 defi-
cient cells.[426]Notably, ZAP70-deficientmice have γδ T cells, but RAG-deficientmice do not.[183]
A second difference between ZAP70 and RAG deficient mice is that the latter lack B cells. The
absence of B cells is reported as important for the generation of pathology in FOXP3 deficient mice,
and the findings here contrast with this in that pathology was worse in the relatively B cell deficient
RAG-/- recipients.[9] Notably however, the method for cell transfer used here did not remove B cells
and so animals were likely to be partially repleted with donor B cells. Given the lesser baseline
immunological deficit of ZAP70-deficient mice, this strain was used for subsequent experiments.
As a method of confirmation of the causative deficit in these animals being deficiency in Tregs, co-
transfer experiments were performed. First, as expected, co-transfer of total wildtype lymphocytes
prevented FOXP3-deficiency transfer disease. To demonstrate absolutely that Tregs alone were suffi-
cient to prevent the manifestations of FOXP3-deficiency, Tregs from mice expressing GFP alongside
FOXP3 were isolated using cell sorting and co-transferred into mice. This too was effective and
is consistent with previous reports of generally reduced autoimmunity with transfer of Tregs.[100]
Such approaches have relevance to IPEX patients in the context of gene therapy: autologous cells
might be removed, transfected with functional FOXP3, expanded and re-infused without risk of
graft versus host type reactions and little risk of rejection.
Having read with interest that transfer of intact Tregs into mice with an AIH-like phenotype lacking
functional AIRE reversed hepatitis[132], and in the context of a direct human disease correlate to
these mice,[348, 437] I used a co-transfer model to explore whether AIRE-deficient Tregs could
prevent hepatitis in FOXP3-deficiency. In contrast to what might be expected from the reported
ability of wildtype Tregs to abolish inflammation in AIRE deficiency, AIRE-deficient Tregs were
able to abolish hepatic inflammation in this model.
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Weaknesses in this approach
Possible criticisms of the work presented in this chapter include the relatively short time course of
the experiments. HumanAILDs typically result in chronic fibrosis, an outcome that was not assessed
here. Further, arguably to draw greater analogies to human disease, a wider variety of autoantibodies
might have been assessed, although testing kits were less available. Arguably, cell populations used
for transfer experiments might have been purer: e.g. rendered devoid of B cells and other non T
cells, but there was concern that this might alter the transferred T cell phenotype.
In addition, only a small number of potential cell transfer recipients were explored. It may have been
preferable to use a strain such as the T-cell receptor alpha chain (TCRα)-deficientmouse which lacks
only αβ T cells so as tominimise deviation fromwildtype. With respect to experiments assessing the
role for AIRE, a determination as to whether intermittent AIRE-negative donormice had developed
hepatitis was not performed.
Future experiments
Future work based on the work presented in this chapter largely revolves aroundmanipulation of the
transfer models presented e.g. by the administration of potentially therapeutic compounds or the
co-transfer of other cell types such as Tregs deficient in specific compounds. An ideal comparison
material would be liver samples from human individuals with the IPEX syndrome or individuals
with dysfunction in AIRE, but such material is not readily available.
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4 OX40-OX40L blockade in regulatory T cell deficiency
4.1 Introduction
The TNF receptor OX40 is primarily expressed on CD4+ T cells after their activation. It is ligated by
its cognate ligand OX40L, which is expressed on activated antigen presenting cells, on some innate
lymphoid cells, on natural killer T (NKT) cells, and on T cells. Ligation of OX40 promotes cell
survival, enhances effector function and tends to decrease regulatory activity.[72] Blockade ofOX40-
OX40L interactions has been demonstrated to be effective in many animal models of autoimmunity,
but not universally.[471]
The autoimmunity of FOXP3 deficiency results from a complete absence of Tregs. There is un-
restrained activation of effector T cells and several organ systems are damaged by infiltration with
activated lymphocytes in what is an ultimately fatal systemic disease. Because mice with FOXP3
dysfunction develop hepatitis and the AMA that are characteristic of the human autoimmune liver
disease PBC, FOXP3 dysfunction has been described as approximating aspects of the human dis-
ease. Previouswork has shownmarked increases in overall survival ofmicewith FOXP3dysfunction
given blocking OX40L antibody or co-deficient in OX40, but the livers of these mice were not ex-
amined in detail, nor were parameters such as ALT, serum IgG or autoantibodies assessed.[105]
One reason for examining the liver specifically is that divergent effects on autoimmunity in different
organ systems have been described in other mouse models of regulatory failure.[492, 505, 291]
This chapter details experiments investigating whether OX40 deficient mice have any major dis-
turbance of the intrahepatic lymphocyte population before assessing whether blocking antibody to
OX40L prevents the hepatitis seen in FOXP3KO transfer disease. It then proceeds to consider a differ-
ent blocking mechanism. An anti-OX40 antigen-binding region of antibody (Fab) fragment is then
considered in the same model before investigating whether inhibition of OX40-OX40L interaction
alters the T-cell dependent Con A model of hepatitis or the T cell independent hepatitis seen after
administration of CCl4. Finally, histological evidence of OX40 expression in human liver disease is
sought.
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Figure 4.1: Basic histology of OX40KO mouse liver. Representative sections stained with H&E are shown
from wildtype and OX40KO mice. Unmanipulated OX40 deficient mice have normal appearances to their livers
without visible infiltrate.
4.2 Results
4.2.1 OX40 deficient and wildtype mice have similar intrahepatic lymphocyte populations
Prior to using antibody preparations to block interactions of OX40 and OX40L, the livers of un-
manipulated mice both sufficient and deficient (OX40KO) in OX40 were examined as a reference
baseline for further experiments. These mice appeared healthy and microscopic examination of
their liver structure was normal without obvious infiltrate (Figure 4.1).
Flow cytometric analysis of intrahepatic lymphoyctes was undertaken and although this did not
demonstrate alterations in total numbers of B cells, total CD4+ T cells or total CD8+ T cells, pro-
portions and absolute numbers of FOXP3+ Tregs were reduced, and the proportion of cells negative
for CD44 was decreased (Figure 4.2).
4.2.2 Blocking anti-OX40L prevents FOXP3KO transfer hepatitis
To investigate the effects of blocking OX40-OX40L interactions on FOXP3KO hepatitis, a transfer
model was used. ZAP70-/- T cell deficient mice were injected with 5 × 106 total FOXP3KO thymo-
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Figure 4.2: OX40KO mouse hepatic lymphocyte populations. The lymphocyte populations of OX40-
deficient mice were examined by flow cytometry and compared to samples from age-matched wildtype mice.
No significant differences in total numbers of (A) B cells, (B) CD4+ T cells, or (C) CD8+ T cells were evident.
However, both numbers (D) and the proportion of CD4 T cells that were FOXP3 positive (E) were reduced; a
higher proportion of CD4+ T cells also expressed CD44 (F). (G and H) flow cytometry panels representative
of results presented in panels E and F. Comparisons with Mann-Whitney U test; n=9v9.
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cytes IP. Mice were then split into two groups and either treated with 250 µg of rat antagonistic
anti-OX40L IgG twice weekly or with an identical dose of non-specific total rat IgG. Mice were then
observed for deterioration for six weeks and either analysed at the point of deterioration or the end
of the experiment.
Overall, mice treated with anti-OX40L showed markedly increased survival with all individuals sur-
viving to the end of the experiment (Figure 4.3A). Similarly, other markers of evidence of systemic
immune activation were decreased by the administration of anti-OX40L including spleen size and
serum IgG and IgE concentrations (Figure 4.3B, E & F). Further, both serum ALT and AMA titres
were reduced by the administration of anti-OX40L.
When the livers of mice treated with anti-OX40L IgG after FOXP3KO thymocyte transfer were ex-
amined, the liver appearances had normalised with complete abolition of lymphocytic infiltrate
when examined microscopically (Figure 4.4A&B). This was confirmed by a significant decrease
in the proportion of liver sections that stained positive for the pan-leucocyte marker CD45 (Fig-
ure 4.4C-E).
Flow cytometric analysis of FOXP3KO thymocyte recipients that had received anti-OX40L showedno
significant differences in numbers of hepatic B cells but showed reductions in both CD4+ and CD8+
T cells (Figure 4.5A-C). Further examination of hepatic CD4+ T cells demonstrated that nearly all
remained CD44-positive but that expression of the activation marker ICOS was markedly reduced
(Figure 4.5D-F).
4.2.3 Blocking anti-OX40 Fab prevents FOXP3KO transfer hepatitis
Having demonstrated that administration of blocking anti-OX40L antibody reduced generalised
and liver autoimmunity in deficiency of Tregs, it was considered that the antibody might have been
directly causing depletion of T cells through fixation of complement. Therefore to both investigate
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Figure 4.3: FOXP3KO transfer hepatitis and anti-OX40L blocking antibody. ZAP70-/- mice received
FOXP3KO total thymocytes and were assessed for the development of generalised autoimmunity and hep-
atitis. In comparison to administering control rat total IgG, administration of 250 µg of blocking anti-OX40L
twice weekly from day 5 after cell transfer, prevented all deaths in the treated group (A), prevented the de-
velopment of splenomegaly (B), reduced biochemical evidence of hepatitis in the form of serum ALT activity,
reduced AMA titre (D), and reduced serum IgG (E) and serum IgE (F). Results represent the combination of
two separate experiments of 21 mice total. p values represent either the log-rank test for survival analysis or
the Mann-Whitney U test. Not all samples were analysed for IgE. Comparisons with Mann-Whitney U test;
n=10v11.
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Figure 4.4: FOXP3KO transfer hepatitis and anti-OX40L blocking antibody. ZAP70-/- mice received
FOXP3KO total thymocytes and were assessed for generalised autoimmunity and hepatitis. Those mice that
were given twice weekly control total rat IgG developed marked lymphocytic peri-venular hepatitis (A). How-
ever, those mice that were treated with twice weekly from day 5 after cell transfer with anti-OX40L antibody
did not develop hepatitis (B). Liver sections were stained for the pan-leucocyte marker CD45 highlighting
the lymphocytic infiltration in control animals (C) and its abolition in those treated (D). (E) When CD45 infilt-
rates were digitally quantified, they were significantly reduced in those mice treated with anti-OX40L antibody.
Results represent the combination of two separate experiments. Comparisons with Mann-Whitney U test;
n=10v11; images A and B taken at × 20 magnification, C and D at × 10.
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Figure 4.5: FOXP3KO transfer hepatitis and anti-OX40L blocking antibody. ZAP70-/- mice received
FOXP3KO total thymocytes and were assessed for generalised autoimmunity and hepatitis. The adminis-
tration of twice weekly blocking anti-OX40L antibody did not alter numbers of liver B220+ B cells (A), but
caused significant reductions in numbers of CD4+ T cells (B), and CD8+ T cells (C). The proportion of CD4+ T
cells expressing CD44 was not altered by anti-OX40L (D), but the expression of ICOS was markedly reduced
(E). Representative plots gated on liver CD4+ T cells are shown (F). p values represent the Mann-Whitney U
test; combination of two experiments with 21 mice in total.
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whether blockade ofOX40would have similar results to blockade ofOX40L and also to seewhether a
reagent unlikely to fix complement was effective, the experiment was repeated using an antagonistic
anti-OX40 Fab fragment.
Results of blockade of OX40-OX40L interactions with anti-OX40 Fab were similar to those with
anti-OX40L antibody. First, mice given anti-OX40 Fab had markedly increased survival (Figure
4.6A), but also decreased markers of immune activation including reduced splenomegaly and levels
of serum IgG, but in contrast to treatment with anti-OX40L, no reduction in serum IgE was ob-
served. (Figure 4.6B, E & F). Similarly, reductions in serum ALT and in AMA titres were seen after
blocking anti-OX40 (Figure 4.6C&D).
Histological examination of livers from mice that had received anti-OX40 Fab demonstrated elim-
ination of the lymphocytic peri-portal, peri-venular infiltrate seen in those treated with control an-
tibody alone. (Figure 4.7A&B). Consistent with this observation was the significant decrease in the
proportion of liver sections that stained positive for the pan-leucocyte marker CD45 (Figure 4.8C-
E).
Flow cytometric analysis of FOXP3KO thymocyte recipients that had received anti-OX40 Fab showed
no significant differences in numbers of hepatic B cells but showed reductions in both CD4+ and
CD8+ T cells (Figure 4.8A-C). Further examination of hepatic CD4+ T cells demonstrated that
nearly all remained CD44-positive but that expression of the activation marker ICOS was markedly
reduced (Figure 4.8D-E). Further, the proportion of liver CD4+ T cells that expressed IFNγ after
stimulation was reduced after adminstration of anti-OX40 Fab.
4.2.4 Concanavalin A induced hepatitis is not affected by OX40 deficency
To investigate whether deficiency inOX40 rendered T cells less able to cause liver damage, the ConA
model of hepatitis was used. Mice were given a single dose of IV Con A before analysis 24 hours
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Figure 4.6: FOXP3KO transfer hepatitis and anti-OX40 Fab fragment: phenotype. ZAP70-/- mice received
FOXP3KO total thymocytes and were assessed for the development of generalised autoimmunity and hepatitis.
In comparison to administering control rat total IgG, administration of 250 µg of blocking anti-OX40 Fab twice
weekly from day 5 after cell transfer, increased survival in the treated group (A), prevented the development
of splenomegaly (B), reduced biochemical evidence of hepatitis in the form of serum ALT activity (C), reduced
AMA titre (D), reduced serum IgG (E), and reduced serum IgE (F). Results represent the combination of two
separate experiments. Comparisons with Log-Rank or Mann-Whitney U test; n=10v10.
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Figure 4.7: FOXP3KO transfer hepatitis and anti-OX40 Fab fragment: histology. ZAP70-/- mice received
FOXP3KO total thymocytes and were assessed for the development of generalised autoimmunity and hepatitis.
Those mice that were given twice weekly control total rat IgG developed marked lymphocytic peri-venular
hepatitis (A). However, those mice that were treated with twice weekly with anti-OX40 Fab did not develop
hepatitis (given from day 5 after cell transfer; (B). Liver sections were stained for the pan-leucocyte marker
CD45 highlighting the lymphocytic infiltration in control animals (C) and its abolition in those treated (D). When
CD45 infiltrates were digitally quantified, they were significantly reduced in those mice treated with anti-OX40
Fab (E). Results represent the combination of two separate experiments. Comparisons with Mann-Whitney U
test; n=10v10.
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Figure 4.8: FOXP3KO transfer hepatitis and anti-OX40 Fab fragment: flow cytometry. ZAP70-/- mice
received FOXP3KO total thymocytes and were assessed for generalised autoimmunity and hepatitis. The
administration of twice weekly blocking anti-OX40 Fab did not alter numbers of liver B220+ B cells (A), but
caused significant reductions in numbers of CD4+ T cells (B), and CD8+ T cells (C). The proportion of CD4+
T cells expressing CD44 was not altered by anti-OX40 Fab (D), but the expression of ICOS was markedly
reduced (E) as were the proportion that produced IFNγ after stimulation (F). Representative plots gated on
liver CD4+ T cells are shown (G) and (H). Comparisons with Mann-Whitney U test; n=10v10.
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later.
Con A was given to wildtype, OX40KO and ZAP70-/- mice. When serum ALT was measured, there
was no significant difference in serum ALT elevation between wildtype and OX40KO mice, although
elevations were entirely absent in ZAP70-/- individuals (Figure 4.9A). A similar patternwas observed
with serum glucose: there was no difference in the reductions of capillary glucose seen between
wildtype and OX40KO animals (Figure 4.9B). Consistent with these observations, the degree of peri-
portal hepatocyte necrosis was similar between wildtype and OX40KO animals but no necrosis was
evident in ZAP70-/- animals (or wildtype animals treated with PBS (Figure 4.9C-F)).
Flow cytometric analysis of intrahepatic lymphocytes in animals treated with Con A revealed no
significant changes in numbers of B- or CD4+ T cells (Figure 4.10A&B) but did demonstrate an
increase in CD8+ T cells that was not altered by deficiency in OX40 (Figure 4.10C). The proportion
of CD4+ T cells expressing CD44 and ICOS was increased by Con A administration but not altered
by deficiency inOX40, whereas, although adminstration ofConA resulted in the expression ofOX40
on CD4+ T cells, this was not seen on OX40KO cells as expected (Figure 4.10D-G)
4.2.5 Carbon tetrachloride induced hepatitis is not affected by anti-OX40L pre-treatment
To investigate whether blocking OX40-OX40L interactions alters the response to chemical liver in-
jury, wildtype mice were pre-treated either with anti-OX40L antibody or control IgG before being
injected with CCl4 IV. The injection of CCl4 caused the development of peri-portal necrosis as de-
scribed elsewhere, but this was not altered significantly by pre-treatment with blocking anti-OX40L
antibody (Figure 4.11).
Pre-treatment with anti-OX40L did not alter the rise in serum ALT seen with CCl4 injection (Fig-
ure 4.12A). Similarly, flow cytometric analysis of intrahepatic lymphocytes after adminstration of
CCl4 with and without pre-treatment with anti-OX40L antibody revealed no significant differences
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Figure 4.9: OX40 deficiency does not ameliorate concanavalin A hepatitis. Wildtype, OX40-deficient and
T cell deficient ZAP70-/- mice were given Con A IV to induce hepatitis with some wildtype animals given PBS as
a control. As previously reported, Con A caused an elevation in serum ALT from which T cell deficient animals
were protected (A). Similarly, Con A caused a reduction in serum glucose from which T cell deficient animals
were protected (B). No difference was seen between OX40KO and wildtype animals (A and B). When livers
were examined similar confluent peri-portal necrosis was apparent in both wildtype animals (C) and OX40KO
animals given Con A (D), but absent from wildtype animals treated with PBS (E) and from ZAP70-/- animals
(F). Comparisons with Mann-Whitney U test; n=4v7v7v4.
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Figure 4.10: OX40 deficiency does not ameliorate concanavalin A hepatitis. Wildtype, OX40-deficient
and T cell deficient ZAP70-/- mice were given Con A IV to induce hepatitis with some wildtype animals given
PBS as a control. No differences were seen in numbers of B- or CD4+ T cells as a result of administration of (A)
and (B), whilst numbers of CD8+ T cells were increased C. No differences in numbers of B cells, CD4+ T cells
or CD8+ T cells were seen in OX40KO deficient mice. Similarly, although Con A increased the proportion of
CD4+ T cells expressing CD44 (D), ICOS (E), and OX40 (F), deficiency in OX40 did not alter activation as
measured by CD44 or ICOS upregulation; (G) CD4+ T cells became activated incuded in OX40KO animals
as expected. p values denote Mann-Whitney U tests. Values presented represent a combination of three
separate experiments; n=4v7v7v4.
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in the increases in B and CD8+ T cells nor in the diminution of CD4+ seen with treatment (Fig-
ure 4.12B-D).
4.2.6 OX40 and OX40L in human liver disease
Having demonstrated OX40 expression in a mouse model of human autoimmune liver disease and
that blocking interactions between OX40-OX40L ameliorated disease in that model, evidence of
upregulation of OX40 in human autoimmune liver disease was sought.
OX40 expression in human explant liver
Samples of human liver taken from explants removed at the liver transplant program based at Uni-
versity Hospitals Birmingham were assessed by immunohistochemistry. First it was demonstrated
that OX40 was expressed in a variety of liver pathologies including AIH and PBC, but was generally
absent in samples from liver explants from patients without known liver disease (Figure 4.13).
Having demonstrated staining of OX40 in sections of liver tissue, dual staining was used to investig-
ate whether OX40 was predominantly expressed on CD4 T cells as reported in other inflammatory
conditions. This was indeed the case with dual-positive CD4+ OX40+ cells typically being evident
in areas of dense CD4+ T cell accumulation (Figure 4.14).
Having demonstrated that OX40+ cells were present in several liver diseases, a semi-quantitative
scale for their assessment was designed to permit basic comparison between diseases (Figure 4.15A).
This was then applied to a total of 87 explant cases from livers from invididuals without a known
liver diagnosis, those with a history of alcohol-induced liver disease, those with PBC, and those with
AIH. Minimal OX40 expression was seen in both the group without known liver disease and those
with alcohol-induced disease; in contrast, significantly greater amounts of OX40 staining was seen
in the PBC and AIH groups (Figure 4.15B).
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Figure 4.11: Carbon tetrachloride hepatitis in anti-OX40L treated mice: histology. Panels depict repres-
entative histology after H&E staining. After administration of CCl4, confluent necrosis was visible around portal
venules with sparing around hepatic venules in both mice administered control IgG (A) and in mice pre-treated
with anti-OX40L blocking antibody (B). Mice treated with vehicle only (mineral oil without CCl4) did not develop
necrosis (C). Images labelled (D) and (E) represent higher magnification images of peri-venular necrosis from
mice given control IgG and anti-OX40L antibody respectively. Representative images are shown.
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Figure 4.12: Carbon Tetrachloride hepatitis in anti-OX40L treated mice. Wildtype mice were given either
mineral oil (vehicle) or carbon tetrachloride:mineral oil as a single IP injection. Some mice were pre-treated
with blocking anti-OX40L antibody. 48 hours later mice were analysed for biochemical evidence of hepatitis
and numbers of B220+ B cells, CD4+ T cells and CD8+ T cells in the liver by flow cytometry. (A) Serum ALT
values were significantly increased in those mice that received CCl4 but were not altered by the administration
of anti-OX40L. (B) Numbers of liver B cells were increased by the administration of CCl4 but not altered by
pre-treatment with anti-OX40L. (C) Numbers of liver CD4+ T cells were reduced by the administration of CCl4
but were not affected by pre-treatment with anti-OX40L antibody. (D) Numbers of CD8+ T cells were increased
by CCl4 but not altered by pre-treatment with anti-OX40L antibody. Plots are combinations of two experiments.
Comparisons with Mann-Whitney U tests between ‘vehicle only’ and other conditions; n=4v8v8.
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Figure 4.13: OX40 is expressed in diseased human liver tissue. Representative sections of human liver
tissue stained for OX40 and counter-stained with haematoxylin. Panels (A) to (C) represent liver from pa-
tients without known liver disease but with varying degrees of steatosis, none of which showed significant
positive staining for OX40. The following three panels represent positive staining in three inflammatory liver
conditions: the autoimmune conditions PBC (D) and AIH (E), and the non-autoimmune condition non-alcoholic
steatohepatitis (F).
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Figure 4.14: Dual staining of OX40 and CD4 in human autoimmune liver disease. Selected liver explant
sections were stained for OX40 and CD4, both separately and simultaneously. Representative section of
explant liver from a patient with PBC presented. The pattern of OX40 expression being within areas rich in
CD4+ T cells was consistent through multiple specimens.
OX40 expression on liver biopsies
In an attempt to assess whether OX40 expression in human liver disease was limited to end-stage
liver disease or present at the point of diagnosis, a number of liver biopsy specimens were obtained
and stained for OX40. These were then scored according the maximum number of OX40 positive
cells in a given focus. Staining was variable between sections and tended to centre on portal areas
with OX40+ cells located within foci of lymphocytic infiltration in a similar manner to the pattern
seen in explant samples (Figure 4.16A-C). When the number of OX40 positive cells was correlated
with the an independent pathologist’s assessment of inflammatory activity, therewas a significant but
weak correlation between increased OX40 expression and increased inflammation although many
or the most inflamed samples did not show OX40 staining (Figure 4.16D). When specimens were
divided according to the patient’s final diagnosis of either normal, non-alcoholic fatty liver disease
(NAFLD), AIH or hepatitis C virus (HCV), there was significantly greater OX40 staining amongst
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Figure 4.15: Semi-quantitative staining of OX40 expression in human liver disease. To allow assessment
of the extent of positive OX40 staining in human liver tissue, a semi-quantitative staining system was devised.
This was performed according the greatest number of OX40 positive cells in any one inflammatory aggregate.
For explant samples these were categorised as a score of 0 for no positive cells, 1 for 1-5 as a single focus, 2
for 5-10 and 3 for >10 by the author whilst unaware of the pathologist-issued diagnosis (A). A total of 77 cases
were examined and graded and demonstrated that explant livers from patients affected by either AIH or PBC
contained significantly more OX40-positive cells than those from patients with no known injury or injury from
alcohol (B). Comparisons with Kruskal-Wallis test with Dunn’s post-hoc test.
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both AIH and HCV cases when compared to normal. (Figure 4.16E).
Given the observation thatOX40 positive staining appeared to correlatewith inflammation, attempts
weremade to correlate the extent ofOX40positive staining in biopsy sampleswith a variety of clinical
variables including those associated with hepatic inflammation. 88 samples were analysed. There
was a significant but weak positive correlation between both the transaminases ALT and aspart-
ate aminotransferase (AST) and OX40 positivity and a near-significant correlation with serum IgG
concentrations (Figure 4.17A-C). In contrast, no significant correlation was seen with hæmoglobin
concentrations, serum bilirubin, serum creatinine, age or Fibroscan resistivity – a measure of the
severity of liver fibrosis (Figure 4.17D-H).
Serum OX40L in primary biliary cholangitis
Having demonstrated expression of OX40 in human liver tissue both at explant to permit orthotopic
liver transplantation and on percutaneous biopsy specimens, evidence of systemic upregulation of
the OX40-OX40L axis was sought. To permit this an ELISA was used to measure serum levels of
soluble OX40L. However no difference was apparent between patients with PBC and healthy control
patients (Figure~4.18).
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Figure 4.16: Liver biopsies of inflammed livers demonstrate cells positive for OX40. Multiple human liver
biopsies were obtained from patients being investigated for liver disease and stained for OX40. Not all biopsies
showed positive staining and where there was positive staining this was seen within foci of inflammation on
lymphocytes (A and B). The most dense staining was seen surrounding bile ducts (C; bile duct starred).
There was a significant but weak correlation between pathologist-assessed extent of inflammation and OX40
staining (D). Significantly more OX40 staining was seen in those ultimately diagnosed with AIH or HCV than
those who were not diagnosed with any liver disease (E). Assessment for trend between inflammation grades
was performed with the nptrend test; comparisons between diseases were made with the Kruskal-Wallis test
with Dunn’s post-hoc comparisons. 88 samples were analysed in total.
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Figure 4.17: OX40 positive staining on liver biopsies correlates with markers of inflammation. Multiple
human liver biopsies were obtained from patients being investigated for liver disease, stained for OX40 and
the extent of OX40 positive staining correlated with various clinical variables. There was a significant positive
correlation as assessed by least squares linear regression with two biochemical indices of liver inflammation:
serum ALT and AST activity (A&B) and a near-significant positive correlation with serum IgG concentration,
an indirect marker of inflammation (C). There was however no significant correlation with hæmoglobin con-
centration, serum bilirubin, serum creatinine, age or fibrosis as measured by Fibroscan resistivity (D-H).
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Figure 4.18: Serum soluble OX40L in PBC and in health. Serum from 28 PBC patients and 23 healthy
controls was analysed for its soluble OX40L content. 12 PBC samples and 8 control samples were below the
assay sensitivity of 28pg/ml. Comparison with Mann-Whitney U-test.
4.3 Discussion
This chapter has presented work suggesting that overall numbers of lymphocytes in OX40-deficient
mouse liver are not different from matched wildtypes although there are fewer Tregs and cells ten-
ded towards a more activated phenotype. It was then demonstrated that a both a blocking anti-
OX40L antibody and a blocking anti-OX40 antibody were sufficient to prevent the development
of FOXP3KO transfer hepatitis and also to reduce markers of generalised autoimmunity. Interfering
with OX40-OX40L signalling however had no effect on either the T cell dependent hepatitis induced
by Con A injection or the chemical hepatitis induced by CCl4 injection. Finally, evidence of OX40
expression in human liver disease was sought. OX40 was found to be upregulated in both AIH and
PBC explanted liver in comparison to undiseased liver and that affected by alcohol; biopsy stud-
ies also demonstrated significantly greater OX40 expression in AIH liver than normal liver but also
demonstrated postivitiy in HCV, and to a lesser extent, NAFLD affected liver. OX40 positive stain-
ing correlated with clinical markers of liver inflammation although systemic serum soluble OX40L
was not elevated in PBC.
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The observation that OX40KO mice have similar numbers of intrahepatic lymphocytes to wildtype
animals represents a baseline with regards to other experiments presented in this thesis and makes
it unlikely that the blocking antibodies used will have major effects on intrahepatic T cell num-
bers. The apparent reductions in intrahepatic Treg numbers in OX40KO animals when compared to
wildtype animals differ from a previous report that numbers were similar between wildtype anim-
als and OX40KO animals.[487] However, Xiao et al. only reported that around 1% of total hepatic
CD4+ T cells were FOXP3 positive in both wildtype and OX40 deficient animal livers compared
with wildtype readings of around 3% [397], around 8% [38] and around 10% [477] in other studies,
and around 10% in wildtype mouse liver in this work. This may have masked changes.
In addition, it is reported that stimulation through OX40 by the agonistic OX86 antibody or by the
creation of mice transgenic so that they over-express OX40L causes increases in peripheral and hep-
atic numbers of Treg, and that OX40 is important for Treg survival.[217, 487] These observations
support the notion that interrupting OX40 signalling may alter Treg numbers. More experiments,
ideally in mice of different backgrounds and in combination with long-term administration of ag-
onistic and blocking antibodies are needed to further investigate this. As well as altering survival or
genesis of Tregs, alterations in their migration induced by OX40 blockade may also be important in
regulatory homeostasis.
The finding that blocking anti-OX40L prevented the development of hepatitis in T cell deficient an-
imals repleted with FOXP3KO deficient cells is consistent with previous work by the Lane group but
extends the observation to specific assessment of the liver.[105] This work also extends observations
to specific measurement of autoantibodies. As noted above, this was important because therapeutic
manipulations in other mice with analogous deficiencies in T cell regulation have shown divergent
effects on inflammation in different organ systems.[492, 505, 291] Importantly when considering
administration of OX40-OX40L for potential human therapeutic use, blocking antibody injections
were started well before the onset of evidence of FOXP3KO transfer disease at day 5 following cell
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transfer. Our animal licence prevented permitting the development of overt autoimmunity before
commencing therapy but this would be a logical extension of the study. In addition, divergent ef-
fects of OX40-OX40L blockade on autoimmunity have been reported in relation to the initiating
insult.[322] Given that OX40 and OX40L are understood to be a cognate receptor-ligand pairing
with no significant interactions with other ligands, it could be argued that blocking OX40 with an
anti-OX40 Fab fragment preparation was functionally equivalent to using a complete antagonistic
anti-OX40L antibody. However, the result that blocking OX40 Fab prevented autoimmunity is im-
portant for two reasons: first, because by lacking the ability to fix complement the reagent is unlikely
to cause depletion of cells expressing its target antigen and second, because the manufacturer (UCB
Pharma) has a directly analogous anti-human compound in production. The effect of blocking anti-
OX40 Fab was generally similar to that of blocking OX40L except for the lack of a reduction in serum
IgE. This may reflect the fact that total IgE in control animals in this experiment was not as elevated
as otherwise so presenting less opportunity for a significant reduction after therapy to be observed.
In addition, because IgE measurements could only be completed on a subset of animals, statistical
power is reduced.
Administration of Con A causes a massive release of cytokines through the non-specific cross-
linkage of TCRs and the subsequent release of cytokines – including IFNγ and TNFα which then
induce hepatocyte necrosis and apoptosis.[415, 129]The fact thatOX40 deficientmice still suffer this
cytokine-mediated hepatitis is consistent with observations that OX40-deficient T cells still retain
the ability to secrete effector cytokines.[471] However, it is possible that in less acute insults that
were more dependent on co-stimulatory signals differences may have been more apparent.[157]
The unchanged ability of CCl4 to cause hepatitis in the absence of OX40 is consistent with the direct
chemical injury caused by that compound , which has otherwise been noted to persist in entirely T
cell deficient mice.[309]
In an attempt to demonstrate parallels between the upregulation of OX40 in mouse FOXP3KO trans-
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fer hepatitis shown in the previous chapter, the efficacy of blocking OX40-OX40L signals in this
model of autoimmunity in this chapter, and human liver disease, evidence of expression of OX40 in
human disease was sought. Staining was uncommon in normal liver but was present in a variety of
liver diseases including both AIH and PBC. This is consistent with a number of studies of human
autoimmunity affecting other organs. However, because differences in the extent of OX40 were not
observed between two non-autoimmune diseases, NAFLD and HCV infection, that are associated
with lymphocytic infiltrate and because OX40 staining was positively correlated with clinical indices
of liver inflammation when multiple diagnoses were assessed together, it may be that the presence
of OX40 in human liver disease simply represents T cell activation rather than a process specific to
autoimmunity per se. In further investigating OX40 expression in human liver disease, other meth-
ods of OX40 quantification including qPCR, flow cytometric analysis and a wider variety of liver
diagnoses would be valuable. In addition, when considering analogies between the work presented
in this chapter and human disease, samples from patients with IPEX would be valuable because of
their pathogenic equivalence.[482]
Weaknesses in this approach
One criticism of this work is that it was not possible to allow overt disease to develop in themice that
received FOXP3KO deficient cells before commencing treatment with either blocking anti-OX40L or
anti-OX40. This related to licensing requirementswithin the animal facilitywhere these experiments
took place. A second potential criticism is the subjective methodology with regards to survival ana-
lyses: animals were not allowed to die, only to deteriorate to the point where one of the animal
technicians became concerned. Although the technicians were blinded as to the treatment groups,
this represents an area of potential subjectivity.
Whilst the experiments presented here using cells frommice deficient in AIRE derived from animals
that had been genotyped as such and were from colonies known to develop lymphocytic hepatitis,
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one criticism of this work is that autoimmune liver disease was not confirmed in these animals prior
to their use as donors. Ideally these experiments would be repeated with animals with manifest
autoimmune liver disease.
The human work presented here does not account for the other multiple parameters that may affect
including gender, age, concurrent pharmacological therapies. Further, the immunohistochemistry
based methodology does not subphenotype the cells assessed nor quantify them absolutely.
Future experiments
This work has confirmed that either OX40 or OX40L blockade is effective in reducing autoimmunity
in the absence of Tregs. A logical extension of this work is to extend assessment of the efficacy of
blockade of OX40 and OX40L interactions in other forms of autoimmunity. For example, AIRE
deficient mice where autoimmunity appears to relate to deficiencies in certain subpopulations of
antigen-specific Tregs or equally to other similar models such as the recently reported mice with
dysfunction of Fzef2 or TRAF6 in which there are failures of thymic selection.[406, 29]
Further, one of the weaknesses of the current assessment is that antibody blockade was administered
prior to the onset of clinically apparent disease in contrast to the likely use of these agents in any
therapy for human disease. A useful further experiment would be delaying treatment until the onset
of observable features of disease and then measuring for efficacy.
An exciting potential application of these findings would be to apply these insights to the human
disease IPEX. There is potentially very great utility in limiting autoimmunity in the lead up to stem
cell allografting in an attempt to limit use of non-specific immunosuppressive agents. Again, those
with AIRE dysfunction and resultant type 2 AIH would be intriguing cases to assess.
To extend the work in human phenotyping presented here, assessment of cell numbers per unit
weight of explant liver could be assessed by flow cytometry. This would also allow concurrent assess-
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ment of other indicators of cell activation, determination of the proportion that expressed markers
of a regulatory phenotype, and comparison with numbers of other cell types present within the liver.
It would be particularly interesting to assess whether OX40 expression delineates those cells specific
for an antigen of interest as has been suggested in some animal models of autoimmune disease and
in human type 1 diabetes mellitus.[478, 264, 92]
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5 OX40 blockade in CTLA4-deficient mice
5.1 Introduction
Having demonstrated that blockade of OX40 is effective in preventing the autoimmunity of transfer
disease, a related question was whether other models of T cell regulatory failure associated with
liver disease may also be ameliorated by blocking OX40-OX40L interactions. Mice deficient in
CTLA4, a key molecule involved in negatively regulating co-stimulation through the CD28 path-
way, develop multisystem autoimmunity with associated lymphocytic infiltrates.[462, 416] Similar
to FOXP3 deficiency[194], there is an ongoing requirement for CTLA4 throughout life with indu-
cible knockouts developing multisystem autoimmunity including hepatitis.[205]
Liver disease in CTLA4 deficient mice as assessed by simple histological examination is described
but has not been further characterised.[462, 205] By analogy, both mice and humans treated with
blocking antibodies to CTLA4, typically as part of cancer immunotherapy, may develop hepatic
autoimmunity.[443, 195, 119, 177] and case series of multi-system autoimmunity in individuals het-
erozygous for dysfunctional CTLA4 exist, some of whom developed hepatic autoimmunity.[366,
222]
In this chapter, evidence of the production of AMAwas sought in a variety of mice that develop liver
injury. CTLA4-deficientmicewere shown to spontaneously develop lymphocytic hepatitis alongside
AMAs, and this was explored further by assessing the efficacy of blockingOX40-OX40L interactions
in ameliorating this hepatic and generalised autoimmunity.
5.2 Results
5.2.1 Antimitochondrial antibodies are present in CTLA4-deficient mice
In order to examinewhetherAMAdeveloped inCTLA4-deficient aswell as a selection of other avail-
able mice with either induced or spontaneous liver damage, or withmulti-system autoimmunity fol-
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Figure 5.1: AMAs in various mice. (A) Sera from a number of mice with immune-dysregulation or liver
injury were screened for the presence of AMA using the ELISA described previously. Having identified the
presence of AMAs in (B) CTLA4-/- mice, these mice were compared against FOXP3KO mice as positive control
and against littermates lacking the genotype of interest. C57Bl/6 = wildtype mice; CCl4 = 8-week carbon
tetrachloride treated; Con A = recovered Con A treated mice; MDR2 = multidrug resistance protein-2 deficient
(Abcb4-/-) mice; OVA-Bil = mice expressing ovalbumin on biliary epithelium injected with OT1 ovalbumin-
specific T cells. Comparisons with Kruskal-Wallis test with Dunn’s post-hoc test.
lowing aberrations in CD4+T cell regulation, sera were collected and assessed according to the same
AMA ELISA described previously (Figure 5.1A). Here, although AMA were consistently present in
CTLA4-deficient mice (Figure 5.1B), they did not develop in other models of generalised autoim-
munity associated with disturbances in Treg function (AIRE deficiency and RelB deficiency), in
exogenous chemical injury (CCl4), in T cell cytokine mediated injury (Con A), direct ovalbumin-
targeted T cell mediated biliary injury (OVA-Bil), or in endogenous chemical injury following dis-
ruption of a key biliary transporter (MDR2-/-).
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5.2.2 Characterisation of CTLA4 deficiency
Having identified AMA in CTLA4 deficient mice, further assessments of the general and hepatic
phenotype of these mice were made. CTLA4-deficient mice demonstrated runting with spleno-
megaly and generalised lymphadenopathy (Figure 5.2A-C). In addition, and consistent with some
analogy to human AILD, CTLA4-deficient mice demonstrated elevations in serum transaminase
activity (Figure 5.2D), and elevations in serum IgG (Figure 5.2E).
Flow cytometric analysis confirmed elevations in hepatic lymphocyte numbers in CTLA4-deficient
animals with these lymphocytes displaying amore activated phenotype including greater expression
of OX40 (Figure 5.3). In addition, proportions of cells expressing FOXP3 consistent with Tregs were
identified and a greater proportion of CD4+ T cells showed evidence of recent proliferation through
Ki67 staining and produced IFNγ after stimulation (Figure 5.4).
Histological examination of liver from CTLA4-deficient animals confirmed dense lymphocytic in-
filtrates with numerous cells in these infiltrates staining positive for CD4, OX40, and Ki67 (Fig-
ure 5.5).
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Figure 5.2: Phenotype of CTLA4 deficient mice. Mice either homozygous for dysfunctional CTLA4, het-
erozygous for functional CTLA4 or with two wildtype CTLA4 genes were analysed at 3-4 weeks of age. (A)
Mice lacking CTLA4 were runted and (B) demonstrated splenomegaly and lymphadenopathy (inguinal lymph
node shown; centimetre scale). (C) The finding of splenomegaly was consistent between groups. (D) CTLA4
deficient mice also demonstrated mild elevations in serum transaminase activities suggestive of liver injury
and (E) demonstrated elevations in IgG. Comparisons with Mann-Whitney U test; n=8v8v7. Centimetre scale
shown in photograph.
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Figure 5.3: Flow cytometric analysis of hepatic lymphocytes in CTLA4 deficiency. Livers from 3-4 week
old CTLA4+/+, CTLA4+/- or CTLA4-/- pups from several litters were assessed for lymphocyte content. (A) B cells
(B) CD8+ T cells and C. CD4+ cells were increased and the proportion of CD4+ T cells positive for (D) ICOS
(E) CD44, and (F) OX40 were increased in CTLA4-/- mice as compared with CTLA4+/+ controls; heterozygous
CTLA4+/- did not differ from CTLA4+/+. (G) representative plots gated on CD4+ T cells. Comparisons with
Kruskal-Wallis test with Dunn’s post-hoc test; n=8v8v7.
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Figure 5.4: CTLA4-/- mouse liver flow cytometric analysis (continued). CTLA4-/- pups have more hepatic
regulatory T cells, more IFNγ producing cells and more proliferating cells. Livers from 3-4 week old CTLA4+/+,
CTLA4+/- or CTLA4-/- pups from several litters were assessed for lymphocyte content. A greater proportion
of CD4+ T cells were (A) FOXP3+ (B) Ki67+ and (C) IFNγ positive (after being stimulated for 4 hours with
PMA/Ionomycin) in CTLA4-/- animals compared with CTLA4+/+ or CTLA4+/-. Representative plots gated on
CD4+ T cells. Comparisons with Kruskal-Wallis test with Dunn’s post-hoc test; n=8v8v7.
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Figure 5.5: Histological analysis of CTLA4 deficient mouse liver. (A) and (B) CTLA4+/+ and CTLA4-/-
mouse liver sections stained with H&E. (C) CTLA4-/- liver section stained for OX40. (D) CTLA4-/- liver sec-
tion stained for CD4. (E) and (F) CTLA4+/+ and CTLA4-/- mouse liver sections stained for Ki67. All images
representative and taken at ×10 and ×20 magnification.
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5.2.3 Blockade of OX40 signalling in CTLA4 deficiency
Having demonstrated similarity between the hepatic and general phenotype of CTLA4-deficient
and FOXP3-deficient animals, the ability of blockade of OX40-OX40L signalling to ameliorate the
autoimmunity of CTLA4 deficiency was assessed. T-cell deficient ZAP70-/- hosts were repleted with
total peripheral lymphocytes fromCTLA4-deficient donor animals. Animals were then treated with
blocking anti-OX40 antibody or total IgG control. In contrast to the significant amelioration of dis-
ease in FOXP3 deficiency, OX40 blockade did not increase survival, nor reduce splenomegaly or
lymphadenopathy (Figure 5.6). Further, there were no significant differences in the hepatic lymph-
ocyte populations as assessed by flow cytometry (Figure 5.7) or by examination of liver histology
(Figure 5.8).
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Figure 5.6: Blocking OX40 antibody does not ameliorate disease after transfer of CTLA4-/- cells.
ZAP70-/- mice deficient in T cells were repleted with total peripheral lymphocytes from CTLA4-/- animals. Some
animals were given blocking anti-OX40 antibody. A smaller number of ZAP70-/- mice were transferred with
FOXP3KO cells to confirm the continued efficacy of the antibody in treating that disease. (A) Survival of mice
that received CTLA4-/- cells was not altered by anti-OX40 antibody; (B) Spleen weight was not altered by
blocking anti-OX40; (C) Mesenteric lymph node weight was not altered by blocking anti-OX40. Comparisons
with Log-Rank or Mann-Whitney U test; n=25.
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Figure 5.7: Blocking OX40 antibody does not ameliorate disease after transfer of CTLA4-/- cells.
ZAP70-/- mice deficient in T cells were repleted with total peripheral lymphocytes from CTLA4-/- animals. Some
animals were given blocking anti-OX40 antibody. A smaller number of ZAP70-/- mice were transferred with
FOXP3KO cells to confirm the continued efficacy of the antibody in treating that disease. No significant differ-
ence were seen in hepatic (A) B220+ B cells numbers, (B) CD4+ T cell numbers, (C) CD8+ T cell numbers,
(D-F) numbers of CD4+ T cells producing IFNγ, IL-4 or IL-17 after stimulation. There were no differences in
the proportions of CD4+ positive T cells positive for FOXP3 (G) or ICOS (H). Comparisons with Mann-Whitney
U test between treated and untreated groups; n=25.
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Figure 5.8: Blocking OX40 antibody does not ameliorate disease after transfer of CTLA4-/- cells.
ZAP70-/- mice deficient in T cells were repleted with total peripheral lymphocytes fromCTLA4-/- animals. Some
animals were given blocking anti-OX40 antibody. A smaller number of ZAP70-/- mice were transferred with
FOXP3KO cells to confirm the continued efficacy of the antibody in treating that disease. Animals treated
with blocking anti-OX40 Fab showed similar lymphocytic infiltrates to control animals (A) and (B) Infiltrates in
treated animals remained rich in (C) CD4+ T cells and (D) Ki67-positive cells.
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5.2.4 Co-deficiency of CTLA4 and OX40
Having demonstrated a lack of efficacy of antibody blockade in ameliorating CTLA4 deficiency
disease, to both examine whether the presence of OX40-OX40L interactions during development
altered the phenotype of CTLA4 deficiency and to exclude an insufficient dosage of blocking anti-
OX40 Fab in the previous experiment, animals co-deficient in CTLA4 and OX40 were produced.
Of note, because of limitations in the laboratory’s mouse breeding programme, these animals were
co-deficient in CD30.
When assessed by degree of splenomegaly or the presence of AMA, there was no significant differ-
ence in the phenotype of animals co-deficient in OX40 and CD30 when assessed at 3-4 weeks of
age.(Figure 5.9).
When intrahepatic lymphocytes were assessed by flow cytometry, there were increases in the num-
bers of CD4+ T cells seen with co-deficiency of OX40 and CD30, but no other differences when
compared with purely CTLA4-deficient animals (Figure 5.10). Correspondingly, histological ex-
amination revealed no significant differences in the lymphocytic, CD4 T cell rich, Ki67-positive cell
rich periportal hepatic infiltrate seen in CTLA4-deficient animals (Figure 5.11).
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Figure 5.9: Co-deficiency in OX40 and CD30 does not protect against CTLA4-/- disease. 3-4 week old
mice that were either deficient in CTLA4 (CTLA4-/-), deficient in CTLA4, OX40 and CD30 (CTLA4KODKO) or
sufficient in CTLA4 but deficient in OX40 and CD30 (CTLA4WTDKO)were killed. Co-deficiency in OX40 and
CD30 did not significantly alter either (A)the splenomegaly associated with CTLA4 deficiency or (B) reduce
the titre of AMA that developed. Comparisons with Mann-Whitney U test; n=8v8v7.
5.3 Discussion
The two major findings presented in this chapter are, first, that the liver phenotype of mice with
dysfunctional CTLA4 is similar to that seen in mice with dysfunctional FOXP3 and, second, that in
contrast to FOXP3 dysfunction, CTLA4 dysfunction is not ameliorated by blockade ofOX40-OX40L
interactions.
Thefinding thatCTLA4-deficientmice develop liver autoimmunitywithAMAs andhyper-expression
of OX40 in a similar way to those with FOXP3 dysfunction is not surprising: uncharacterised liver
infiltrates have been demonstrated in multiple other models of regulatory failure.
By screening a number of mice with different mechanisms of systemic autoimmunity with both
autoimmune and otherwise induced liver injury, our assay showed that the development of AMAs
was not universal with liver inflammation in contrast to the uncertainty regarding AMAs expressed
by others.[150] One reason for this may be that Hohenester et al., used much older mice than those
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Figure 5.10: Co-deficiency in OX40 and CD30 does not protect against CTLA4-/- disease: flow cyto-
metry. 3-4 week old mice that were either deficient in CTLA4 (CTLA4-/-), deficient in CTLA4, OX40 and CD30
(CTLA4KODKO) or sufficient in CTLA4 but deficient in OX40 and CD30 were killed and their livers analysed.
(A) There were no differences in numbers of B cells between groups; (B) There were markedly greater num-
bers of CD8+ T cells in both strains deficient in CTLA4; (C) There were greater numbers of intrahepatic CD4+
T cells in CTLA4 deficient animals, with slightly more CD4+ T cells in CTLA4KODKO mice than those purely
deficient in CTLA4. (D) Fewer CD4+ T cells were ICOS-positive in mice sufficient in CTLA4 whilst (E) no
significant differences were seen in the proportion of cells that expressed CD44 between groups. (F) OX40
expression was consistent with genotype. Comparisons with Mann-Whitney U test; n=8v8v7.
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Figure 5.11: Co-deficiency in OX40 and CD30 does not protect against CTLA4-/- disease. 3-4 week old
mice that were either deficient in CTLA4 (CTLA4-/-), deficient in CTLA4, OX40 and CD30 (CTLA4KODKO)
or sufficient in CTLA4 but deficient in OX40 and CD30 were killed. When stained with H&E, lymphocytic
infiltrates were similar between CTLA4-/- (A) and CTLA4KO.DKO animals (B) but absent in CTLA4-/- sufficient
DKO animals C. Infiltrates in CTLA4KODKO animals were rich in Ki67 (D) and CD4 (E) positive cells.
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assessed here, and generalised autoimmunity in aged C57Bl/6 mice is well described.[134]
CTLA4 is nearly exclusively expressed by Treg and by activated and memory effector T cells.[137,
333] As such, the failure of interruptions of OX40-OX40Lmight reasonably be ascribed to an inabil-
ity to compensate for the loss of immune regulation caused by a loss of non-TregsCTLA4. Consistent
with an important immune regulatory role for non-Treg CTLA4, some groups have reported being
able to selectively delete CTLA4 on Treg without provoking the massive autoimmunity seen in com-
plete CTLA4 deficiency.[166, 327] In these models, loss of Treg CTLA4 results in both expansion
in numbers and increased activation of conventional T cells, but not organ infiltration. This phen-
otype contrasts with the lethal multi-system autoimmunity seen in mice with induced deficiency in
CTLA4 across all cells.[205] Supporting a key role for non-Treg CTLA4, one that is more important
than that for Treg CTLA4 is the observation that bone marrow chimeras of CD4 deficient mice with
CTLA4 deficient mice are able to control multi-system autoimmunity whereas chimeras with mice
deficient in all T cells are not.[102]
Such a failure of OX40 blockade to regulate autoimmunity in CTLA4 deficiency despite its appar-
ent efficacy in FOXP3 dysfunction makes it challenging to predict whether OX40-OX40L blockade
might be of therapeutic utility in human CTLA4-related disease. In both therapeutic CTLA4 block-
ade related autoimmunity and constitutive abnormalities in CTLA4, it remains unclear as towhether
the dominant driver of pathology is interruption of Tregs or of the action of CTLA4 on conventional
T cells. If the former, OX40-OX40L blockade may be effective; if the latter, it seems less likely to
work.
Weaknesses in this approach
One criticism of these experiments is the lack of a positive control in the antibody OX40-OX40L
blockade experiments. It is possible that the antibody used was not effective. However, the anti-
body used was drawn from the same batch as that used in successful therapy of animals with FOXP3
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dysfunction, and lack of efficacy of co-deficiency in OX40 is consistent with the results of the anti-
body blockade experiments and excludes an effect from insufficient dosing.
An additional criticism of the co-deficiency experiments presented here is that rather than being
purely co-deficient in OX40 and CTLA4, the mice bred here were triply deficient: in OX40, CD30,
and CTLA4. This breeding strategy was a constraint of the mouse colonies available. Previous work
has shown that dually OX40- and CD30 deficient mice appear healthy but have impaired memory
responses.[106] In co-deficiency experiments involving FOXP3 andCD30 andOX40, the expression
of OX40 wasmore important with CD30-deficient FOXP3-deficient animals dying only shortly after
those purely deficient in FOXP3.[105]
Future experiments
To further assess whether OX40-OX40L blockade is sufficient to control the loss of immune regula-
tion induced by the loss of Treg CTLA4, a logical extension of this work would be to assess whether
OX40-OX40L blockade suppressed the activation and expansion seen in the specific inducible de-
ficiency models.[166, 327] Supportive in vitro experiments examining the effect of OX40-OX40L
blockade on proliferation and activation of combinations of Tregs and conventional T cells with
and without CTLA4 would also be feasible. An additional question is whether the autoimmunity
produced by generalised deficiency of CTLA4 induced during adulthood is controllable by OX40-
OX40L blockade, and indeed this has been tried and shown to be ineffective (Unpublished observa-
tion, Kajsa Wing, Karolinska Institutet; communication to Lane Group).
The uncertainty as to whether the anti-cancer efficacy of CTLA4 blockade was related to activity on
Tregs or on effector T cells led one group to develop a mouse which expressed the human form of
CTLA4. By co-transfer experiments of Tregs and conventional T cells and the use of anti-human
and anti-murine blocking anti-CTLA4 antibodies, it could be demonstrated that the anti-tumour
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effect required blockade of effector T cell CTLA4.[329] A similar model would permit delineation
of the defect controlled by OX40 blockade.
A furthermethod of investigating the question of the role of non-Treg CTLA4would be to repeat the
CTLA4 deficient transfer experiments reported here, but into a third group of animals also transfer
CTLA4-sufficient cells depleted of Tregs andOX40; such experimentsmight however be complicated
by transdifferentiation of conventional T cells into Tregs.
Finally, combiningwork from the preceding chapter and this, if Tregs fromCTLA4-deficient animals
could be purified, it would be interesting to see if they could control autoimmunity when transferred
into the FOXP3-deficient transfer model reported in the preceding chapter. If the results were con-
sistent with those of selective CTLA4 depletion on Treg reported elsewhere[166, 327], then some
resolution might be expected. However, this contrasts with a report that CTLA4Ig is able to rescue
FOXP3 deficient mice.[385]
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6 OX40 blockade in Roquin sanroquemutant mice
6.1 Introduction
Mice homozygous for the sanroquemutant Roquin 1 gene have impaired post-transcriptional regu-
lation of mRNA and have greatly increased expression of T cell co-stimulatory molecules alongside
the development ofmulti-organ lymphocytic infiltrates.[438, 497]Key amongst these co-stimulatory
molecules are ICOS and OX40.[439] Liver disease is described but its assessment has not been pub-
lished other than as images of plain histology. No human equivalent mutation is recognised, al-
though the RoquinMM phenotype has been described as analogous to human systemic lupus eryth-
ematosus, in which there may be hepatitis.[383] A further aspect of Roquin dysfunction is a loss
of control of IFNγ production and subsequent increased expression.[341] Given that others have
reported the development of intrahepatic lymphocytic infiltrates and AMA in increased IFNγ pro-
duction, an association between RoquinM/M and AMA was considered.[14]
Having demonstrated that Roquin sanroque mutant mice develop AMA and lymphocytic hepat-
itis, further experiments to assess whether blockade of OX40-OX40L interactions ameliorated this
phenotype were performed. In addition, given the elevations in IFNγ production seen in Roquin
mutant mice and their association with liver disease elsewhere, the efficacy of antibody blockade of
anti-IFNγ was assessed.
6.2 Results
6.2.1 Roquin sanroquemutant mice develop antimitochondrial antibodies
As demonstrated in Figure 5.1, RoquinM/M mice were seen to develop AMA in a screening of sera
fromanumber of differentmousemodels of liver injury. To confirm this, a larger sample of RoquinM/M
micewere compared to both FOXP3KO mice andwildtype littermates of RoquinM/M mice. RoquinM/M
mice consistently developed AMA (Figure 6.1).
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Figure 6.1: AMAs in various mice including RoquinM/M. The sera of RoquinM/M mice mice were compared
against FOXP3KO mice as positive control and against littermates lacking the Roquin genotype of interest
using the AMA ELISA described above. Comparisons with Kruskal-Wallis test with Dunn’s post-hoc test.
6.2.2 The phenotype of the Roquin sanroquemutant mouse
Having demonstrated AMA in RoquinM/M mice, further analysis of the phenotype of RoquinM/M
liver and the intrahepatic lymphocyte population was performed. In comparison with wildtype
Roquin controls, RoquinM/M mice demonstrated splenomegaly, lymphadenopathy, elevations in
serum ALT activity, elevations in serum IgE and IgG concentrations, and also the presence of high
titre AMA (Figure 6.2).
Flow cytometric analysis of RoquinM/M intrahepatic lymphocytes revealed greater numbers of B,
CD4+ T, and CD8+ T cells (Figure 6.3A-C). In addition, a greater proportion of CD4+ T cells ex-
pressed ICOS, OX40 and FOXP3 (Figure 6.3D-F).
Histological examination of RoquinM/M mouse liver demonstrated peri-portal lymphocytic infilt-
rates that were not present in age-matched wildtype animals (Figure 6.4), with significant propor-
tions demonstrating positive staining for OX40, Ki67, and CD4 by immunohistochemistry.
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Figure 6.2: RoquinM/M mice demonstrate evidence of systemic autoimmunity. RoquinM/M mice aged
16-20 weeks were compared with wildtype mice. When compared to wildtype mice, RoquinM/M mice showed
marked splenomegaly (A), lymphadenopathy as assessed by weighing the mesenteric lymph node chain
(B), elevations in serum ALT (C), elevations in serum IgE (D), elevations in serum IgG (E), and AMA (F).
Comparisons with Mann-Whitney U test; n=9v26.
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Figure 6.3: RoquinM/M mice demonstrate evidence of elevations in hepatic lymphocyte numbers and
activation. RoquinM/M mice aged 16-20 weeks were compared with wildtype mice. When compared to wild-
type mice, RoquinM/M mouse liver contained more B cells (A), more CD4+ T cells (B), and more CD8+ T cells
(C). Of the hepatic CD4+ T cell population, significantly more were ICOS positive (D), OX40 positive (E) and
FOXP3 (F). Statistical comparisons were performed using the Mann-Whitney U test; n=9v26.
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Figure 6.4: RoquinM/M mice develop hepatic inflammation. RoquinM/M mice aged 16-20s week were
compared with wildtype mice. When compared to wildtype mice (A), liver from RoquinM/M mice demonstrated
peri-portal lymphocytic infiltration (B). These infiltrating cells were frequently OX40+ (C; D=isotype control),
frequently Ki67 positive (E) and contained numerous CD4+ cells (F). Representative images shown.
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6.2.3 Anti-OX40 antibody blockade in Roquin sanroquemutant mice
The presence of lymphocytic peri-portal infiltrates, evidence of liver damage and AMA, and hyper-
expression of OX40 led to an attempt to ameliorate RoquinM/M disease by blockade of OX40-OX40L
interactions through an OX40 Fab.
A comparison of RoquinM/M treated with either blocking anti-OX40 Fab or total rat IgG control over
fourweeks demonstrated no significant difference to the gross autoimmunephenotype of RoquinM/M
mice in terms of spleenweight and lymphadenopathy (Figure 6.5). Further, no significant differences
were apparent in serum AMA titre, ALT activity, serum IgG, or serum IgE (Figure 6.6).
Histological examination of animals treatedwith andwithout blocking anti-OX40 Fab revealed a per-
sistence of lymphocyte-rich peri-portal infiltrates in treated animals, and no variation in the extent
of OX40 positivity (Figure 6.7). Flow cytometry of intrahepatic lymphocyte populations demon-
strated no alteration in the increased numbers of B and T lymphocytes present after blockade of
OX40 signalling, and no reduction in the proportion of CD4+ T lymphocytes showing evidence of
activation (Figure 6.8). Similarly, stimulation of CD4+ T lymphocytes and analysis of cytokine se-
cretion patterns showed no difference in the number of IFNγ, IL-4, or IL-17 secreting CD4+ T cells
present (Figure 6.9).
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Figure 6.5: Antagonistic anti-OX40 Fab does not reverse splenomegaly and lymphadenopathy in
RoquinM/M disease To investigate whether blocking OX40-OX40L interactions could ameliorate autoimmunity
in RoquinM/M mice, mice were treated with twice weekly anti-OX40 Fab 250µg for four weeks. Animals were
then killed and compared to littermates that had received total rat IgG as a control. Treatment with anti-OX40
Fab made no difference to either (A) splenomegaly or (B) lymphadenopathy of the mesenteric chain. Com-
parisons with Mann-Whitney U test; n=12v13v4.
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Figure 6.6: Antagonistic anti-OX40 Fab does not reverse markers of autoimmunity in RoquinM/M dis-
ease. To investigate whether blocking OX40-OX40L interactions could ameliorate autoimmunity in RoquinM/M
mice, mice were treated with twice weekly anti-OX40 Fab 250µg for four weeks. Animals were then killed
and compared to littermates that had received total rat IgG as a control. Treatment with anti-OX40 made no
difference to the elevations in serum ALT (A), AMA titre (B), IgG (C) or IgE (D); n=12v13v4.
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Figure 6.7: Antagonistic anti-OX40 Fab does not reverse liver inflammation in RoquinM/M disease. To
investigate whether blocking OX40-OX40L interactions could ameliorate autoimmunity in RoquinM/M mice,
mice were treated with twice weekly anti-OX40 Fab 250µg or isotype control for four weeks. Examination after
staining with H&E demonstrated peristing infiltrates in both untreated (A) and treated mice (B). Heavy staining
for OX40 was also evident in the inflammatory infiltrate of both untreated (C) and treated (D) mice.
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Figure 6.8: Blocking OX40 antibody does not affect RoquinM/M liver infiltration. To investigate whether
blocking OX40-OX40L interactions could ameliorate autoimmunity in RoquinM/M mice, mice were treated with
twice weekly anti-OX40 Fab 250µg for four weeks. Flow cytometric analysis of hepatic lymphocytes demon-
strated persisting numbers of B cells (A), CD4+ T cells (B), and CD8+ T cells (C) after treatment with anti-OX40
Fab. Similarly, anti-OX40 Fab did not reduce the elevations in numbers of OX40+ (D), ICOS+ (E), and CD44+
(F) in RoquinM/M disease. Comparisons with Mann-Whitney U test; n=12v13v4. Representative plots gated
on CD4+ T cells are shown (G).
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Figure 6.9: Blocking antiOX40 Fab does not affect IFNγ production in RoquinM/M mice. To investigate
whether blocking OX40-OX40L interactions could ameliorate autoimmunity in RoquinM/M mice, mice were
treated with twice weekly anti-OX40 Fab 250 µg for four weeks. Blocking OX40 made no difference to number
of IFNγ (A), IL-17 (B) or IL-4 (C) secreting CD4+ T cells assessed after in vitro stimulation. Comparisons with
Mann-Whitney U test; n=12v13v4.
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Figure 6.10: Co-deficiency in OX40 does not ameliorate RoquinM/M disease. To investigate whether
co-deficiency in OX40 and CD30 ameliorated the RoquinM/M phenotype, RoquinM/M mice were crossed and
back-crossed with CD30,OX40 deficient mice to generate RoquinM/M.CD30-/-OX40-/- mice (RoquinM/M.DKO).
These mice were then compared with pure RoquinM/M mice. Co-deficiency in OX40 and CD30 made no
significant difference to the splenomegaly (A) or lymphadenopathy (B) in RoquinM/M mice (p=0.831 and p=0.05
respectively). Comparisons with Mann-Whitney U test; n=12v12.
6.2.4 Co-deficiency of OX40 in Roquin sanroquemutant mice
To further assess whether developmental OX40-OX40L signalling contributed to the RoquinM/M
phenotype, and to exclude an insufficient dose of blocking OX40 in earlier experiments, RoquinM/M
mice with and without concurrent deficiency in OX40 and CD30 were compared. The use of mice
concurrently deficient in CD30 was mandated by breeding considerations.
Consistent with findings from antibody blockade experiments, no significant difference was seen in
the degree of splenomegaly or lymphadenopathy in RoquinM/M mice with and without concurrent
OX40 and CD30 deficiency (Figure 6.10). Similarly, histological examination of liver revealed no
significant differences between groups (Figure 6.11), and no difference in intrahepatic lymphocyte
populations including the proportion producing IFNγ (Figures 6.12 and 6.13).
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Figure 6.11: Co-deficiency in OX40 does not ameliorate RoquinM/M liver infiltration: histology. To in-
vestigate whether co-deficiency in OX40 and CD30 ameliorated the RoquinM/M phenotype, RoquinM/M mice
were crossed and back-crossed with CD30,OX40 deficient mice to generate RoquinM/M.CD30-/-OX40-/- mice
(RoquinM/M.DKO). These mice were then compared with pure RoquinM/M mice. The extent of lymphocytic infilt-
ration was similar in RoquinM/M (A) and RoquinM/M.DKO (B) mice, despite deficiency in OX40 (representative
images stained for OX40).
6.2.5 Treatment of Roquin sanroquemutant mice with anti-interferon-γ
Having demonstrated that RoquinM/M mice have increased numbers of IFNγ-producing intrahep-
atic lymphocytes, are reported to generally hyper-express IFNγ and that generalised hyperexpres-
sion of IFNγ in a different model is reported as causing mice to generate AMA and develop intra-
hepatic lymphocytic infiltrates, an attempt was made to see whether blockade of IFNγ signalling in
RoquinM/M mice was effective in ameliorating their autoimmune phenotype.
Administration of blocking anti-IFNγ over four weeks produced a decreased in splenomegaly (Fig-
ure 6.14A), but no significant decrease in lymphadenopathy (Figure 6.14B). Similarly, flow cyto-
metric analysis of intrahepatic lymphocytes revealed that blocking anti-IFNγ reduced numbers of
infiltrating CD8+ T cells and reduced the proportions of CD4+ T cells expressing OX40, but did not
alter other flow cytometric parameters (Figure 6.15). When infiltrating T cells were stimulated and
their cytokine expression profiles examined, the proportions producing IFNγ and IL-17 were not
altered, but the proportion producing IL-4 was increased (Figure 6.16).
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Figure 6.12: Co-deficiency in OX40 does not ameliorate RoquinM/M liver infiltration: flow cytometry. To
investigate whether co-deficiency in OX40 and CD30 ameliorated the RoquinM/M phenotype, RoquinM/M mice
were crossed and back-crossed with CD30,OX40 deficient mice to generate RoquinM/M.CD30-/-OX40-/- mice
(RoquinM/M.DKO). These mice were then compared with pure RoquinM/M mice. Flow cytometric analysis of
hepatic lymphocytes demonstrated no differences in numbers of B cells (A), CD4+ T cells (B), and CD8+ T
cells (C). When CD4+ T cells were further examined, there were no significant differences in the proportion that
were CD44+ (D) or ICOS+ (F); OX40 was not expressed on RoquinM/M.DKO CD4+ T cells (E). Comparisons
with Mann-Whitney U test; n=12v12.
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Figure 6.13: Co-deficiency in OX40 does not ameliorate RoquinM/M: IFNγ production. To invest-
igate whether co-deficiency in OX40 and CD30 ameliorated the RoquinM/M phenotype, RoquinM/M mice
were crossed and back-crossed with CD30,OX40 deficient mice to generate RoquinM/M.CD30-/-OX40-/- mice
(RoquinM/M.DKO). These mice were then compared with pure RoquinM/M mice. After in vitro stimulation, no
significant difference (p=0.962) in the number of hepatic IFNγ-producing CD4+ T cells was present. Compar-
ison with Mann-Whitney U test; n=12v12.
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Figure 6.14: Anti-IFNγ antibody partially ameliorates RoquinM/M disease. An anti-IFNγ blocking anti-
body was administered to RoquinM/M mice aged between 16-20 weeks 500µg twice weekly for four weeks.
(A) Administration of blocking anti-IFNγ significantly reduced spleen weight in RoquinM/M mice, but (B) did
not significantly affect mesenteric lymph node weight (p=0.250). Comparisons with Mann-Whitney U test;
n=8v8v4.
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Figure 6.15: Anti-IFNγ antibody partially ameliorates RoquinM/M disease. An anti-IFNγ blocking antibody
was administered to RoquinM/M mice aged between 16-20 weeks at a dose of 500µg twice weekly for four
weeks. This treatment did not affect the number of hepatic B cells (A), did significantly reduce the number of
CD8+ T cells (B), and did not affect the number of CD4+ T cells (C). Blocking anti-IFNγ did not affect numbers
of Ki67 CD4+ T cells (D), did reduce numbers of OX40+ CD4+ T cells (E), and did not alter numbers of ICOS+
CD4+ T cells (F). Comparisons between RoquinM/M groups with Mann-Whitney U test; n=8v8v4.
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Figure 6.16: Anti-IFNγ antibody partially ameliorates RoquinM/M disease. Treating RoquinM/M mice with
blocking anti-IFNγ did not alter the proportion of CD4+ T cells that were positive for IFNγ after stimulation (A)
and (C), nor the proportion that were positive for IL-17 (D). However, treatment with anti-IFNγ increased the
proportion of cells that were positive for IL-4 after stimulation (B) and (E); n=8v8.
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6.3 Discussion
This set of experiments has shown that RoquinM/M mice demonstrate lymphocytic hepatitis, AMA,
hyper-expression of OX40, and some features analagous to human AILD. In contrast to mice de-
ficient in FOXP3 however, there appears to be no change in their phenotype when OX40-OX40L
interactions are blocked with either antibody or constitutively. The administration of a blocking
IFNγ antibody appears to slightly ameliorate disease.
That RoquinM/M disease greatly increases IFNγ production and results in lymphocytic infiltration
andAMA is consistentwith the findings of another groupwho generated amousewith a different de-
ficit in IFNγ regulation and subsequent over-expression.[14] It is unclear however how much of the
RoquinM/M mouse’s phenotype is due to IFNγ and how much can be explained by over-expression
of ICOS and OX40, and how much relates to other dysregulated processes. For example, anim-
als transgenic for ICOS-ligand generate lymphoid hyperplasia, although specific aspects of autoim-
munity were unreported.[494] Mice constitutively expressing ICOS are not yet reported. Similarly,
constitutive expression of OX40L can drive autoimmunity.[40, 295]
These experiments serve to highlight that the autoimmune phenotype of RoquinM/M mice is multi-
factorial consistent withmultiple downstream effects of disruption of the Roquin regulatory protein.
Weaknesses in this approach
One criticism of this work is the lack of a positive control in the OX40 and IFNγ antibody blockade
experiments. Nevertheless, in the OX40 blockade experiment, antibody from the same batch was
efficacious in blocking autoimmunity in FOXP3 deficiency, and results were consistent with the lack
of effect of constitutive OX40 blockade.
In the IFNγ antibody blockade experiment, differences were seen between groups including the
induction of a larger population of IL-4-secreting cells in the IFNγ-treated groups. These changes
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suggest biological activity of the antibody used, although do not exclude the possibility of under-
dosage
Breeding constraints meant that RoquinM/M mice bred to also be deficient in OX40 were also defi-
cient in CD30: separation of the two variants is relatively uncommon because they are located close
together on chromosome 4. Given the lack of differences in groups, this is unlikely to have had a
great effect, but it would be preferable to compare groups of animals sufficient in CD30.
Future experiments
To expand on this work, it would be revealing to investigate whether blockade of signalling through
ICOS together with blockade of signalling through OX40 would be sufficient to ameliorate the
RoquinM/M phenotype. Notably, co-deficiency in ICOS has been reported to ameliorate but not
abolish the RoquinM/M phenotype.[497] Blocking ICOS antibodies would also be a consideration.
The experiments with comparing RoquinM/M mice treated with blocking anti-IFNγ antibodies could
usefully be extended either by increasing the duration of administration of blocking anti-IFNγ an-
tibody or, with the advantage of preventing concerns about sufficient dosing, by breeding animals
deficient in IFNγ with and without the RoquinM/M for comparison.
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7 Factors affecting expression of OX40L by T cells
7.1 Introduction
OX40 and OX40L represent an exclusive receptor-ligand pair. OX40 expression and its regulating
factors are well established. Briefly, there is constitutive expression on murine regulatory T cells
with expression after TCR ligation on multiple subsets of both CD4+ and CD8+ T cells. The situ-
ation appears to be similar in humans, although human Tregs require stimulation prior to expres-
sion. Lower levels of inducible expression are reported on NKT cells, natural killer (NK) cells and
neutrophils.[74]
The expression of OX40 on non-Tregs requires T cell receptor ligation.[121, 433] In addition, the
upregulation of OX40 on T cells is slower, reduced and more transient in the absence of CD28
signals.[121, 448, 355] There is a relationship with IL-2, with exogenous IL-2 leading to increased
expression of OX40[74] but increased signalling through OX40 also leading to greater T cell pro-
duction of IL-2.[351] Further, a similar feedback mechanism seems to exist with a related gamma
chain cytokine: IL-4 augments and sustains OX40 expression [417], and the expression of IL-4 is
augmented by ligation of OX40.[314] The effects of OX40 ligation are numerous but may be sum-
marised as reducing Treg function [442, 335], promoting T cell survival through the induction of
anti-apoptotic regulatory proteins[355], promoting the formation of memory[120], and in influen-
cing proliferation: with conflicting suggesting positive[197] and negative effects.[213]
The availability of OX40L, as the only known ligand of OX40, will influence activity through OX40.
OX40L is more widely expressed than OX40 with constitutive expression reported on the lymphoid
tissue inducer subset of innate lymphoid cells.[196, 228] In addition, induced expression is repor-
ted on dendritic cells[172, 215], B cells [399, 400], macrophages[479], mast cells [186, 123], various
malignancies[253, 489, 380], endothelia[159], microglia[456], cardiac myocytes[368, 369] and air-
way smooth muscle in asthma.[381]
The original description of OX40L was however on human CD4+ T cells following HTLV infec-
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tion of human CD4+ T cells.[420, 282] This was later identified as OX40L.[19, 407] Subsequently,
there have been reports of OX40L expression on both human[211, 210] and murine T cells[197,
278, 393] without viral infection, including marked expression on gut-derived CD8+ intraepithelial
lymphocytes.[452]
On antigen-presenting cells, OX40L isminimally expressed on quiescent cells, however expression is
upregulated by activation.[352] In addition, the cytokines IL-18, TNFα, and TSLP are all reported to
upregulate OX40L, as is signalling through CD40.[313, 97, 148, 164, 270] On neonatal CD4+CD3-
lymphoid tissue inducer cells, TL1a induces increased expression of OX40L.[198]
In contrast to the situation for OX40, factors controlling expression of OX40L on T cells are poorly
described. However, similar toOX40, T-cell receptor ligation is required for expression.[452]Obser-
vations from several groups working on both murine and human T cells have revealed other factors
that appear to influence expression, and these are summarised as Table 1.3. The function of OX40L
expression on T cells is uncertain, although one analysis suggested that a reduction in T cell:T cell
interaction reduced proliferation and reduced survival both in vitro and in vivo.[393] Much other
work in this area has involved animals completely deficient in OX40L in all cells or over-expressing
OX40L more widely and so effects cannot be attributed to T cells alone.[294, 295]
During experiments using spleen cell preparations from CTLA4 deficient mice, variable expression
of CD4+ T cell OX40L between mice lacking CTLA4 and their CTLA4-sufficient littermates was
noted. This suggested a role for the CD80/CD86/CD28/CTLA4 axis in the expression of OX40L on
CD4+ T cells, something which has not previously been explored but which complements observa-
tions regarding a role of CD28 in T-cell expression of OX40.
The following series of experiments sought to examine factors affecting the expression of OX40L on
CD4+ T cells and to consider the physiological role of OX40L expression. These assessments were
made in relation to factors already known to affect OX40 expression, factors known to affect OX40L
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expression on non-T cells, and with specific reference to the CD80/CD86-CD28-CTLA4 axis which
has a major role in OX40 regulation.
7.2 Results
7.2.1 Signals through the T-cell receptor and CD28 control OX40L expression by CD4+ T cells
During experiments assessing splenic and liver-infiltrating lymphocytes in CTLA4-/- mice and their
wildtype littermate controls, cultures of lymphocytes were prepared and examined for OX40 and
OX40L expression (Figure 7.1). Initially, this occurred during efforts to investigate variations in
other lymphocyte markers. It was noticed that OX40L is typically expressed on a minority of CD4+
T cells fromwildtypemice after stimulation with soluble agonistic anti-CD3 antibody (Figure 7.1A).
In contrast, expression of OX40L on CD4+ T cells from CTLA4-/- animals was noted to be consist-
ently reduced comparedwithwildtype littermate controls. Interestingly, there was reciprocal expres-
sion of OX40L with markers of cell activation including OX40 (Figure 7.1B), ICOS (Figure 7.1C),
CD44 (Figure 7.1D), CD25 (Figure 7.2E), and CD69 (Figure 7.2F). These findings were consist-
ent across multiple animals with the proportion of CD4+ T cells expressing OX40 3-4× higher in
CTLA4-/- animals and OX40L 3-4× higher in wildtype animals (Figure 7.2G).
Given that a major function of CTLA4 is to negatively regulate signalling through CD28, we pro-
ceeded to investigate the effects of manipulating CD28 signals. Stimulation through CD28 was ma-
nipulated using either an agonistic antibody or by blocking endogenous ligands by adding CTLA4Ig
to cultures. Others have demonstrated that widely available human pharmaceutical CTLA4Ig is ef-
fective in binding murine CD80 and CD86.[152] Using this model, it became clear that increased
signalling through CD28 is associated with decreased expression of OX40L on CD4+ T cells. Pre-
venting signalling through CD28 by endogenous ligands with CTLA4Ig augmented OX40L expres-
sion (Figure 7.3A); this finding was consistent across multiple wildtype mice (Figure 7.3B).
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Figure 7.1: OX40L and activation markers are reciprocally expressed on CD4+ T cells. Continues into
Figure 7.2
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Figure 7.2: OX40L and activation markers are reciprocally expressed on CD4+ T cells. When CTLA4+/+
and CTLA4-/- cells were stimulated in the presence of anti-CD3 antibody, there was reciprocal expression of
OX40 and OX40L (A), of ICOS and OX40L (B), and CD44 and OX40L (C). These findings were consistent
over multiple experiments (D). The same pattern was seen for CD25 and OX40L (E) expression and CD69 and
OX40L expression (F) on wildtype cells under different conditions. (G) Conversely, loss of CD62L, which is
associated with activation related to loss of OX40L expression (All plots are representative of >8 experiments
and gated on live CD4 T cells)
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Figure 7.3: The expression of OX40L onCD4+ T cells is negatively regulated byCD28 ligation. (A) When
total wildtype splenocytes are stimulated in culture with agonistic anti-CD3 antibody, there is reciprocal ex-
pression of OX40 and OX40L; if the same culture is repeated with anti-CD3 and anti-CD28, there is increased
expression of OX40 and OX40L expression is suppressed; if the culture is repeated with CD28 signalling
prevented by CTLA4Ig, OX40 expression is suppressed and OX40L expression increased (plots represent-
ative of >10 experiments; gated on CD4+ T cells). (B) The findings of CD28 signalling negatively regulating
CD4+ T cell OX40L expression are consistent. (C) Findings are not due to altered cell proliferation or survival
because absolute cell counts demonstrate the same pattern. Kruskal-Wallis test with Dunn’s post-hoc test;
n=12v12v12.
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One potential explanation for the variation in the proportion of CD4+ T cells expressing OX40L is
that differential proliferation of subpopulations might alter the proportion remaining positive. To
address this possibility, counting beads were used to quantify the number of cells expressing positive
for OX40L from multiple cultures from the same stock cell suspension. Again, there was a decrease
with CD28 ligation and an increase with the addition of CTLA4Ig (Figure 7.3C).
Having demonstrated that the addition of CTLA4Ig to cultures greatly increased staining for OX40L
but accepting that the quality of flow cytometry staining for OX40L in the literature is variable, at-
tempts were made to confirm the specificity of the staining seen in these experiments. First, splen-
ocytes from mice with expressing Cre-recombinase under the control of the VAV1 promoter, which
is transcribed in all haematopoeitic cells including T cells, with and without Lox sequence flanked
OX40L genes were isolated. These CD45.1- cells were then cultured with anti‐CD3 and CTLA4Ig.
CD45.1+ wildtype cells were added to cultures to act as internal controls for OX40L expression.
Consistent with results from commercial genotyping, those mice that were OX40L(fl) did not have
detectable OX40L signal by flow cytometry (Figure 7.4A-B).
To further investigate the role of ligation of CD28 in controlling expression on OX40L on CD4+
T cells, cells isolated from mice deficient in CD28’s two endogenous ligands, CD80 and CD86, were
used. In cultures of CD80KOCD86KOCTLA4KO splenocytes, CD4+ T cells upregulated OX40L in a
manner similar to that seen in wildtype cells stimulated in the presence of CTLA4Ig. The addition
of CTLA4Ig to CD80KOCD86KOCTLA4KO did not further increase expression of OX40L, whilst the
addition of anti-CD28 agonistic antibody prevented significant expression (Figure 7.5A).
By combining splenocytes fromCD45.1 allotype-markedwildtypemice andCD45.2 allotype-marked
CD80KOCD86KO mice, the requirement for the addition of CTLA4Ig to induce strongOX40L expres-
sion on both cell types was restored (Figure 7.5B). This suggested that interaction with CD80 and
CD86onCD45.1+ cellswas sufficient to down-regulateOX40L expression onCD45.2+CD80KOCD86KO
cells i.e. down-regulation could occur in trans.
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Figure 7.4: Flow cytometric staining of OX40L staining is consistent with genotype. (A) Culture of cells
from VAV1-Cre flOX40L mice with anti-CD3 and CTLA4Ig demonstrated consistent absence of OX40L expres-
sion in mice genotyped as VAV-Cre flOX40L; co-culture with wildtype CD45.1-positive BoyJ cells provided a
positive control. (B) This was a consistent finding. Comparisons with Mann-Whitney U test; n=12v12.
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Figure 7.5: CD80 and CD86 negatively regulate OX40L through interaction with CD28. (A) Unstimulated,
CD80KOCD86KO cells do not express OX40L. When stimulated with anti-CD3 and anti-CD28, these cells
behave as wildtype cells and upregulate OX40 without OX40L. However, in contrast to wildtype cells there
is a marked upregulation of OX40L in response to anti-CD3 alone that is not augmented by the addition
of CTLA4Ig. (B) When co-cultured with wildtype CD45.1+ cells, CD80KOCD86KO CD4+ T cells have their
anti-CD3-induced expression of OX40L prevented by the presence of wildtype cells; this can be prevented
by the addition of CTLA4Ig (All plots gated on live CD4+ T cells). Comparisons with Mann-Whitney U test;
n=10v10v10 and 8v8.
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Having observed thatmanipulating the strength of CD28 signals could alter the expression ofOX40L
on CD4+ T cells in the context of agonistic signalling through the TCR, it was not clear whether
TCR signalling was necessary for OX40L expression or whether it was simply a negative response to
CD28. To investigate this possibility, cells were stimulated with combinations of CD3 and CTLA4Ig.
CTLA4Ig alone was inadequate to cause expression of OX40L and unstimulated cells expressedmin-
imal OX40L (Figure 7.6A).
To establish whether the requirement for agonistic CD3 antibody was specific to that antibody or a
more general function of a requirement for activation via the TCR(Figure 7.7A), two other methods
of TCR ligation were investigated. First, cells from RAG-OT2 mice, in which all CD4+ T cells ex-
press a TCR specific to a sequence in ovalbumin, were stimulated in the presence of CTLA4Ig with
the OTII-specific ovalbumin peptide isqavhaahaeineagr. Consistent with results from stimula-
tion with agonistic anti-CD3, OX40L was upregulated (Figure 7.7B). Second, similar results were
obtained when the lectin Con A, which non-specifically cross-links and activates TCRs, was used to
stimulate wildtype cells (Figure 7.7C).
It has been noted that OX40L expression on CD4 T cells is inversely related to the strength of TCR
signal[278]; others have previously considered the fact that CD28 signalling strength can be related
to TCR signal strength.[3] Combining these two observations, cells were cultured with varying con-
centrations of agonistic anti-CD3 antibody alone or in the presence of CTLA4Ig to block variations
in CD28 signalling. Consistent with the work of others, the strength of CD3 stimulation was in-
versely correlated to OX40L expression (Figure 7.8A). However, in the presence of CTLA4Ig, this
relationship was not apparent andmoreOX40Lwas expressed with 0.1 µgml−1 and 1 µgml−1 of anti-
CD3 than with 0.01 µgml−1 (Figure 7.8B). A similar reversal in the effect of strength of ligation on
OX40L was apparent in the presence of a neutralising antibody to IL-2.
Next, to determine whether our results were related to movement of OX40L between intra- and
extracellular compartments, we repeated flow cytometry with and without fixation and permeabil-
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Figure 7.6: Signals through the T cell receptor are required for OX40L expression. Total splenocyte
preparations from wildtype mice were cultured in with and without anti-CD3 antibody and with and without
CTLA4Ig. Without anti-CD3 there was minimal expression of OX40L with and without CTLA4Ig. However,
after the addition of anti-CD3 antibody, OX40L expression was increased; this increase was augmented by
the addition of CTLA4Ig (All plots gated on CD4+ T cells). Kruskal-Wallis test with Dunn’s post-hoc test; n=12
per group.
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Figure 7.7: Various methods of ligating the T cell receptor induce OX40L expression. (A) As demon-
strated previously, culturing wildtype cells in the presence of CTLA4Ig alone resulted in no or low expression
of OX40L but the addition of anti-CD3 antibody resulted in an increase in OX40L expression. (B) Similarly,
cultures of RAG-OT2 cells expressing a T cell receptor specific to an ovalbumin peptide expressed minimal
OX40L when cultured with CTLA4Ig alone but increased expression when ovalbumin peptide was added. (C)
Similarly, the lectin concanavalin A was a sufficient to provoke CD4+ T cell expression of OX40L. Comparisons
with Mann-Whitney U test; n=8 per group.
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Figure 7.8: Signal strength through the TCR affects OX40L expression. (A) Wildtype total splenocytes
were cultured in the presence of different concentrations of agonistic anti-CD3 antibody. There was minimal
expression without agonistic antibody but a reverse relationship between the concentration of antibody and
expression (n = 8 per condition; nptrend test across three samples with anti-CD3). (B) The experiment above
was repeated with the addition of CTLA4Ig. Here there was a greater expression of OX40L with concentrations
of anti-CD3 above 0.01 µg/ml but no difference between 0.1 µgml−1 and 1µgml−1. (n=8 per condition; Kruskal-
Wallis tests with Dunn’s post-hoc analysis across three samples with anti-CD3). (C) A further repeat with
blocking anti-IL-2 antibody in place of CTLA4Ig was performed. Here, greater concentrations of anti-CD3
were associated with greater expression of OX40L (n=4 per condition; nptrend across all samples treated with
anti-CD3).
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isation prior to application of anti-OX40 and anti-OX40L antibodies. Notably, detection of CTLA4
is greatly increased by intracellular staining.[243] No difference in OX40L signal was apparent, but
fixation and permeabilisation reduced the signal for OX40 (Figure 7.9).
7.2.2 CTLA4 controls OX40L expression as a negative regulator of CD28 signalling
Having demonstrated that deficiency of CTLA4 was associated with an absence of expression of
OX40L on CD4+ T cells, it remained uncertain as to whether this effect was through uncontrolled
signalling through CD28 or a mechanism directly mediated by CTLA4 itself. Possibilities include
signalling through a ligand of CTLA4 induced by CTLA4-binding or by signalling through CTLA4
itself as is reported to be involved in other T cell pathways.[414] To further investigate this, CTLA4-/-
cells were cultured in the presence of anti-CD3 and CTLA4Ig. In contrast to the effect of CTLA4Ig
on wildtype cells, the addition of CTLA4Ig to cultures of CTLA4-/- cells did not induce OX40L (Fig-
ure 7.10). CTLA4-/- cells were then cultured alone or mixed with CD45.1 marked CTLA4+/+ cells as
a source of CTLA4. When cultured alone, wildtype cells expressed OX40L and CTLA4-/- cells did
not express OX40L consistent with previous experiments. However, on mixing the two cell types
together, the ability of CTLA4+/+ cells to express OX40L was lost (Figure 7.11). This suggested that
factors other than a cell’s ability to express CTLA4 or signal throughCTLA4were controllingOX40L
expression on CTLA4+/+ cells.
To further investigate the possibility of a role of signalling through CTLA4, an agonistic anti-CTLA4
antibodywas added to cultures of wildtype andCD80KOCD86KO cells. The latter cell typewas chosen
to prevent the activity of endogenous ligands. Here the addition of varying concentrations of anti-
CTLA4 antibody made no difference to the OX40L expression of either cell type (Figure 7.12).
Cells gathered frommice deficient inCTLA4-/- typically display an activated phenotype at harvesting
and are likely to have already received signalling through CD28. To create mice with CTLA4-/-
212
!
"#
$
!"#$%
&'()*+,-./(,0+0+1 2+()*+,-./(,0+0+1
3456.7
34589
3456.7
4:%;#21
;
<
Ex
ter
na
l s
tai
nin
g
Int
ern
al 
sta
ini
ng
0
20
40
60
80
%
 C
D
4 
T 
ce
lls
 O
X
40
L+
OX40L
p = 1
Ex
ter
na
l s
tai
nin
g
Int
ern
al 
sta
ini
ng
0
10
60
70
80
90
100
%
 C
D
4 
T 
ce
lls
 O
X
40
+
OX40
p < 0.001
Figure 7.9: Comparison of extra- and intracellular staining for OX40 and OX40L. (A) To assess whether
intracellular staining would alter signal for OX40 and OX40L, fluorescent antibodies to the two antigens were
applied before and after fixation and permeabilisation. There was no apparent difference in staining for OX40L
but there was a reduction in the OX40 signal when staining was performed after fixation and permeabilisation.
(B) The findings in A were consistent across multiple samples (n = 8 vs 8; All plots relate to live CD4+ T cells;
Mann-Whitney U-test)
213
!
"#
$
%&
'
(
!
"#
$
&)*+#,)
%&
'
(-
.
&
)*
+
#/
0
!"#$*
&)*+#1!+
2
CT
LA
4w
t
CT
LA
4k
o
0
5
10
15
20
25
30
35
%
 C
D
4 
T 
ce
lls
 O
X
40
L+
p < 0.001
%&'(-.-&)*+#/0
&
Figure 7.10: CTLA4-/- cells do not express OX40L in the presence of CTLA4Ig. (A) Wildtype and CTLA4-/-
splenocyte cultures were stimulated with anti-CD3 agonistic antibody. In CTLA4+/+ but not CTLA4-/- cultures
there was some expression of OX40L. (B) With the addition of CTLA4Ig, there was an increase in the ex-
pression of OX40L in CTLA4+/+ but not CTLA4-/- cells. (C) The finding that the addition of CTLA4Ig did not
induce expression of OX40L of CTLA4-/- CD4 T cells was reproducible over multiple experiments. (Plots are
representative and gated on CD4+ T cells). Comparisons with Mann-Whitney U test; n=8 per group.
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Figure 7.11: CTLA4-/- cells prevent expression of OX40L on wildtype cells. (A) As previously, CTLA4-/-
deficient splenocyte cultures in the presence of agonistic anti-CD3 antibody and CTLA4Ig did not produce
OX40L on T cells whilst this combination produced strong expression of OX40L on wildtype (CD45.1+) cells.
Co-culture of the two cells types prevented expression of OX40L on wildtype cells. (B) This was a consistent
finding (n = 8 per condition; plots are representative and gated on CD4+ T cells). Comparisons with Mann-
Whitney U test.
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Figure 7.12: An agonistic CTLA4 antibody does not affect OX40L expression. Total splenocytes were
isolated from either wildtype mice or mice deficient in CD80 and CD86 and cultured in the presence of agonistic
anti-CD3 antibody. As previously, CD80KOCD86KO cells showed upregulation of OX40L that was recapitulated
on wildtype cells with the addition of CTLA4. Addition of varying concentrations of agonistic anti-CTLA4 anti-
body did not alter OX40L expression. As previously, the addition of anti-CD28 decreased OX40L expression
(n = 4 per condition; bars shown as median ± range).
cells that were not activated, bone marrow chimeras of CTLA4-/- and CD45.1 marked wildtype cells
were created. As described elsewhere, and in contrast to CTLA4-/- mice, which die by 4-5 weeks
of age, these mice remained healthy for weeks after chimerisation was confirmed and at sacrifice
cells were not abnormally activated.[13] When cells from these mice were cultured, both CTLA4-/-
and CTLA4+/+ cells behaved as previously: OX40L expression was suppressed by stimulation with
anti-CD3 and anti-CD28 whilst OX40L was strongly expressed when stimulated with anti-CD3 in
the presence of CTLA4Ig (Figure 7.13). These findings were identical between CTLA4-sufficient
(CD45.1+) and –deficient (CD45.2+) cells.
As a second approach to preventing in vivo ligation of CD28 in CTLA4-/- mice, mice deficient in
CD80 and CD86 were crossed and then backcrossed with mice haplosufficient for CTLA4 over
generations to produce mice triply deficient in CD80, CD86 and CTLA4. The genotype of these
mice was confirmed by commercial genotyping. Again as described elsewhere, these mice remained
healthy.[261] On stimulation, these triple knockout mouse cells were confirmed to be deficient in
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Figure 7.13: Bone marrow chimeras from CTLA4-/- and wildtype mice express OX40L normally.
(A) Bone marrow chimeras were created by irradiating CD45.1+ wildtype mice and injecting approximately
2 000 000 CTLA4-/- cells intravenously. (B) Chimerism was confirmed on peripheral lymphocytes several
weeks after irradiation (representative plot gated on live T cells). (C) Cell preparations produced from chimeric
mice demonstrated suppressed OX40L expression when cultured with anti-CD3 and anti-CD28 and increased
OX40L expression when cultured with CTLA4Ig. (D) These findings were consistent across samples (9 cell
preparations from 3 mice in each group). This experiment performed with the assistance of Dr F Gaspal.
Comparisons with Mann-Whitney U test.
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CTLA4 (Figure 7.14A) and demonstrated equal CD4+ T cell expression of OX40L after stimula-
tion with anti-CD3 as compared to both CD80KOCD86KOCTLA4WT and CD80KOCD86KOCTLA4KO
littermates (Figure 7.14B).
7.2.3 CD4+ T cells require direct interaction with non-T cells to upregulate OX40L
During the course of the experiments described here, cultures of pure CD4+ T cells were generated
(typically to >95%purity); Figure 7.15A). It was observed that these cells did not expressOX40L after
culture with anti-CD3 and CTLA4Ig (Figure 7.15B). It was considered that a soluble factor from non
CD4+ T cells might be necessary to drive expression of OX40L. To test this, purified CD4+ T cells
were cultured in wells across 0.4µm-pore Transwell® membrane with a total splenocyte preparation
on the other side of the membrane thus permitting permeation of soluble molecules but not cells.
Here, purified CD4+ T cells did not express OX40L whilst total cells did (Figure 7.15C). However,
when CD45.2+ purified CD4+ T cells were added to cultures of CD45.1+ total splenocytes, OX40L
expression was again seen on CD45.2+ cells suggesting that direct contact with non CD4+ T cells
was necessary for expression (Figure 7.15D-E).
It was not clear as to with which cell type direct contact was required to promote the expression
of OX40L. In order to investigate this, mixed cultures of purified CD4+ T cells and purified B220+
T cells were prepared. Here B220+ preparations were made to over 95% purity by magnetic bead
purification (Figure 7.16A). The addition of B220+ cells to pure CD4+ T cell cultures stimulated
with anti-CD3 and CTLA4Ig restored OX40L expression on T cells (Figure 7.16B). Because CD45
allotype marked B220 and CD4+ T cells were used, it was possible to demonstrate that there was no
significant T cell contamination (Figure 7.16C) and that expressed OX40L was all on cells derived
from T cell donor mice (Figure 7.16D).
The experimental procedure above was then repeated with the addition of bead-purified CD11b+
cells. Here CD11b preparations were less pure than B220+ preparations with a typical purity of 70-
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Figure 7.14: CD80KOCD86KOCTLA4KO mice express OX40L normally. (A) Mice co-deficient for each
of CD80, CD86 and CTLA4 were bred. Cells were compared with those from CTLA4+/+ littermates after
stimulation with anti-CD3 and anti-CD28 antibodies to confirm deficiency of CTLA4. Findings were con-
sistent with those from commercial genotyping. (B) There was no difference in OX40L expression between
CD80KOCD86KOCTLA4KO and CD80KOCD86KOCTLA4WT cells: both similarly upregulated OX40L after cul-
ture with CTLA4Ig. (All plots relate to live CD4+ T cells). Comparisons with Mann-Whitney U test; n=6v6.
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Figure 7.15: CD4+ T cells require direct interactions with APCs to express OX40L. (A) CD4+ T cells
were purified to ≥95% purity (representative plot). (B) When cultured with anti-CD3 and CTLA4Ig, purified
CD4 T cells did not upregulate OX40L. (C) Similarly, purified CD4 T cells did not express OX40L when cultured
across a transwell membrane from a total cell population that did express OX40L. (D) However, when purified
CD45.1+ CD4s were mixed with a total CD45.2+ splenocyte population, they regained the ability to express
OX40L. (E) These findings were consistent between multiple cultures; n=6v8v8v8.
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Figure 7.16: B220+ B cells are sufficient to allow CD4+ T cells to express OX40L. (A) CD45.1+ wildtype
mouse splenocytes were enriched to approximately 95% purity using anti-B220+ antibodies and magnetic
beads. (B) Purified CD4+ T cells from wildtype CD45.2+ animals were cultured with and without enriched
B220+ cells for 72 hours in the presence of anti-CD3 and CTLA4Ig.. There was significantly increased ex-
pression of OX40L on CD4+ T cells in the presence of B220+ cells. (n = 7 per sample; Mann-Whitney U-test).
(C) Representative plot gated on live cells showing that B220+ cells were CD45.1+. (D) Representative plot
gated on CD4+ T cells showing that OX40L expression was on CD45.1 negative (CD45.2+) cells.
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75% (Figure 7.17A).However, againCD4T cell expression ofOX40Lwas restored by co-culture with
CD11b+ cells (Figure 7.17B). In these experiments, some contaminating CD45.2+ non-CD11b+
cells could be seen (Figure 7.17C-D).
Given that both B cells and many CD11b positive cells directly interact with T cells through the
CD40-CD40L pathway, total splenocyte cultures were repeated in the presence of agonistic anti-CD3
with either CTLA4Ig or IL-2. These cultures were performed with or without blocking antibodies
to CD40 or CD40L (Figure 7.18).
7.2.4 OX40-OX40L interactions do not modulate CD4 T cell OX40L expression
Having demonstrated reciprocal expression of OX40 and OX40L on CD4+ T cells, I considered
whether an interaction between the two might either affect OX40L expression or affect its detection
by flow cytometry. To investigate this possibility, I used splenocytes from OX40KO mice as a source
of CD4+ T cells. To confirm that these cells were deficient inOX40, they were stimulated in the pres-
ence of agonistic anti-CD28 antibody. Here, CD4+ T cell expression of the molecule ICOS, which is
upregulated in response to CD28 co-stimulation and reciprocally expressed with OX40L, was sim-
ilar between control and OX40KO cells (Figure 7.19A). However, a complete lack of expression of
OX40 in response to CD28 ligation was demonstrated on OX40KO cells as expected (Figure 7.19B).
WhenOX40KO CD4+T cells were cultured with anti-CD3 antibody alone, a small amount of OX40L
was detectable. However, when CTLA4Ig was added to block endogenous signalling through CD28,
there was a significant increase in OX40L expression consistent with findings on wildtype cells. This
increase could be prevented by the addition of agonistic anti-CD28 antibody (Figure 7.19C).
It has been suggested for human CD4+ T cells that OX40 may be able to transendocytose or ‘rip’
OX40L from non-T-cells to T cells in a manner analogous to that described for interactions between
CD28 and CTLA4.[346, 39] To further investigate the relevance of ripping of ligand to mouse CD4
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Figure 7.17: CD11b+ cells are sufficient to allow CD4+ T cells to express OX40L. (A) CD45.1+ wildtype
mouse splenocytes were enriched to approximately 75% purity using anti-CD11b+ antibodies and magnetic
beads. (B) Purified CD4+ T cells from wildtype CD45.2+ animals were cultured with and without enriched
CD11b+ cells for 72 hours in the presence of anti-CD3 and CTLA4Ig.. There was significantly increased ex-
pression of OX40L on CD4+ T cells in the presence of CD11b+ cells. (n = 8 per sample; Mann-Whitney U-test).
(C) Representative plot gated on live cells showing that CD11b+ cells were CD45.1+. (D) Representative plot
gated on CD4+ T cells showing that OX40L expression was primarily present on CD45.1 negative (CD45.2+)
cells.
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Figure 7.18: CD40 and CD40L ligand blockade and OX40L expression. Total wildtype splenocytes were
stimulated with agonistic anti-CD3 antibody and CTLA4Ig and with either anti-CD40 antibody or anti-CD40L
antibody (A) or with anti-CD3 and IL-2 40ng/ml (B) with either anti-CD40 antibody or anti-CD40L antibody.
In the presence of anti-CD3 and CTLA4Ig, the addition of anti-CD40 antibody significantly decreased OX40L
expression, whilst it was not significantly changed by the addition of anti-CD40L. No significant changes were
seen in the presence of IL-2 whereOX40L expression was not seen (p=0.191 across conditions). Comparisons
with Kruskal-Wallis test and Dunn’s post-hoc test; n=8 per group.
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Figure 7.19: OX40KO CD4+ T cells express OX40L normally. Splenocyte cell suspensions were prepared
from OX40KO mice and cultured in the presence of: (A) and anti-CD3 and (B) both anti-CD3 and anti-CD28
to demonstrate absence of OX40 expression (p=0.495) but a preserved ability to express ICOS and (C) anti-
CD3 alone or with either anti-CD28 or CTLA4Ig. (All plots relate to live CD4+ T cells; comparisons either with
Mann-Whitney U-test or Kruskal-Wallis test with Dunn’s post-hoc analysis; n=8 per group)
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T cells cultures, and also to control for potential inconsistencies in culture conditions between
OX40KO and wildtype cells, CD45.2+ OX40KO cells were mixed in approximately 1:1 ratios with
CD45.1+ BoyJ wildtype splenocytes. Here, it could be demonstrated that both OX40KO and wild-
type cells upregulated OX40L to similar levels when cultured in the same conditions (Figure 7.20).
Further, the fact that there were no differences between co-cultured OX40KO and OX40-sufficient
cells suggested that OX40-OX40L interactions such as ripping were not important for CD4+ T cell
expression of OX40L in this system.
To further investigate the possibility of a need for direct contact with OX40L expression on non-T-
cells to permit expression on CD4+ T cells, we used our earlier observation that purified CD4 T cells
in culture did not upregulate OX40L. Co-cultures of purified wildtype CD4 T-cells and OX40L-
deficient cells were made to see whether this permitted expression of OX40L. By using mice with lox
sites around their TNFSF4 (OX40L) genes and expressing Cre-recombinase under the PGK-1 pro-
moter, OX40L-deficient splenocytes were generated.[225] First, we confirmed that the combination
of PGK-Cre with a floxed OX40L locus prevented the expression of OX40L when total cells were
cultured in the presence of agonistic anti-CD3 antibody and CTLA4Ig. In contrast, cells from PKG-
Cre onlymice were able to upregulate OX40L in amanner similar to wildtype cells (Figure 7.21A-B).
As previously, wildtype CD4+ T cells lost the ability to upregulate OX40L after purification (Fig-
ure 7.21C-D), but when mixed with total splenocytes either sufficient or insufficient in OX40L, the
ability of the purified CD4 T cells to express OX40L was restored (Figure 7.21E-F). This finding was
consistent over multiple experiments (Figure 7.21G).
7.2.5 Gamma chain cytokines downregulate OX40L expression
Others have reported that cytokines may modulate OX40L expression, both on CD4+ T cells and
on antigen-presenting cells. The finding that preventing CD28 signalling greatly increases OX40L
expression provides a useful platform to investigate the modulating capacity of cytokine signalling
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Figure 7.20: OX40-sufficient and -deficient cells express OX40L similarly in co-culture. (A) When cul-
tured as approximately 1:1 mixtures, splenocytes from CD45.1-negative OX40-negative mice and CD45.1-
positive wildtype mice expressed OX40L in a similar manner and (B) this was consistent between cultures
(p=0.089 and p=0.854 respectively)(plots gated on live CD4+ T cells; 8 samples per group; Mann-Whitney
U-test)
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Figure 7.21: Transfer of OX40L from other cells is not important for its expression by CD4+ T cells.
Total splenocytes from various mice were cultured with anti-CD3 and CTLA4Ig for 72 hours. (A) PGK-Cre cells
expressed OX40L on CD4+ T cells; (B) PGK-Cre OX40Lfl cells did not; (C) total CD45.1+ wildtype splenocyte
cultures expressed OX40L+ cells; (D) purified wildtype CD4+ cells did not; (E) and (F) purified CD4+ T cells
expressed OX40L when mixed with either PGK-Cre or PGK-Cre OX40Lfl cells. (G) Graphical representation
of (D-F). All plots are gated on CD4 T cells; 6 samples per group; Kruskal-Wallis test with Dunn’s post-hoc
test.
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on OX40L expression. My earlier observations that CTLA4-/- cells could downregulate OX40L on
wildtype T cells in trans also raised the possibility of a soluble mediator.
The ability of exogenous IL-2 to alter the expression of CD4+ T cell OX40L was investigated. The
addition of IL-2 to cultures of wildtype splenocytes stimulated with agonistic anti-CD3 in the pres-
ence of CTLA4Ig caused a dose-dependent decrease in OX40L expression (Figure 7.22A). When
cultured with 40 ngml−1 of IL-2, OX40L expression was entirely abrogated and when cultured with
lower concentrations, there was a dose-dependent reduction in OX40L expression.
As with culture of CD4+ T cells with agonistic anti-CD28 antibody, the addition of IL-2 simultan-
eously upregulated expression of OX40. To confirm that OX40 expression was not significant in the
downregulation of OX40L expression, the experiment above was repeated with OX40 deficient cells.
Again, OX40L expression was greatly reduced by the addition of 40 ngml−1 of IL-2 suggesting that
OX40 expression did not directly influence OX40L expression (Figure 7.22B).
Combining the observations that CD28 and IL-2 both downregulate OX40L expression with others’
demonstration that IL-2 production is CD28-ligation dependent[427], it was hypothesised that the
downregulation of OX40L expression seen with CD28 ligation was partially IL-2 induced. To test
this, wildtype cells were cultured in the presence of agonistic anti-CD3 and CD28 antibodies with
and without a neutralising antibody to IL-2. As previously, culture with anti-CD28 prevented the
expression of OX40L. However, the addition of neutralising anti-IL-2 antibody partially restored
OX40L expression (Figure 7.22C). This suggested that, at least in part, the action of ligating anti-
CD28 antibody was mediated through increasing IL-2 production.
A major mediator of the effects of IL-2 is signalling through signal transducer and activator of tran-
scription 5 (STAT5).[136] As a method of testing whether this pathway was important in the con-
trol of T cell OX40L expression, the specific inhibitor pimozide was employed.[138] Consistent with
findings from experiments with exogenous IL-2 and with anti-IL-2 blocking antibody, pimozide
upregulated OX40L in the presence and absence of IL-2 (Figure 7.23).
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Figure 7.22: IL2 downregulates OX40L expression. (A) Wildtype splenocytes were cultured in the presence
of anti-CD3 and CTLA4Ig with and without varying concentrations of IL-2. There was a dose-dependent
decrease in OX40L expression with increasing concentrations of IL-2 (12 samples per group; nptrend test).
(B) The effect of IL-2 was similar in OX40ko splenocytes. (C) The addition of anti-IL-2 antibody increased
OX40L expression when splenocytes were cultured with anti-CD3 and anti-CD28. (all plots representative
and gated on live CD4+ T cells). Mann-Whitney U test; n=8 per group.
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Figure 7.23: STAT5 blockade permits expression of OX40L. The addition of the STAT5-inhibitor pimozide
did not cause any change in expression of OX40L on unactivated CD4+ T cells (A; p=0.159), but in contrast,
pimozide caused upregulation of OX40L on CD4+ T cells stimulated in both the absence (B) and the presence
(C) of exogenous IL-2. Mann-Whitney U test; n=8 per group.
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Figure 7.24: IL-4 downregulates OX40L expression. (A) The addition of IL-4 to cultures of wildtype spleno-
cytes stimulated with anti-CD3 antibody in the presence of CTLA4Ig reduced OX40L expression and increased
OX40 expression (representative plots; gated on liver CD4+ T cells). (B) The effects were consistent over mul-
tiple samples. Mann-Whitney U test; n=8 per group.
It is reported that IL-4 can downregulate OX40L expression, although it is not clear whether this
finding would persist in conditions of controlled CD28 ligation. Splenocytes were therefore cultured
with and without exogenous IL-4 in the presence of anti-CD3 and CTLA4Ig. Here, the addition of
IL-4 entirely prevented the expression of OX40L (Figure 7.24). Similar to findings with IL-2, there
was a concurrent upregulation of OX40.
IL-2 and IL-4 both interact with receptors containing the IL-2 receptor gamma subunit. It was there-
fore considered whether other cytokines interacting with similar receptors might have similar ef-
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fects. IL-7 is one such example and when added to cultures down-regulated OX40L and upregulated
OX40 in a dose-dependent manner (Figure 7.25).
It has been suggested elsewhere that the TH1 cytokines IFNγ and IL-12 modulate OX40L expres-
sion on T cells. No difference was seen in CD4+ T cell OX40L expression in response to exogenous
IL-12 (Figure 7.26A), but an increase was observed in expression with the addition of IFNγ (Fig-
ure 7.26B). A number of other cytokines suggested as affecting OX40L expression either on T cells
or on other cells types were also assessed, but found no significant difference in OX40L expression
was demonstrated on cells treated with exogenous TGFβ, IL-18, interleukin-1 beta (IL1β) or TL1a
(Figure 7.27).
7.2.6 CD8+ T cells regulate OX40L similarly to CD4+ T cells
Having demonstrated that CD4+ T cells express OX40L in response to TCR signals without CD28
signals, several of the experiments reported here were repeated with CD8+T cells in total splenocyte
cultures. Consistent with results for CD4+ T cells, CD8+ cells upregulated OX40L when stimulated
in the presence of CTLA4Ig but down-regulated OX40L when stimulated with agonistic anti‐CD28
antibody. (Figure 7.28A-B). Again, consistent with findings from CD4+ T cells, each of the gamma-
chain cytokines IL-2, IL-4 and IL-7 down-regulated OX40L expression (Figure 7.28C-D).
7.2.7 Mycophenolic acid and rapamycin upregulate OX40L by T cells
Anumber ofmethods of inducing damage to T cell DNA includingmitomycinC, 5-fluorouracil, and
X-ray irradiation have been described as potent inducers of OX40L on CD4 T cells.[210] I examined
whether the lymphocyte-specific inhibitor of guanine nucleotide synthesis mycophenolic acid could
alter OX40L expression on T cells. The addition of mycophenolic acid to cultures increased expres-
sion of OX40Lwhen added in addition to agonistic anti-CD3 (Figure 7.29). Assessment of two other
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Figure 7.25: IL-7 downregulates OX40L expression. (A) The addition of IL-7 to cultures of wildtype spleno-
cytes stimulated with anti-CD3 antibody in the presence of CTLA4Ig reduced OX40L expression and increased
OX40 expression (representative plots; gated on liver CD4+ T cells). (B) and (C) The effects were consistent
over several samples. Comparisons with Kruskal-Wallis test with Dunn’s post-hoc test; n=8 per group.
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Figure 7.26: IFNγ increases expression of OX40L. (A) The addition of IL-12 to mixed wildtype splenocytes
cultures did not significantly alter expression of OX40L CD4+ T cells (p=0.629). (B) The addition of IFNγ to
the same cultures augmented OX40L expression. (n = 8 per group; Mann-Whitney U-test)
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Figure 7.27: Not all cytokines affect OX40L expression. Wildtype total splenocytes were cultured for
72 hours in the presence of 1 µgml−1 anti-CD3 antibody and CTLA4Ig with and without additional (A) IL-18
(p=0.275); (B) TGFβ (p=0.193); (C) TL1a (p=0.323); and (D) IL1β (p=0.560). The addition of these cytokines
did not affect expression of OX40L on CD4+ T cells. (n=8 per group; Mann-Whitney U-test)
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Figure 7.28: CD8+ T cells regulate OX40L similarly to CD4+ T cells. (A) When cultured with agonistic
anti-CD3 antibody, CD8 T cells express OX40L on a small minority of cells. The addition of anti-CD28 to
cultures reduced expression whilst addition of CTLA4Ig greatly increased expression. (B) These findings
were consistent between cultures. (C) The addition of IL-2, IL-4 or IL-7 reduced OX40L expression when
added to cultures containing anti-CD3 and CTLA4Ig. (D) These findings were consistent between cultures.
(n = 12 per condition; Kruskal-Wallis tests with Dunn’s post-hoc tests to test significance from leftmost control
group; plots gated on live CD8+ T cells)
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immunosuppressant agents active on T cells revealed that ciclosporin A – a calcineurin inhibitor –
decreased OX40L expression (Figure 7.30A); the addition of dexamethasone made no difference to
OX40L expression (Figure 7.30B).
Because CD28 signalling is partly effected by signalling through themechanistic target of rapamycin
(mTOR), rapamycin was added to cultures of wildtype cells stimulated with either anti-CD3 or the
combination of anti-CD3 and anti-CD28. In both instances the addition of rapamycin induced an
increase in expression ofOX40L (Figure 7.31). Interestingly, the addition of rapamycinwas sufficient
to induce double-positive OX40-OX40L cells whereas in previous experiments expression of OX40
and OX40L was generally reciprocal.
7.2.8 OX40L may be associated with reduced proliferation
To assess the expression of OX40L in relation to whether cells had proliferated, wildtype CD4+ T
cells were stained intracellularly for the nuclear protein Ki67, a marker of proliferation. Here, when
cells were stimulated with anti-CD28 or deprived of CD28 signals by adding CTLA4Ig, there was
reciprocal OX40L andKi67 staining (Figure 7.32A). To further assess proliferation, cells were loaded
with themembrane dye CFSE and stimulated. Again a reciprocal pattern betweenOX40 andOX40L
expression was apparent: with OX40 expression greater on those cells that had diluted CFSE and
OX40L expression greater on cells that had not diluted CFSE (Figure 7.32B-C).
In an attempt to assess the functional role of OX40L on T cells with respect to proliferation, experi-
ments to estimate the increase in their number in response to a standardised stimuluswas conducted.
To control for variations in culture conditions between culture wells and for the fact that my sources
of OX40L cells was from Cre-recombinase positive cells, and so relatively hypoproliferative, cells
were cultured in approximately 1:1 mixes with CD45.1+ wildtype cells. Prior to culture, and at the
end of culture, the ratio of CD45.2:CD45.1 CD4+ T cells was calculated and a further ratio of the
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Figure 7.29: Mycophenolic acid upregulates OX40L expression. The addition of mycophenolic acid
(1 μg/ml) to cultures of total wildtype splenocytes stimulated with agonistic anti-CD3 increased expression
of OX40L on CD4+ T cells (8 samples per group; plots gated on live CD4+ T cells; Mann-Whitney U-test).
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Figure 7.30: Ciclosporin reduces OX40L expression. (A) Wildtype total splenocytes were cultured in the
presence of anti-CD3 and CTLA4Ig with and without ciclosporin A 0.25 µgml−1 for 72 hours. Those cultures
treated with ciclosporin A expressed significantly less OX40L. (B) Wildtype total splenocytes were cultured in
with anti-CD3 and CTLA4Ig with and without dexamethasone 1µm for 72 hours. There was no difference in
CD4+ T cell expression of OX40L (p=0.932). (8 samples per group; Mann-Whitney U-tests)
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Figure 7.31: Rapamycin induces expression of OX40L. (A) Total splenocytes were cultured in the pres-
ence of agonistic anti-CD3 antibody with and without rapamycin (1 µm). The addition of rapamycin increased
expression of OX40L on CD4+ T cells. (B) The addition of rapamycin also increased expression of OX40L on
CD4+ T cells cultured with anti-CD3 and anti-CD28 (plots are representative and gated on live CD4+ T cells;
8 samples per condition; Mann-Whitney U-test)
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Figure 7.32: OX40L expression on CD4+ T cells is associated with reduced proliferation. Represent-
ative plots (from >8 experiments per condition; all panels gated on live CD4+ T cells) demonstrating (A) re-
ciprocal expression of Ki67 with OX40L; (B) that OX40L expression is predominantly on cells that have not
diluted CFSE; (C) that OX40 expression, in contrast to OX40L expression, is primarily on cells that have diluted
CFSE.
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Figure 7.33: OX40L deficient CD4+ T cells are hyperproliferative. Cells from CD45.1+ wildtype and
CD45.2+ RORGt-Cre mice with and without flox’d OX40L genes were mixed in approximately 1:1 ratios and
cultured for 72 hours in the presence of anti-CD3 antibody. (A) Ratios of CD45.2+:CD45.1+ cells were cal-
culated at the beginning and end of culture (representative plots gated on CD4+ T cells). (B) The absence
of OX40L was confirmed by separate culture with anti-CD3 and CTLA4Ig. (C) At the end of the experiment
the proportion of Cre-positive OX40L-deficient cells was greater than cells Cre-positive but OX40L-sufficient;
Mann-Whitney U test; n=14 per group. (D) In some experiments CFSE was added and was diluted more in
OX40L deficient cells (representative overlay).
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initial and final cell counts calculated (Figure 7.33A). A higher final ratio would therefore suggest a
relatively more positive change in the number of CD45.2+ cells and indirectly greater proliferation.
The relative proliferation of Cre-recombinase positive andCre-flOX40LOX40L-deficient T cells was
compared over three days of culture in the presence of anti-CD3. Deficiency in OX40L was checked
by co-culture with anti-CD3 and CTLA4Ig. Although Cre-recombinase expressing cells increased
in number less than CD45.1+ cells, overall OX40L deficient cells increased in number more than
their OX40L sufficient littermates counterparts (Figure 7.33B-C). In some wells, CFSE was added
and dilution in representative samples was greater in cultures of cells lacking OX40L than those
with OX40L (Figure 7.33D).
7.2.9 Human T cells regulate OX40L similarly to murine T cells
Given that the literature on T cell expression of OX40L describes several similarities between human
and murine cells, human peripheral blood mononuclear cells were cultured with either anti‐CD3
and CTLA4Ig or anti-CD3 and anti‐CD28. Here, human CD4+ T cells behaved similarly to murine
T cells by downregulating OX40L expression in response to CD28 signalling and upregulating it in
the absence of CD28 signals (Figure 7.34).
Further, similar tomurine cells, human cells downregulatedOX40L in response to IL-4 (Figure 7.35)
and upregulated OX40L in a dose-dependent manner after exposure to mycophenolic acid (Fig-
ure 7.36).
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Figure 7.34: Human cells downregulate OX40L in response to signals through CD28. (A) Human total
peripheral blood mononuclear cells were cultured for 72 hours in the presence of either agonistic anti-CD3
antibody, anti-CD3 and anti-CD28 or anti-CD3 and CTLA4Ig. There was an upregulation in OX40L on CD4+
T cells at the end of culture with the addition of CTLA4Ig and (B) this was consistent between experiments.(12
samples per condition; Kruskal-Wallis test with Dunn’s post-hoc test; plots are representative and gated on
live CD4+ T cells).
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Figure 7.35: Human cells downregulate OX40L in response to IL-4. Human peripheral blood mononuclear
cells were cultured for 72 hours in the presence of anti-CD3 and CTLA4Ig. IL-4 was added to some cultures.
Cultures with added IL-4 demonstrated greatly reduced OX40L expression on CD4+ T cells (plots are gated
on live CD4+ T cells; 8 samples per group; Mann-Whitney U-test).
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Figure 7.36: Human cells upregulate OX40L in response to mycophenolic acid. Human peripheral blood
mononuclear cells were cultured in the presence of agonistic anti-CD3 antibodies for 72 hours in the presence
of varying concentrations of mycophenolic acid (MPA). Increasing concentration of mycophenolic acid was
associated with increased CD4+ T cell expression of OX40L (plots are gated on live CD4+ T cells; 8 samples
per condition; nptrend test).
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7.3 Discussion
The experiments presented in this chapter originated from the observation that CTLA4-deficient
mice did not express OX40L on CD4+ T cells whilst some expression was evident on T cells from
their CTLA4-sufficient littermates.
The phenotype of mice deficient in CTLA4 is of widespread lymphadenopathy, lymphocytic organ
infiltration and early death. There is an increase in numbers of circulating and tissue lymphocytes
with both CD4 and CD8 numbers increased; cells generally express markers consistent with ac-
tivation such as CD69, CD25, CD44 and a loss of CD62L.[416, 462] A number of mechanisms of
action for CTLA4 have been proposed including regulatory signals originating via ligation of CTLA4
or through CTLA4’s ligands after interaction with CTLA4. However, the majority of the effect of
CTLA4 appears to be a function of modulating signalling through CD28 by its major ligands CD80
and CD86: this is proposed to be a combination of high affinity regulatory binding by either cell-
bound or soluble CTLA4 and by transendocytosis or the ‘ripping’ and internalising of ligand from
the surface of expressing cells.[362, 93, 449, 450]. Mice co-deficient in CTLA4 and either CD28 or
CD80 andCD86 are protected from their otherwise lethal phenotype.[261, 262] It therefore appeared
that the CD80-CD86-CD28/CTLA4 axis was important in controlling T cell OX40L expression.
These experiments show that it is signals through CD28 that are key in regulating OX40L expression
and that CTLA4 is only involved as modulator of signals through CD28. This was evident when
agonistic anti-CD28 was used to ensure maximal signalling through CD28 or when CTLA4 was
used to prevent the action of endogenous CD28 ligands (CD80 and CD86). Notably, endogenous
ligands could act to downregulate OX40L in trans: wildtype cells down-regulated expression on
CD80KOCD86KO cells. Signals through CD28 have multiple cellular effects including the activation
of many signalling kinase cascades and further work will be required to determine which is most
important in decreasing OX40L expression.[3]These observations fit well with the observations that
signalling through CD28 augments OX40 expression[355], although is not absolutely required for
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it, and the observation presented here that OX40-OX40L expression is typically reciprocal.
A series of further experiments was performed with the intention of demonstrating conclusively
that it was themodulation of signals through CD28 rather than a direct interaction with CTLA4 that
explained changes inOX40L expression. First a clone of an agonistic anti-CTLA4 antibody described
as being able to signal through CTLA4 was used in both wildtype and CD80KOCD86KO splenocyte
preparations.[414] This made no difference to OX40L expression in either cell type, although this
experiment was hindered by the lack of a positive control for signalling throughCTLA4; nonetheless
this antibody at the concentrations used here is described as having effects on T cells.
To further clarify whether CTLA4 had an important role, mice chimeric for wildtype and CTLA4-
deficient T cells were created. Consistent with results reported elsewhere, thesemice did not become
ill and T cells were not activated.[13] The resulting unactivated, but CTLA4-deficient, cells behaved
identically to wildtype cells. Finally, another method of producing non-activated CTLA4-deficient
T cells was employed: generating CD80KOCD86KOCTLA4KO triple-knockout mice. These mice lack
the major ligands for CD28 and so activation of this system is minimal. As expected, these mice also
remained healthy and ex vivo T cells were not activated.[261] Cells from these mice also behaved
identically to those from CD80KOCD86KO animals. Thus there is firm support for the notion that
CTLA4 is not directly required to permit OX40L expression, but that it acts as an important negative
regulator of CD28 signalling.
The observation that CTLA4-/- cells could inhibit the expression of OX40L on co-cultured CTLA4-
sufficient cells in the presence of CTLA4Ig suggested that a mechanism other than ligation through
CD28 was involved. IL-2 is both upregulated as a result of CD28 ligation and positively regulates
OX40 expression.[101, 433] IL-2 is one of a family of related cytokines each of which contains the
common cytokine receptor gamma-chain and which also includes IL-4, -7, -9, -15, and -21.[236]
IL-4 is also noted to upregulate OX40.[417] It was therefore logical to investigate whether these
cytokines influenced OX40L expression in addition.
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In a series of experiments where T cells were cultured in the presence of CTLA4Ig to prevent en-
dogenous CD28-ligation, I have demonstrated that administration of IL-2, IL-4 or IL-17 prevents
OX40L expression on activated CD4+ T cells whilst increasing OX40 expression in a manner sim-
ilar to that seen with CD28 administration. Importantly, when an anti-IL-2 antibody was added
to cultures of anti-CD3 and anti-CD28 treated splenocytes, expression of OX40L could be partially
restored without preventing OX40 expression: some double-positive cells were produced. This sug-
gests that the negative regulation ofOX40Lmay bemore sensitive to IL2 than toCD28 signals, whilst
OX40 expression in response to stimulation with anti-CD28 signals may be maintained.
Although it has pleiotropic effects, inhibition of mTOR signalling by rapamycin reduces IL-2 ex-
pression. The observed effect of rapamycin on OX40L expression may therefore potentially be ex-
plained through preventing the action of IL-2. Notably, in others’ work OX40L expression may take
many days or be of relatively low level: one potential explanation is supplementation of cultures
with either or both of IL-2 and anti-CD28 antibody[278], while those who used CD3 alone revealed
OX40L more quickly.[393]
Others have suggested a direct interaction betweenOX40 onT cells andOX40L on other cell types in
producing T cell expression of OX40L. Work on human T cells cultured with CHO cells engineered
to express a fluorescently marked OX40L has suggested transfer analogous to the transendocytosis
reported for ligands of CTLA4.[346, 39] Others have suggested that an interaction between OX40
and OX40L limits staining for OX40L. This was in response to the observation that staining OX40L
on OX40-deficient cells was reduced when they were co-cultured with OX40L-deficient cells activ-
ated so that they expressed OX40.[393]
To address the potential importance of interactions between OX40 and OX40L on OX40L expres-
sion, several experiments were performed that suggest that such an interaction is not important.
First, OX40-deficient cells upregulate and downregulate OX40L similarly to wildtype cells in re-
sponse to CD28 signals and exogenous IL-2; second, OX40-deficient cells co-cultured with wild-
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type CD45-allotype-marked cells showed no difference in the response to stimulation with either
CD28 or CTLA4Ig in otherwise identical culture milieu; third, OX40L-deficient T cells do not ac-
quire OX40L when co-cultured with OX40L sufficient cells; fourth, OX40L-deficient non T cells are
sufficient to support the expression of OX40L on purified CD4+ T cells that are otherwise unable to
express OX40L when cultured alone. These experiments provide evidence against significant OX40-
OX40L interactionswith respect to ripping. However, it should be noted thatmy observations do not
currently extend to human T cells. My results showing the importance of IL-2 in negatively regulat-
ing OX40L expression raise the possibility that the trans downregulation of OX40L seen in Soroosh
et al.’s experiments was due to IL-2 being produced by activated, OX40-expressing cells.[393] This
last would be consistent with my findings with regard to the concentration of anti-CD3 agonistic
antibody being inversely related to OX40L expression.
Theneed for direct contact ofmurineCD4+T cells with non-T cells to induceOX40L expressionwas
unexpected. The mechanisms also remains unexplained by these experiments other than to demon-
strate that B220+ B cells and probably CD11b+ cells are individually sufficient to support OX40L
expression in the right circumstances. One possible candidate for this were CD40-CD40L interac-
tions: interactions with APC CD40 are described as regulating OX40L expression and it is plausible
that signals through CD40L might influence T cell expression: T cells do not express CD40.[90]
However, culture with antibodies intended to block this interaction did not greatly impair expres-
sion of OX40L: the small reduction in expression with the anti-CD40 used may be explained by its
partially agonistic effects and release of an unknown cytokine. Further possibilities for the identity
of this interaction include a soluble molecule not stable over the distances required by our trans-
membrane system, or another membrane protein.
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Weaknesses in this approach
Whilst these results suggest that the loss of OX40L on T cells might cause increased proliferation,
they are from in vitro experiments only and may be influenced by differential survival. Further,
the use of a Cre-recombinase system whilst assessing survival is not ideal because the presence of
Cre-recombinase itself has an anti-proliferative effect in T cells.[252] Thus, in vivo survival and pro-
liferation studies comparing cells constitutively deficient in OX40L and wildtype cells are neces-
sary. In addition, whether OX40L regulation is upregulated in vivo, rather than in vitro, in response
to TCR stimulation without CD28 co-stimulation is as yet unexplored but could be conducted in
CD80KOCD86KO mice. Finally, it has not been demonstrated that the OX40L expression induced in
these experiments is functional, either in terms of binding OX40 or by ligating OX40 on other cell
types.[393, 211, 210]
Future experiments
These experiments suggest several avenues for further investigation. One is identifying the key path-
way that negatively regulates OX40L expression in response to CD28 stimulation or stimulation by
IL-2, IL-4 or IL-7. One possibility is STAT5which is activated in common by all cytokines in the IL-2
family but which does not require ligation of CD28 except as a mediator of IL-2 transcription.[431]
Investigations using staining for STAT5-phosphorylation and the use of specific inhibitors represent
potential methods of exploring this further. A possible common role for the IL-2 receptor common
gamma chain could be further investigated with mice deficient for the gamma chain.[50] Such in-
vestigation could be combined with an assessment of the activity of other related cytokines active
through the common gamma-chain subunit, for example IL-9 and IL-15.
The negative relationship of variable TCR signal strength of OX40L may be explicable by variable
induction of IL-2.[334] This could be confirmed by investigating various concentrations of agonist
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antibodies in the presence of blocking IL-2 antibody. Exploration of the mechanisms of regulation
with respect to CD28 and IL-2-family cytokines of the other TNF ligands expressed by CD4+ T cells
would be instructive; possibilities include: CD30L, LIGHT, 41BBL, GITRL and CD27L. Determ-
ining the precise cell types that are able to support the induction of OX40L would be possible by
sequential cultures of purified CD4+ T cells with appropriately purified non-T cell populations. The
use of flow cytometric cell-sorting should allow cell populations of greater purity. A better under-
standing of the cell types that were capable of supporting OX40L induction would then inform the
use of blocking antibodies or cells from knockout mice in determining the molecular basis of the
direct interaction.
Summary
The experiments presented in this chapter investigated the expression of the TNF receptor ligand
OX40L on murine CD4+ T cells. Having noted that CTLA4-deficient T cells did not express OX40L
when stimulated with anti-CD3 antibody but that CTLA4-sufficient cells did express OX40L, the
role of CTLA4-CD28 was explored. It was demonstrated that OX40L required signals through the T
cell receptor and that signals through CD28 negatively regulate expression; correspondingly the ad-
dition of CTLA4Ig to block signals through CD28 increases expression. Ligation of CD28 causes in-
creased production of IL-2 and, when co-cultured with wildtype cells, CTLA4-deficient cells down-
regulatedOX40L expression. Exogenous IL-2 downregulatedOX40L expression, whilst the addition
of an anti-IL-2 antibody to cultures promoted the expression of OX40L. The related gamma-chain-
containing cytokines IL-4 and IL-7 had similar actions to IL-2. Thus, it appears that IL-2 may be a
key mediator of CD28-control of OX40L expression.
Combination cultures of purified CD45-allotype marked T cells with mixed splenocytes, purified B
cells and purified myeloid lineage cells in direct contact and across Transwell® membranes demon-
strated a requirement for an unidentified direct interaction between CD4+ T cells and non-T cells
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to permit expression of OX40L. In general across all experiments, OX40 and OX40L were recip-
rocally expressed: others have suggested interactions between the two molecules in inducing T cell
expression of OX40L. However, OX40-deficient CD4+ T cells upregulated normally and there was
no difference in expression between cell types in co-cultures of wildtype and OX40-deficient cells.
OX40L-deficient T cells did not acquireOX40Lwhen co-culturedwithOX40L-sufficient cells, whilst
OX40L-sufficient cells were sufficient to supportOX40L expression in purifiedwildtype T cells in co-
culture suggesting that OX40-OX40L interactions were not important. Early experiments suggested
that loss of OX40L might be associated with increased proliferative capacity. Analogous CD28/IL-
2 dependent regulation of OX40L was seen on CD8+ T cells and on human CD4+ T cells. These
findings build on hitherto limited knowledge of the regulation of OX40L expression on T cells.
254
CD80
Ciclosporin A
Mycophenolic acid
Rapamycin mTOR
mTOR
CTLA4
HLA II
TCR
CD28
APC
T Cell
CTLA4
CD86
Antigen /
other ligand
OX40L
Unidentified direct 
interaction
Anti-proliferative 
effect?
OX40
IL7 / IL7R
IL4 / IL4R
IL2 / IL2R
STAT5
Calcineurin
B  A  
C  
D  
E  
Figure 7.37: Proposed summary diagram of control of OX40L expression on T cells. T cell expression
of OX40L requires ligation of the TCR, which in vivo occurs through the presentation of antigen by HLA II (A).
An unknown second direct signal between APC and the T cell is also necessary for expression of OX40L (B).
The ligation of CD28 promotes the expression of OX40 (C) as well as causing release of IL-2. IL-2 and other
gamma-chain cytokines cause a STAT5-mediated reduction in OX40L expression (D). Ciclosporin reduces
OX40L expression whilst mycophenolate enhances it, the latter through an unknown mechanism (E).
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8 General discussion
8.1 Aims of this project
The series of experiments presented in this thesis aimed to build on the laboratory’s prior work
demonstrating that blockade of OX40/OX40L interactions could greatly increase overall survival in
mice deficient in Tregs. Following others’ observation that FOXP3-deficient mice shared some sim-
ilarities with important human autoimmune liver diseases, this project aimed to assess whether such
OX40/OX40L blockade also ameliorated hepatic autoimmunity in Treg deficient animals. The same
approach was then applied to other mouse models of autoimmunity associated with T cell regu-
latory failure which also developed liver-related autoantibodies and lymphocytic hepatic infiltrates.
Finally, variations in OX40L expression by T cells were apparent during experimentation and the
factors influencing OX40L expression were further explored.
The aims established for this project as presented at the end of the introductory chapter are repeated
below followed by a summary of findings.
1. To establish a Treg deficient model of liver injury that re-capitulates findings reported else-
where, to demonstrate that the disease of Treg deficiency could be transferred between anim-
als, and to explore requirements for its generation.
2. To assess whether prevention of OX40-OX40L signals could control autoimmune liver disease
in the context of Treg.
3. To assess whether prevention ofOX40-OX40L signals could control disease in a secondmouse
model of regulatory failure resulting in generalised and hepatic autoimmunity: the CTLA4-
deficient mouse.
4. To assess whether prevention of OX40-OX40L signals could control disease in amousemodel
of regulatory failure resulting fromexcessive co-stimulation and IFNγproduction: theRoquinM/M
mouse.
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5. To assess factors controlling expression of OX40L expression on CD4+ T cells.
8.2 Findings by aim
1. This work has demonstrated that mice deficient in FOXP3 and therefore Treg, develop lymph-
ocytic hepatitis. This work confirms and extends the original description of such hepatitis
in these animals[504] by recording elevations in serum ALT activity, IgG, IgE, and serum
TNFα as well as providing additional phenotyping of liver-infiltrating T cells. In addition, it is
demonstrated that transfer of intact Tregs is sufficient to prevent the FOXP3-deficiency phen-
otype and that antigen specificity among transferred Tregs, at least to those antigens presented
by AIRE, is not essential.
2. This project has demonstrated that blockade of OX40-OX40L interactions are sufficient to
prevent the development of autoimmune liver injury in FOXP3 deficiency. In addition, im-
munohistochemical work has demonstrated an upregulation of OX40 in various human liver
diseases including AILDs.
3. Although CTLA4-deficient mice demonstrated CD4 T cell-dense hepatic infiltrates alongside
AMAs and multisystem autoimmunity in a similar manner to FOXP3-deficient animals, no
significant difference was seen in the extent of this autoimmunity when OX40-OX40L inter-
actions were prevented. This was true for both antibody-mediated blockade and constitutive
deficiency in OX40.
4. RoquinM/M mice also demonstrated CD4 T cell-dense hepatic infiltrates alongside AMAs and
multisystem autoimmunity with marked increases in ICOS expression and in IFNγ produc-
tion by CD4+ T cells. Autoimmunity was not altered by OX40 blockade. This was true for
both antibody blockade and for constitutive deficiency in OX40.
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5. The examination of factors controlling T cell expression of OX40L has resulted in the novel
observations that OX40L expression is negatively regulated by signalling through CD28 via
IL-2 and other related members of the gamma-chain cytokine family including IL-4 and IL-7,
perhaps acting through STAT5. Further, a requirement for direct interaction between CD4+
T cells and non T cells for the expression OX40L was established whilst the lack of transfer of
OX40L to OX40L-negative cells in co-culture with OX40L sufficient cells made direct trans-
fer of OX40L unlikely. Finally, a possible association between loss of OX40L expression and
increased proliferation was demonstrated. Notably, similar findings were present in murine
CD8+ T cells and human CD4+ T cells.
Incidental findings
In addition to exploring its stated aims, this project resulted in several incidental findings. The
first of these was the paradoxical observation that, in contrast to human autoimmune and biliary
disease, mice appeared to have serum ALP activity that was reduced in association with hepatic
inflammation. Further laboratory assessment using heating of the serum suggested that the ALP
present in the mouse serum analysed was heat-labile and therefore likely of bone origin. This lead to
a search of the literature and the consistent finding that in the C57Bl/6mouse strain, ALPwas absent
from the liver.[241] From the perspective of this project, this led to a discontinuation ofmeasurement
of serum ALP activity. Serum ALT was assessed instead. This finding of an inverse relationship
with liver damage and ALP activity has wider ramifications: serum ALP activity is widely reported
in the literature in relation to mouse models of biliary injury including in models on a C57Bl/6
background.[338, 425, 339, 187]. The findings presented here, together with the work of Linder et
al., question this approach.[421, 241]
Adoptive transfer of T cells from FOXP3-deficient mice was necessary to permit the generation of
multiple similar subjects to permit cohort experimentation. In developing the adoptive transfer
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model, it was noted in preliminary experiments that transfer of FOXP3-deficient cells into ZAP70-/-
hosts produced less marked disease than transfer into RAG-/- hosts. The major difference between
these hosts is the presence of B cells in the former but their absence in the latter. Although in this
series of experiments, experiments were continued with ZAP70-/- hosts because they closer to the
wildtype phenotype, such findings point to a potential anti-inflammatory role for B cells. This ob-
servation contrasts with that reported by Aschermann et al who crossed FOXP3-deficient mice with
µMT-/- mice co-deficient in B cells. The group recorded increased survival and reductions in tissue-
specific infiltrates in the absence of B cells.[9] Notably my methodology differed by involving adopt-
ive transfer: certainly the effects of the absence of B cells were apparent with the absence of AMA
and an absence of B cells on flow cytometry (Figure 3.12). It is possible that the differences in T cell
homeostatic proliferation in the two models may account for the variation in liver inflammation.
The small numbers of B cells transferred at adoptive transfer may also have been important. A fur-
ther consideration is the potential residual presence of some γδ T cells in ZAP70-/- animals, and
these may regulate the T cell driven autoimmunity of Treg deficiency, and may perhaps explain this
difference.[426]
Having established that adoptive transfer of intact Tregswas sufficient to prevent hepatic andmultisys-
temautoimmunity associatedwith FOXP3deficiency, the samemodelwas used to investigatewhether
transfer of Tregs from mice deficient in the protein AIRE; AIRE is involved in the presentation of
otherwise antigens that are otherwise restricted to their usual tissue of expression to developing
T cells in the thymus. As such, it is important in the generation of antigen-specific Treg. In so
doing, I sought an indirect answer to the question of whether antigen specificity was necessary for
control of generalised regulatory failure, which is important when considering Treg therapy.[410]
The issue is also of specific interest to hepatology: mutations in AIRE underlie a proportion of cases
of AIH.[437]
Our demonstration that AIRE-deficient Treg were able to effectively suppress autoimmunity in the
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FOXP3-deficientmodel suggests that antigen-specificity – at least on the spectrum dictated by AIRE
– is not important for Treg control. This contrasts with work reported by a German group who
transferred intact Tregs into AIRE-deficient mice with hepatitis and prevented the development of
hepatitis.[132]
8.3 Application to human disease
This work supports a potential therapeutic role for blockade of OX40 / OX40L interactions in con-
trolling the autoimmunity seen in complete deficiency of Treg in mice. Notably however, the lack of
therapeutic effect seen in controlling the multi-system immunity of either CTLA4 deficiency or in
RoquinM/M mice suggests against a generalised immunosuppressive effect. It is intriguing therefore
to consider whether these observations might be applicable to human diseases associated with a loss
of regulatory control.
Compounds with effective blocking activity of OX40 / OX40L interactions in humans are already in
existence: for example, after evaluation in non-human primate models of asthma[372], an OX40L-
specific blocking antibody has been trialled in patients with atopic asthma.[107] Although this study
did not demonstrate efficacy in the clinical endpoints considered – primarily responses to allergen
challenges – there were no significant adverse effects with a dosing regime of four doses over three
months. Notably, small molecule inhibitors and agonists of OX40 are in development although have
not yet entered clinical trials.[392] Caution with regard to increased susceptibility to infection is
however warranted when using blockade of OX40-OX40L interactions: details of a single human
invididual homozygous for loss of function missense mutations in OX40 has been reported.[46]
Although this person was relatively healthy until the age of 19, she had suffered from childhood
Kaposi’s sarcoma and visceral leishmaniasis, although it is not clear if the latter was related to her
immunodeficiency. In mice, susceptibility to leishmaniasis, an infection primarily controlled by the
action of Th2 cells, is not increased in deficiency of OX40L.[424]
261
The contrasting effectiveness of OX40 / OX40L blockade in preventing autoimmunity in mice with
total deficiency of FOXP3 and in those with deficiency of CTLA4 suggests that if blockade were to
be assessed in human disease, directly analogous models are likely to be important. The rare IPEX
syndrome results in loss of Treg function and lethal autoimmunity in affected humans. Current
treatment is with non-specific immunosuppression followed by allogeneic stem cell transplant for
which mortality may reach 50% and which appears to have a worsened prognosis with increasing
age.[221]Thus, given the highmortality of IPEX and the potential value of a temporising therapy, an
argument might be made for trials of the agent in IPEX sufferers prior to allografting. One caution
if such an approach were to be tried would be careful definition of the precise subtype of IPEX being
evaluated: in contrast to FOXP3-deficient mice, some IPEX patients still generate Treg but these are
largely non-functional.[85]
A further potential situation where OX40 blockade might be proposed for translation to human
therapy is in preventing or ameliorating autoimmunity during checkpoint inhibitor therapy for can-
cer. Anti-CTLA4 antibodies have becomewidespread in treatingmalignancies includingmelanoma,
but are associated with colitis in some 35% at standard doses and hepatitis in 5%.[474] Notably, the
mechanism of action of ipilimumab appears to be partially dependent on fragment crystallisable re-
gion of antibody (Fc)-mediated depletion of Tregs.[384, 370] In addition, the development of colitis
is associated with colonic Treg depletion.[302] As such, it is feasible that OX40 blockade in combin-
ation with ipilimumab may represent an autoimmunity-limiting option in cancer immunotherapy,
although notably the occurence of Treg depletion in human cancer immunotherapy has recently
been challenged.[375]
The Lane group has gone someway towards supporting an approach of OX40 blockade to ameliorate
autoimmunity in a mouse melanoma model where the addition of an anti-OX40 antibody to the
combination ofCTLA4 andPD-1 blockade reducedhepatic autoimmunity.[304]. Such interventions
need careful assessment: the timing of OX40 blockade in relation to the autoimmune precipitant has
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been shown to alter its effect in other models of autoimmunity [471, 356]; more importantly, it is
not clear whether interfering with OX40 may affect anti-tumoral immunity in other models: in the
Birmingham mouse model, a significant difference in anti-melanoma responses was not apparent.
However, building on the observation that OX40 agonism appears to have anti-tumour effects in
cancers including prostate cancer, a potentially negative effect on anti-tumour immunity cannot be
discounted.[174]
8.4 Extending this work
Animal work
One of the striking aspects of this work is of the differing efficacy of OX40-OX40L blockade in
preventing autoimmunity between mice deficient in FOXP3 and CTLA4 despite these mice having
relatively similar OX40 blockade in cells only deficient in CTLA4 on Tregs. Given that CTLA4 is
expressed by both Tregs and activated effector T cells, this suggest a role for the absence of non-Treg
CTLA4 in provoking autoimmunity in my model.[166] It would be intriguing to study the effect of
OX40-OX40L blockade in two alternativemousemodels. First, inmice deficient in CTLA4 onTregs
alone, autoimmunity still develops [483]. If OX40 controlled this autoimmunity, it would be further
evidence for amajor role for non-Treg CTLA4 in driving the autoimmune response. Second, it is un-
clear as to whether timing of OX40 blockade dictates why it is unsuccessful in germline CTLA4 defi-
ciency. To trial this, one could repeat the experiment in an inducible knockout of CTLA4 which also
develops hepatic and multisystem lymphocytic infiltrates.[205] Preliminary data show that OX40 is
not effective in this manner (Kajsa Wing, personal communication), and this is consistent with the
observation that germline OX40-deficient mice are not protected from marked autoimmunity.
OX40-OX40L blockade was ineffective in ameliorating autoimmunity in RoquinM/M mice. This is is
likely because OX40 hyperexpression is either a less important mediator of autoimmunity or there
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are redundant mechanisms generating autoimmunity. Although OX40 is upregulated in RoquinM/M
mice, greater upregulations are seen in the alternative T cell costimulatory molecule ICOS.[438] It
has been demonstrated that reductions in ICOS signalling ameliorate the autoimmune phenotype
seen in RoquinM/M disease[497], and that in other situations OX40 and ICOS cooperate to promote
the overdevelopment of follicular T cells, a characteristic of RoquinM/M mice.[404] Therefore, com-
binatorial blockade of ICOS and OX40 signalling would be a logical next experiment.
In addition to considering OX40 and ICOS hyperexpression in the RoquinM/M mouse, it is not-
able that isolated hyperexpression of IFNγ is sufficient to produce hepatic infiltration with activated
T cells and the production of AMA.[14] Although antibody blockade of IFNγ was not sufficient to
abrogate autoimmuntiy in the experiments reported here, it might be that combinations of ICOS,
OX40 and IFNγ blockade would be more effective.
Two different strains of mice that develop hepatic autoimmunity associated with a failure to gener-
ate self-antigen specific Tregs have been reported: AIRE dysfunction and themore recently reported
FezF2[406] dysfunction. Given the efficacy of OX40-OX40L blockade in the autoimmunity of com-
plete Treg deficiency, it is likely that OX40-OX40L blockade would be efficacious in these models.
This is of particular interest becauseAIRE dysfunction has a direct human correlate inAPECED.[98]
OX40L expression on T cells
With regard to OX40L expression on T cells, several avenues are appropriate for following up on the
key findings of this project: that OX40L is negatively regulated by CD28 ligation through the pro-
duction of IL-2 in a mechanism that appears to involve STAT5; that an uncertain direct interaction
between T cells and non T-cells is required to support the expression of OX40L; and the demonstra-
tion of an association of OX40L expression with reduced proliferation.
Of the mechanisms above, the first might reasonably be assessed by using cells from animals either
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constitutively deficient in STAT5 or by assessing inducible knockouts. These could be assessed
alone and in co-culture experiments where STAT5-deficient cells might be expected to express more
OX40L than their wildtype counterparts and be resistant to IL-2-induced downregulation.[457]
The obsevation – of the requirement for direct interaction to induce OX40L – should ideally be con-
firmed by using a different conformation of culture chamber: ideally where cells were closer together
but still separated by a cell-impermeable membrane to reduce the likelihood of an unstable soluble
mediator causing the effect. Further co-culture experiments with different purified preparations of
support cells other than the B220+ and CD11b+ positive populations would permit a search, per-
haps in conjunction with databases of molecular expression, for a potential cell-surface molecule
permitting OX40L expression.[137] The role of OX40L in affecting cell turnover could valuably be
further assessed by increasing the number of experiments presented here. In addition to expand-
ing in vitro work, similar methodology in vivo could be used to assess survival[254], as could the
creation of bone marrow chimeras of OX40L-sufficient and OX40L-deficient animals.
Human translation
A further characterisation of human OX40+ T cells in health and disease would be enlightening in
the context of these results: is upregulation seen only on CD4+ T cells? What state are these cells
in and what are their subtypes? Is upregulation seen primarily in autoimmune conditions or other
causes of chronic inflammation such as viral hepatitis? Extraction of lymphocytes from human liver
is well-reported and consistent and would provide a mechanism to answer these questions.[76] As
described above, there is a rationale for extending this work into humans by trialling OX40 / OX40L
blockade in either IPEX or AIRE-deficiency. There is a potential role in ipilimumab-associated
autoimmunity associated with Treg depletion. Given that we have demonstrated increased expres-
sion of OX40 on T cells and within the livers of mice lacking Treg, it would be a logical step to look
for upregulation of OX40 in inflamed tissue from IPEX and AIRE-deficient patients and in tissue
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samples from patients with ipilimumab-associated colitis or hepatitis. Were widespread upregu-
lation of OX40 to be seen such tissues this might further support a rationale for trialling OX40 /
OX40L blockade in that disease, although it is noted that OX40 expression was also upregulated in
RoquinM/M and CTLA4-deficient mice where OX40 / OX40L blockade is not effective.
8.5 Overall summary
The interactions of the TNF-receptor OX40 and its ligand OX40L primarily act to sustain activated
T cells, especially CD4+ T cells. Mice deficient in Tregs develop lethal multisystem autoimmunity
which shares some features with human autoimmune liver disease including production of CD4+
T cell rich hepatic infiltrates and the presence of the autoantibody AMA. Previously the Lane group
has demonstrated that interruptingOX40 / OX40L interactions increases survival in Treg deficiency.
In this series of experiments, I recapitulate the presence of selected features of human autoimmune
liver disease in mice lacking Tregs including CD4+ T cell rich liver infiltrates and AMA. In addition,
this project draws further parallels with human disease by recording evidence of liver damage by
elevations in serumALT activity and demonstrating elevations in serum IgG and IgE concentrations.
I go on to demonstrate increased expression of OX40 on T cells in these mice. I then demonstrate
that replacing healthy Treg either as a component of total cells from syngeneic mice or sorted Treg
alone is sufficient to control disease. Antigen specificity of transferred T cells was unlikely to be
important because cells from AIRE-deficient mice were also able to abrogate autoimmunity.
The effects of blocking antibodies to OX40L and a non-depleting blocking anti-OX40 Fab were ex-
amined in FOXP3-deficiency. Both treatments totally abrogated autoimmunity but blockade of
OX40-OX40L interactions did not prevent hepatic damage in the T cell cytokine mediated model of
Con A liver damange nor in chemically mediated CCl4 liver injury.
Twoothermodels of systemic autoimmunity associatedwith deficits inT cell regulation – theCTLA4-/-
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mouse and the RoquinM/M mouse were examined for analogous hepatitis. This was present in both
animals but in neither was liver disease ameliorated by either antibody blockade of OX40-OX40L
interactions or co-deficiency of OX40.
During these experiments variablility inCD4Tcell expression ofOX40Lwas noted and subsequently
explored in a number of culture experiments. I demonstrate that OX40L expression on both CD4+
and CD8+ murine T cells requires TCR ligation but that it is negatively regulated by signals through
CD28. The effects of these signals through CD28 appear to limit OX40L expression through the ac-
tion of IL-2 and other related gamma-chain cytokines partly through the action of STAT5. Further,
for CD4 T cells to express OX40L, direct contact with non T cells including either B cells or macro-
phages is essential. OX40L expression appears to be associated with reduced proliferation. Human
CD4+ T cells appear to behave similarly.
These results suggest that interruption of OX40-OX40L signals may powerfully control T cell medi-
ated autoimmunity in some forms of dysregulation. However, the effect is not universal. These res-
ults suggest potential value in OX40-OX40L blockade as a therapy in some forms of human autoim-
mune disease, but the specific situations will need to be carefully chosen.
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